var title_f34_32_35328="Negri bodies in rabies";
var content_f34_32_35328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Negri body in rabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows a neuron without Negri bodies, while panel B shows a Negri body in infected neuron (arrow). Panel C shows a Negri body in Sellers stained brain tissue with dark blue basophilic granules in the inclusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: file://www.cdc.gov/ncidod/dvrd/rabies/diagnosis/diagnosi.htm. Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35328=[""].join("\n");
var outline_f34_32_35328=null;
var title_f34_32_35329="Perineal hypospadias";
var content_f34_32_35329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perineal hypospadias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perineal hypospadias and bifid scrotum in 46,XY infant with Drash syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35329=[""].join("\n");
var outline_f34_32_35329=null;
var title_f34_32_35330="Dix Hallpike maneuver";
var content_f34_32_35330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dix Hallpike maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the patient sitting, the neck is extended and turned to one side. The patient is then placed supine rapidly, so that the head hangs over the edge of the bed. The patient is kept in this position and observed for nystagmus for 30 seconds. In patients with benign paroxysmal positional vertigo, nystagmus usually appears with a latency of a few seconds and lasts less than 30 seconds. It has a typical trajectory, beating upward and torsionally, with the upper poles of the eyes beating toward the ground. After it stops and the patient sits up, the nystagmus will recur but in the opposite direction. Therefore, the patient is returned to upright and again observed for nystagmus for 30 seconds. If nystagmus is not provoked, the maneuver is repeated with the head turned to the other side. If nystagmus is provoked, the patient should have the maneuver repeated to the same (provoked) side; with each repetition, the intensity and duration of nystagmus will diminish.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35330=[""].join("\n");
var outline_f34_32_35330=null;
var title_f34_32_35331="Ferumoxytol: Patient drug information";
var content_f34_32_35331=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ferumoxytol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     see \"Ferumoxytol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7890587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feraheme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14329048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Feraheme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ferumoxytol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12211 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-A7765D755B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35331=[""].join("\n");
var outline_f34_32_35331=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7890587\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14329048\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013870\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013869\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013874\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013875\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013877\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013872\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013873\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013878\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013879\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=related_link\">",
"      Ferumoxytol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_32_35332="Ketorolac (ophthalmic): Drug information";
var content_f34_32_35332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketorolac (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=see_link\">",
"    see \"Ketorolac (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/51/43827?source=see_link\">",
"    see \"Ketorolac (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8346944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acular LS&reg;;",
"     </li>",
"     <li>",
"      Acular&reg;;",
"     </li>",
"     <li>",
"      Acuvail&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8346945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acular LS&reg;;",
"     </li>",
"     <li>",
"      Acular&reg;;",
"     </li>",
"     <li>",
"      Apo-Ketorolac&reg; Ophthalmic;",
"     </li>",
"     <li>",
"      ratio-Ketorolac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8347271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8350501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seasonal allergic conjunctivitis (relief of ocular itching) (Acular&reg;):",
"     </b>",
"     <i>",
"      Ophthalmic:",
"     </i>",
"     Instill 1 drop to affected eye(s) 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammation following cataract extraction (Acular&reg;):",
"     </b>",
"     <i>",
"      Ophthalmic:",
"     </i>",
"     Instill 1 drop to affected eye(s) 4 times daily beginning 24 hours after surgery; continue for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain, burning/stinging following corneal refractive surgery (Acular LS&reg;):",
"     </b>",
"     <i>",
"      Ophthalmic:",
"     </i>",
"     Instill 1 drop to affected eye(s) 4 times daily as needed for up to 4 days after surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain and inflammation associated with cataract surgery (Acuvail&reg;):",
"     </b>",
"     Instill 1 drop to affected eye(s) 2 times daily 24 hours before surgery and on the day of surgery; continue for 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8350500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/51/43827?source=see_link\">",
"      see \"Ketorolac (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Ophthalmic uses:",
"     </b>",
"     Children &ge;2 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8353219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as tromethamine [drops]: 0.4% (5 mL); 0.5% (3 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acular LS&reg;: 0.4% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acular&reg;: 0.5% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as tromethamine [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acuvail&reg;: 0.45% (0.4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8346947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8353208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     May contain benzalkonium chloride which may be absorbed by contact lenses; contact lenses should not be worn during treatment. May be administered with other ophthalmic medications including antibiotics, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics; wait at least 5 minutes before administering other eye drops.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8346948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Temporary relief of ocular itching due to seasonal allergic conjunctivitis; postoperative pain and/or inflammation following cataract extraction;  reduction of ocular pain, burning, and stinging following corneal refractive surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8320260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acular&reg; may be confused with Acthar&reg;, Ocular",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ketorolac may be confused with Ketalar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8346963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Transient burning/stinging (Acular&reg; and Acular LS&reg;: 20% to 40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctival hyperemia, corneal edema, corneal infiltrates, iritis, ocular edema, ocular inflammation, ocular irritation, ocular pain, ocular pressure increased, superficial keratitis, superficial ocular infection, tearing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &le;1% (Limited to important or life-threatening): Corneal erosion, corneal perforation, corneal thinning, corneal ulcer, dry eyes, epithelial breakdown",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8346954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Hypersensitivity to ketorolac or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8346955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding/hemostasis: May increase bleeding time associated with ocular surgery. Use with caution in patients with known bleeding tendencies or those receiving anticoagulants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corneal effects: Corneal thinning, erosion, or ulceration have been reported with topical NSAIDs; discontinue if corneal epithelial breakdown occurs. Use caution with complicated ocular surgery, corneal denervation, corneal epithelial defects, diabetes, rheumatoid arthritis, ocular surface disease, or ocular surgeries repeated within short periods of time; risk of corneal epithelial breakdown (leading to possible loss of vision) may be increased. Use for &gt;24 hours prior to or for &gt;14 days following surgery also increases risk of corneal adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed healing: Healing time may be slowed or delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, or other nonsteroidal anti-inflammatory agents; bronchospasm or exacerbation of asthma may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic corticosteroids: Concurrent use may lead to delayed healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postsurgical patients: To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic solution: May contain benzalkonium chloride which may be absorbed by contact lenses; contact lenses should not be worn during treatment. Allow at least 5 minutes between applications with other eye drops.  To avoid contamination, do not touch tip of container to any surface.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Acular LS&reg;: The safety and efficacy of Acular LS&reg; have not been established in postcataract surgery patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8349375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8346949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8346950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies; therefore, the manufacturer classifies ketorolac ophthalmic as pregnancy category C. When administered I.M., ketorolac crosses the placenta. Refer to the Ketorolac (Systemic) monograph for details. The amount of ketorolac available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses. Because they may cause premature closure of the ductus arteriosus, the use of NSAIDs late in pregnancy (including ketorolac ophthalmic drops) should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8346952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8346953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, ketorolac enters breast milk. The use of systemic ketorolac is contraindicated in breast-feeding women. Refer to the Ketorolac (Systemic) monograph for details. The amount of ketorolac available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses. The manufacturer recommends that caution be used when administering ketorolac ophthalmic to breast-feeding women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8353223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acular LS Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (5 mL): $185.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acular Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $185.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acuvail Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45% (30): $206.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ketorolac Tromethamine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4% (5 mL): $106.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $106.28",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acular (AR, AT, BR, CH, CL, CN, CR, DE, DK, DO, FI, FR, GB, GT, HK, HN, IE, IN, IT, KP, MY, NI, NL, PA, PE, PH, SG, SV, TH, TR, TW, ZA);",
"     </li>",
"     <li>",
"      Acular LS (AR, CO, HK);",
"     </li>",
"     <li>",
"      Aculare (BE);",
"     </li>",
"     <li>",
"      Kenalgesic (CO);",
"     </li>",
"     <li>",
"      Ocudol (VE);",
"     </li>",
"     <li>",
"      Oftalgesic (DO);",
"     </li>",
"     <li>",
"      Poenkerat (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8349383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9772090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Following application of ketorolac tromethamine 0.5% ophthalmic drops 3 times/day, the mean plasma concentrations of ketorolac are ~4% to 8% of the minimum concentration observed following oral doses of 10 mg 4 times/day.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/32/35332/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9151 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-9F549ED38C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35332=[""].join("\n");
var outline_f34_32_35332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8347271\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8350501\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8350500\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160063\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160064\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346947\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353208\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346948\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8320260\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346963\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346954\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346955\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299557\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349375\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346949\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346950\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346952\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346953\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8353223\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390231\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8349383\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9772090\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_32_35333="Survival after AIDS diagnosis in US 1998 to 2005";
var content_f34_32_35333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Survival after AIDS diagnosis in the United States, 1998-2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 670px; background-image: url(data:image/gif;base64,R0lGODlhBAKeAvcAAKahnaqlorKtqsG9umVbVP3+/7m1sikXCnpybZ+fn5uVkYuFgOXk5PDw8MnFw1dMRE9DOn9/f6yopZONibOwrdDNy2tjXIR9eZGKhpCQkImCfjEgE7u4teDe3enp6XRqZcDAwMC+vZ2YlMTAvpWQjFtQSdXS0M/Pz9LQzjQlG/z8/M3KyOLg30g7MkM1K9za2MvIxdjW1aGcmf///9vY1u/u7ufm5ZiSj+Xi4IF6dX11cPj4+NvZ2Pj29Y6IhOTk4nBwcOvp6J+alvTz8xgEAMbCwNbV1LCwsODg4PHw7t7b2vn39vDu7YaAfNbU0rGqpr25t/Ty8fz7+nVtaPb29t7d3cbEweno5vr6+tDQ0Layr/z6+u3r6v79/fr4+O3s7O7s7AAAAPLy8s/Lyq+tqzoqH2FWTvX08vr8/Gxsa354dP78+6SemT4xKfLw8Pf183hva/Lz8f39+66qp25lX+Ph4N/c24J8d9PR0KKem4R6dX92cYF4c6GbmMvJyMfGxPj2+IV8dqijn6SfnPb5+Pv69+7u7ePi4PX3+fv7/HBnYL+7uePi4vr8+d7e27izsfr5+dnX1+vr6bCsqfz9/f37/PPy819WUPj5+vb09fX19dPS0Pb19fLz9Pj49uzq6/n5+I+HgQ0AAPn6+vDu7+3t7PL08vX29urn54R6cvLy89zc29/g4uXi46ikofHx8fX19PDw8d3b27e2tIh/e3BoZOLh4T4vJHhtZ9bU1e/v7+7u8KmgnPHy8dfY1quppu7t7X92biENApaOivPw8Z+YlO/x8O3u7+Lk4uHj49/d39HPzo6Ff+3t7efn5szLy////v7//4CAgEBAQP/+///+/j8/P/7+/v7//v7+/zAwMKCgoP///RAQEGBgYA8PD1BQUCAgIC8vL19fX09PTx8fH//+/f7//f7+/f/+/Lq4t////Nvb2uvr68PCwODf3tvb20w/NoZ+eIyHguHh4N/f31NHQP7+/NPS0mleWE5EPt7f297f3p6YkUExI+Li5CH5BAAAAAAALAAAAAAEAp4CAAj/AGcIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cv3IBIQgJGUzDJtG0hp06Yx3TYty0EgiisSNrxyGpCKDbxZxgx44F/AIGZkAd2AYINt0qQ5Pjh5xmaRrxkyXq2wNUUQtE9LO0LwiLRtpQX6libYoG7iA31nKC469erPgVdKC0M9jLfDYUIjkRba47Yw4KQx/wWB3CBqiyDCiDc5vXuYyBO9hQGCOrtEINR5z5he3XX1+QJl0U0304Rjn0HpiffbSAs21B5D23UXURbTRdaANmFgeNkM8mGojUAddnMgQfyF0Y1g+GkzoGBHhBGOgbyVqJ506jVg4GiqbRPaEeBMk4FAqIEwjTfBZTANOPqhhkQGQlq3TYQCGYmkQL8ZSaRomoFDWXI9/ojENNZJuN82Rq7XAGJTkpeFjjMYaRmLXQpE3hGa6ecmEMzNwOOQIEAJ5W8UUhiamuQh4ZtgqOk2w3ZHQLZeFuCEV15B6QFRp57IJUoiaoVBCk6RRya5W6RZfOnkDO9ZWVoWWW65qGaWNf8AgoHcgemNYUho5o1jarJJkIHWDZReZGCCkNmMYOp3BG0zZHbkjAuC0KOPAjmbWmhVDgnqlFgeadiCDUA2zXoDQZpYdn5yF+ERT3I3A2o8grMaYkA0OBCY70UJoIFIZJEhh2EYRt2ZM1IqGDg1mtgmgBhm4e+H03kTnUrTiVfsdCLuBh5+l9mKHzgzcIwwb2CKmIGB2gCRYMjzjYxqhgZ6g0SG0ngDcnIbz5cFyq6aCATCP6ooTcMYqydfvdqA0CI4HO9nIr65zje0hN+FF97KK5tI3cwgI7xddt/92E04/s2Q3nsiPjkgYiMSlF44Q4exZhhik00QdSq6iOF1Iof/QbLeLu6c4WV4xzyzNjXfLOe48t0qYmEo49kN4gM6nXFvdIsY3LACFbuowvJ1A85yBWkon3j51sy2YabPWHiwfR9xeOKoKhZON9IAYbdASKxdLNbqpff4ymCGgyHZH1eIYL5Od5xdehDPKJ/x2gR3kHw65ss5dQJxP10441qPUoX4kT2dfgiXpmLZM2A4w+TNgudfcA+uDH8D8ueLf2MuApGB+OlrXzecJqbaxY9/jFPP+QSCsKvNIIDrexB+pAUedw0kAzQzDPBQ96HOhaEBBCIgCLXhL4uFwWwzalFqAkbAg6xMhSNs0Y/uppgH5et+8gOTQNz3IAPuz1/h8J/4/96lmXzpsIUY9AbbyOM3g8gnapThnH/cc8JjUacbtPHXdbKmmAZkABwY4k6wuHjA930If/Lq3/8MOCAl5gmD33rejBJUKTkh64TtO6GLugcfYTFvZmizD8potTAMYfFlzBPNvzi3PTxybxv1MtCGUvK9IQmmh0fUYSb1GBkj4rGFZDQg8/J1hGmIqIMeTGUPBzLKaQwrNdzpYWYw5LdNtrA9s8wPifClsjm6Dj7fwV4LGxcGwehwgw9apdt8KZ4OfbAgqbNPvlrJPh32kJqlPCVBOMa5IybTOrD8WgHx9x6U2ZFY9pkZ2TYHJnJt0IAqygAGxSieUE6zk4rJ5r/yBf8pA51oIN8EDDNXhkITppKalEokhbZhIN7JE2G4yRcGFQOa1Wxjcqv619Le90H8DdCPfTxJxUh0oHlutFgY7JrfpvOjIzqNOysbGUsNWDsQeOMIIKjcBdWzUWWiKmnyEVs3dJSB+nTHG0zCjzx5Kr+AIhUESr2gyqrmL9y1k6bxM1FpHtQi5h2TmUtrUmhC6EeJNQyF8oNmDaWpGJnSrZonrFhoWmlTnOrUg+zyJJWC9zCcAoFCbVuYEqVxoyVlKDRgysARMESym4IAQxICYTig+ktUTRY/0sDfZStrQLcyybGVM6KOwESb9IBDrFVlGz3taNCyMfY7Ic0CBpNWGh3/IWxDOJ3Oh2bWDToFqyAY7Ea9DAMjhBnmdBF7oBIJSbGC7VVCQBDRp/xjoGmUpgEIE24qeWeg084Iuz7jIx+RQEsSFiS64NlqYE0kog1Bijrh8M2BpCEi7YZMuurFVnboG97kAGu65TsdVgF2nRbOwECU+Wo9Z4SfyWXHX64Snom2BCODRHOuXczuhmyJhO7S9D3kxRuzBPQevS7Kw4vFmzhL90yW1es//sGbncqrn4FctMSoU8x3cPyux3FWfxpeVHkdky+EuchVLHNwaAIcvIIRD486FByYQoov6szVReQq2ZXe5c8tE6TK/DTkhsCb3v3Ud5I8cSlPEokVJqXY/4u7U4hm+3IQHVGwxjxRGhPRvBc174TNVwGWNmKE54TMk85OhC+5erLjbngZ0ZCOtKQnTelKW/rSJ7ENkBojk1JyuiCtiQ1IRP2QziyqTwiBDERmU5AlSYN0MdH0eUO6EVZj+iwEfW5MZpcn1o6JQUh2CPdeipDzDBghyvwO+ERUUITkGiTP/vInO+LThET71kCRVmK8tBtHVStLznXaF+V1JlztZiDlXtS5czUkx7A7Vu8iDqyFEyeAFcY04FYQrmAFhOtq5lpjUlWUQhWgVv26TYnBE0OGPVJ4kSre78IyorYdoGm1bWBUsrd4GENw+Yxr09TSU48k5rZpcbtRH/9vVr4LUkpwNNRsPep3wFN+JoIzytuisbh2dMWr3VzK44t+t8yVRDqOz1Bcuxr4m7B9GCWCKXuBZN18BAzQ99B3gLdbmKuyDsfeUW6AQqpZsEo2oqU17Xhobl2OzZbA66j9ZdqImYtHNjubGfBoU1s4HkdavOOVrcGN6dtyfNc2A4XjVupzUVsjWczjKUbwVZNGeEjk9ICdzZQsfDvOENdQs+dPuEATYNxGQx3Mq82q6Jrc1S0HNce7re3+ERFlf/ZWuEWXbHhPGtM/4kUwNlk8KtRis6u+5P36bX0kXewAk7hEIk55fgWBINjDLfxQbqOIrhxjZfdnxvilMYhrLHL/BcVUIjEx/I47POERmTe2FfqIhcokTHWqR9DtFEiO62l/hWZrr2p9MYwvpB7VF25eUzYIkxoNpT/v4S8JtFoqBEcExHwXYx8TdG3X93xgEhz6pz2QwWwNZEG71xHxNE8b9E7ER0CHAyAEkYKXETHhxE0mJm2p9GzvlC8wmH0LtnaihE96gnkfoj/eQEs1Bh3ic36tpUmO1ElwkxpGZWDV0ixHYCACJR5ed3341z1LuCBso4I71A1LtVp0xEwyWDbtBEsfln3jci3IZB/t4YKpsWLtEW03yD6WBUvbsDQppnJCGIId4SKUBYY1MjZ/SFKKpVP4wiweJDeKNGhQJX95/6UYfrYwGgMyzyZZg+hJj6hZl8iDnlVXOTVA+fJUUbUQ7TQr9mFL6zdZSHCAIBAk4CFWBCFcSjMgsgIeOPWKv2OLDxQ8qJEBU5VWWPiHG2SJmEVSu9FQKaU013FYQfU+QwUCRVWCuPhgGeJXgKVfAsUteAVbdMiKqFExUXhCovhWfFhrpfd7zXZjV1V1IhIOFvUv5gGPelJe/eJjkDhtA4Fe0xVt6lhZJPZ8/aiDQBZeIZYhRFZDZ9YQZBYOCQZl6rd31JEFmVFf4tFgkEUQ3vBfq1EyAKNksadyFBmOZWZj5wiIG+dji9YAxfNyhEUdIMNeKvheLnKLOZhkF5liGf8Ch6eoMOVij3Q4kSaSWcfTUPxlX+WoE/gRbCyjlDFhZy5zlMJGa1AZabR4EFV5E/KBZVMZlVvZlV75lXyBiP43KUEClmZ5liiRBapmED4ShVtlVgWElnI5lxlxgcZhNzfVPojCZ3TZl34ZEUKCIJGRGqiyOAuRDQJxDX+5mH8ZmJQymKhjmAmhmDOgmNDAmJgpl45JEIRBJWIjJ4pjR/9RHRGQmaZplpvZigLRDerjGFPiPw0RARFAmadZm0cJBCrCaYgBJNqQMgGiDYkxRAaRDdkgmzOAmLaZnMpJEMZ5mcv5nLYpm3IADdUAndaZmRGQBhVgB19wnd5Jl9RADTP/EAHiQB13wA0zwA3REA3VGQ3f+Z5QGQ3QQAkR0ALBkA9EUAEzEA3qOQPOCZ8AunvcgJ4RAATOgAdhYA9U0AUzUA2IaQ4BGqG7lxqUgA/UMQjYIJ7YMAMbKqEeamnRIJvRsAREEAZEYAfRkA0d+qEsGmnyGaIREA0FcAPUkQ9RAKHRIJ4tuqN9AQ0wyg3YgAOiQB0lgAfmgJ48mqR5QQ3rKZviGQ3MUB2ioACSoKRWmhfGKRCtMKQEUAZhQAAUwAACgQ3rmaPQ8J8C4Z4CoaNX2qZekaX76QPUQQDgcABlYAG/8AJR8J9sSg1dUJ1nuqYIQZtuWqhPAaczwAIpQB0u/7AH8WCnFkACc1AB7SAH7nkNZ0qmA5EN4hmoA0GohhqqTAGn1XAPILAB1CEKdGAPopACitAEgXAHIhACL2AKmsqhnqqmorqrUYGoM0ANRlAC1ZEC+uAC8ZAPTRAAv0ACGuADAYACzZCm+zmtM4AOBwGqLKELgKELBHECIMCtA+Gt4MqrvOqrM3AO7aAGQxoGwmAPCBAKcJAPdzALy2AFeaAHehAAY3AFUtCg/qkTJ1Ad33ACM6AL5UkdCVCwBxsGCXs21GEN5NqmiBqo2NADglAGQyoKG1ACFyACGkAAiqAAAxADKCABGnABwwAAi4ACHqAC0aCY2PoSJxABIDAOYf9ADgsDBLoQBt+Qszvbs+lRDrKZsBFrpYjanvtpDlYQD+wqChprD3BAAjegA/kQqYuAB8sAAnMgAk2gA/0wAvygC4mAEy2Cs9ZgH2cLAmk7A2kbtBFAtEWrpOZaELZQC6JABMLgtAfQBgSQAwogAnqQD3SgAWRgBTHAAr5AAT6gAU2AAYMwCxXwAjZgDFhwnDNQAAXRqdS6uf8qENWpmNZqELp6EGtbutlhuoBRDtbwDTcbt3JbmgpBDaAAAgQwpMKQt62qDwRwBwogBMwABxBwCy2gBlAQCe8QA38gAAqwADqgBxpwA3MwACugBB6wA4G6nv66opY5ECk6rZf6r9b/Wp2C+qsCYQjkwLACgbqoOxA7i4+u+6FzSxDnQA3V0AgwAAcHIArCsAHCwK4pAAH5gAAT4AokUAsu0KoW8AR2kAmYAAqa4AEmYAB5MAEacLILcAOTYLg4AAygcJkMKp7haRDYwKebKhD/CQ2KWQ/lqTKhgUE6y7M+C8MJwCQREAbl8L48Gr/yyw3VqQLwcAMt4LQbcABEIAoHAAGXUAIfQAKCMAh7YA9t4K4kIAFQMAat0AP7SQiS8AIw8Ah54AN6wAdNMAEAMAswQANXcAYMir2VORCaa8Ic6p5lOhA1DGMGWx0Je8cIuzDUMbA4vKM6LBDncJnZoKuGwAE6cMAl/xoGB9ACJVAC9mAPD5APEzAHc3ADzHABCPABBGAGH4ABVvAF4QkN2DAKccAATgAFgkAC86ABd6ABU+wAh/sFkJCmMloQ1VkNnkqdM1APIBACoIG5MyCu3fqtA+HLcfnHEhrI3Eu+Pvqr2NAOf3AHixoGTpsC8WAGl9ACB3AALlAL8+AKI2ACJyAAH1AGwuACeiABI/ACXwAK0joDSxAEdlABUCADPqAGOdAEJFDGfsAOQfAGZ6AJnNAFbByzBYHQymyozCyt1RCeG7qhA5oNVSACBOACbdC/wvAACzAIgXAJ9qAPJUAAH3ADVrAPjjAGFEACe1ALBEDSGiAIDqAM7f9ABe7ZoZQQBTYQAwawyqEgD8EQCLTQBE0wDFCgBLoAComABZCABUzNoASh0B6hrcYsLAVkagu9lcyMpNMKDTqKvdzApDawCAtAB5dwCyUqDEhMAPlQAvpgDyXwAATgA1BgC5qgAprgDDQgAHCA1sJQBiUwBRgQACMQCVywAwOhy0vgAauAAhXw2I+AAXewAFJ7AzdAAlKLDywRsH1MsCfAujzr2aDtxwLB2cmc1ZTW0BCRDSrwCnbwCHfwAPHQBmVgD/lwCfEw0g/QApGcAilAB/rKA90JCy8QAgHgA3TwqHe7vxCAABLgALLwBZfZvYIsBizgBCaQC9ltAk4QrYT/Ot0F4Zyj28xtPN4IMbM127rnewRlOwPr3d4FWw5WhtrYptoOsaHfuwaooAVN8AGyrQ+XANIP8MgEQAcWEMREoA+UPAIMcArXgA1kmgk8AAUKkAMEUM2tGg8EoAGTgAcM0AlIip7mIN68HN5ufOIE8Z+FbMsFYd6Yg7PDxj0xjkdAUA7ledr0HWn23RDXG89S4AxWoAAf8Mj6AAElcAkPMA4YwAsSoABwYAYPAOB7MMCzgAKaIMjRoAJuUAVWIAjycNYlercpYA86kAcjEAM2sAPZgKYpLhCIqaY56uadepniq8twzMZsbBBrO+Mv0z0nlB5qG1g5Pmk73hCf++bu/3mm0IAOS0ADv6ABtWAPvP0AlC7XCvAL82ABl0AAjwzJ9nABI4ADpbADTLqh1YAOmBAEyyABJKADJVDNB6APdOADADAAKGAHQQALENq51ToDI46eZQrC5N3GuGrCbC4QunC+RMvnfL66qxsG4kCwg15phb4Q2Lrm6FCdTxoNWGADIeADbW0Ps50CREAEgG0BFkAAIG0PEJC/RBAPOiACAjACvqAJ1BDW1GAO1XAOnpAEDDACGuDWkBwPIj0FTSAE0bsMSPAKUD0Q0ACkBMGeiX3sA7Hrx7zCnfHe6u037Z0Asinf41AP007tsJsRbOycz+zw6em5XcAEDnADasDJ9v/gAi3gAvZABwjwympwAUKgAAgg4I+86SQwBoaACem56OQbDXGAAmSwvHxABwQQyUfO1opAC1JLAhggAgYwvTbQAz4qn8RuuXPMuXQ8msM82qLd2QSxthJxvjYs7Qkg3+VAtHFvw0RLDqw79yOPFdWuEPjt8Jc53e45yuL9q5bgAS9QBCJQC0iOxHugAGwQCrWAAE1wAXBwCbUAB0Oev41c0rPg4UNg8b5eDUPgATxgBQGAAQigCLfN6fmQAzfQBz6AAHQwBRqgAJMQAkbgAZqwA1SwAzvwp7x+EMgMGlZNKXFJzBIhtOd7w/VgwyAg3/Xw/OUQ/WEg8kJrsz2791b/0fcKIb4GUeL7qaY6eqbIOQOWgALbcAdRL9fqHtg+MAE+kAMYQAGPMAjMasBD2siXABB3FHB4xuPHq2gzFGKbgaWBrWcGBpGYd0eNnmC4zOizV6KEGQJwFmAIpUGDiEdjaNjgpNDlS5gxZc6kWVNhmDAzMoQBMgNImAw7e/7M4FJXmHI2lS5l2tTpU6hRpU6lWtXqVaw1I0TI2lXhtR02rNyAQyffJY61Qk2Ac4nAlAskKET6AWMCHTMl9LmIZ4+ODgx5UnYABioaNZfUenCx4QwVqlVWAvj4YIFAPh3zAFCgAICEhjtN5t1wpW6ZExM0hmDpsnAGwxnQYsuEJjtm/8Kl2WYkTBBm3IwIYbgG3yocuPHjYUB4Zd7c+XPo0aVPp7mVutRrCblBStLBnYgp9h6YMeM2n94HlzRQgOHHwLY+NzDAIfDgQYlLl+ggaILh14hl7CiFkoQQm6EahdAhJJYOYHiEDRIW0IG/GySYJIBibiBhgpIwqKMaFWbDRjeFEopGt9q4YchEEmv7yiXZbDtwtt1C+EYcXY4bTjjidFSoHhDK+aae64o08kgkk1TSJuuWpOkamGCbIZsoYpjEh7IsaCIPss6yr4S/NJigj0lmmSUAETQoaw8FBFEglByaWMAHBQIYwAlnMqGmAIUMZAgUVdphYQwJbmjigjvuYP/mBgGK4AEYMVQRgwoEXYoGGmxirAYaA1+CjZpOS8QNNxSv6c0aXRI6IgxyZiAnjCNWbfXVI+o5YgZdylHOSV579fVXYGdqMliYzElsBsSiiQYdULjwIw8+4FBDBzoIKOEBffC7xIx8crgjBxn+qAIedUjYI5B5Bvnll0FkUIAEDHTYgxkAFhmDnSs8Mae112a7BpQG6niGA8/UhAMBhPdYQBB7XwhiB4V0U1ZZmEA1EZtMaZwBSktnAAEnkJcTJwxrwhBHoZFLPvljkE8m9mWYY5b5qmFhli0aPmerVCFoqunCEltWmGMCHeCYwgILdNDggoNFEAADRRCYQBAtoDj/84ZQRlraBxGeMGAOBXxoQoMFFiABAChMYKABOV5CDEFIouDiEBZYeIeHEfLwIQc9+LhjgkEGQAGPTbKQJQhONkVntxmPjU3G2BLiZyvKidQlgQgSyBFXzDVX6IitEph5dNJLN12hmkvXdMaJFYLbEmciUQeDKe64YZ5aCKiFvvzyUyRODOZwxwR8BhCEhDsQyCGUPOaYw5VBhJAPgT00YIODFWJwZonGRU2IoWsgaeadFTjIA4Mm7rhADwTg2GOCOUCoIJIXXmDnHUP4hYlimHo+/X8ABhCAqXsZqFwnqikxLhrc4EaJdnOpGUACDA6QAQb4QIdaTAAAQtjbhDQg/wMAaEANGgjACnxhCxt4gAV+mMMNyIYos5UJbAu4wAvnIQQo4KEVzcDCpVzEMWQpBBSa0MQQNBGFIMTAACIIBR/45i2LXOAGk4CBLD4BjBrUABjAYEISdhZEAYZRjGPkFQFfJhtsmMhTLnpRz/zEM2h0gRNiEYEOcuADIQRACE2ohQXuII8pXMIjBHgfGayAAln8wBmHcMIIfuFC5TVBAZsZwQgmYagp8EcIWrCCEX5AhSjtD0ZyBEY7SsEFZ/DAARRIU/sQ9ko4zAMSlcINdY6gK54o5AQj+0ZPcPUqVuWoHiMj2ebIeExkFsmMyaQJQ1Twiiq4wxWfoQUC8kEANf/MQwN6yMEHCGAPCNyHDh8QiARGUAF21MEZP0DBEpuQAyFUUZEMMAEH+rC0O1RPAepAgS2+sIPF9alEDOlUjGJzjSUQ4xM/YChDD2EDIL4EcjKCEuQat7OICmscEfhGGESnqyO8SnTj4JFvPGaNCIzsN8xkaUu9skyXvqSWPDPHDprBgBg8QgMIYEYfXDGHSfxCBFiy1iVqwYeyqc8HMjCAA5wQAxb6QAfy8IFgrLCJVeAABy9YgQA+AwcdCGQSI8ADA97QMwQl5ByMA+PETKQs2VzDoLLRjYE2pTFRztQlHCORsIRzApPNQFYz6KgujvKNl3zMGjFlbGOhAtPGWvT/gTPgEzS8wIABsGEC85BHWDHwCBSYIAQiaAJgfmGASYhgsxhYgAYwoIBfPGISfZjASOYxQgWkhAcdaEUdTAAFAGBAA3xQ2jCGQYJh3MAAFeiAJKgAjcVxAxrGkuxLsqEs2DAEGm7d2It0VqlQKUVXQCKZx8qLk5vkxCUkFZ1j3fteYXEFvhKtDRsVYixLHUYFlrABVynQBKlx0gGLKNQ8ajgaGQjiF08QxA0WcIeR3IANFPjDCtTRhwWoIQcaIIEEFlGBF7DgELIYgwEEMIlJSEABd5hCWCs0CwPE+A8v4IIUZCSbu7qkGiS6lDlqY6xKXZeterWJLthr3sUqdgbo/12yenVi0vlGGb6Qjax9qaGbFkFDuudQ4zlG4Qx1ZKC1fOCDFGMrARG8awJ84I8C5vAIoVJEAzcYwAsc8QMGRMIKLVxAaeOihRU4wgNDoIZsdnAFFDwCw2Ur2wUQYNo/LKMCFUABvl4RIh0/kGJQyrH/8FpkcXyjvYd9ck9GdgLAuoykvpRyqxtLZSmfKIEdq001QLWpLmiiFD+gAQx+MQE1qOECCxABFGKghDEI4AaJGltrp4CfeZHAFVAAcSsY8IMYLEJvCFBDf9iw3E9mQ2IJAUUNGIEPKNwzEBdAlLzuoAEhUHgVusAC5DgW14jRhMgzKBnIFvuTUA9JsEgBaf9yQOZqhLcU1vNlI48ZuFfbcDrIM1ABJ4ChBAcM4g46UEAINiGLOrRiHxWAQqHkkQ9FkCAPItiQD0JzAwo8gwZVYAQOePAHASgAA3dw3wQE4IdVMGAI1UAQglTghSV4wQuc8AANQsBnnu8hFBjAAJ0MsIJV/KAxKeyEboCsFMxRrr2gywCRdLmVEygEBJRbeMLdTrq2s7S6sz5QbaCUEIv2FY5shIYYXkABDOxhCnpYwA3mMAITVIEBDLACBuK0gAkIYQ4UkAAJ3jlsDAxCCzDwxTuujbc8hEJewxYBe/jxikZ0t1+ZggYVgPEDIyziCBTQglflcbA9yMuJGGADPxn/QIwd7AAUoJjJNTJKnQxYwxrj2NwJxrH8tM/A+dB/Cebefn2sxB37UdENQoFBvkfkYRga2AMcfLCIF9ThBTDQgggwwLTq5UEAFHCFu0iwtxz4xwExUEYdfiALP3gEIdi5TFoACbCCGPgBQ4CEGfCxBsKUIEIMUHiFK2AoBngHFDiTz0CAwdODvmkCEcCeZ/CDZ1CFgMqv16gvTlEgrCAZXVksXfiGb+CobzAsGaTBHAEBknKy7evBp9A+H3SKiuqZ2ogGTHiFT7CBEViAD7iAeIOBF8ABBrgCZbACQZgAPQiEJugPN+MAClCADLsAH5iACasiHGiMd4CBALCgPdAD/0RJFGLTggpgADEIkdYoEO+agS1AIgawAT9skEkgAUTJAVrAgSA6h4cLr0z7NNcxEEWUCctBr974DfaaxBk4sgTotyBsrG3QBm1gNYXIgmkYxWnoCWkIh1EExeqQr03MCimRCVmrhCCAAQEQgXnIAQT4GwGAAR7gBwZoBVlYgVnog/dTHg3ogzkQAEHIg3eRkAuYgEn4AyOoAjyzgwpwgCIYgUXgMx2Yghy4gc2LAXpoBkyDkrVCjAJQoxLBAkwAhVGAID5BkbWiL1Fiq6lQsh4hjnxEjiZrxZjqhgaYAW3IgpnYBm+YAWmQBqcAQn9ciplCEYN6oALQBF2wAdlRgP+dSpQ5k4AsAAZAAARS6IAiGAQfEDZEmQcFmISvcbA9kBOumYM/eIdXYEA9hAVJ4IEBkIGS9BZ5IIEA+IMOaAZAgMgGWqAGAiPZeBt8o40huwpdCLW028fi2BFWZLKGTCZRVAhpKIqYaIBwQAKE9AYQCMilYMirVArb+JQZkS7p8h8D2S8biAEHMIA8wEUR+ANBwwKFwAIuWD+63LlcXIA8koAACAAZiBAE4IN5CADEiwEjcAInkAUWYAQ7WAYoYINbhIP8Y8zBQYFlSMAGsLEuaA2i45m7U72YKM3usUemOAEZjD5LrESTOrL0OstkAoFp0EqFjAlpOMgZ2AZpAIL/cFgOpTBL25yJtOQGY2md/omNr3MJ3RgCJZiDC9CwbJKBRaCBdqCC1qipGpAFdzifGoIhN1MHMgibCSCBG5iALZSHJvBJK6ABW7g2drCCQbgB44oQ9cmBHJgQBLiA3FqGgwAF1QSiZKklxOi+lzg+mXBNk1G+E4jBGZRBG5zQGvSY4BAO4jzOMMJN3ezKbgDLlziC3HwJJEjIhKQclOLQrJAR7EpKmOAT/rEul8ACYGABPBiAyssBsAJB7HEEYAiRbMCEL0A24ALMCPggLdi/DmCBKjACK5gEjNwDWpgACRgAPGAHeIAHWbADrXoBJ6iAFfCDIiADTIIDWsiDWCGD/9J4hg7gAi+4L4FaxKY4AeW707SbvnGIPj2FzTu1hvaq0+ezhltRiOSzBq7UCeVL1ENNVBatCq9UCG8o1JfozZg4AnCAiRNFURVlxUd1ilfsmMdhHO0Co4LimRS0qO2wBC7oABYSxG9RGCEYgEhoB01oDXQYhSR4BweovESxCAyQATYoBvUsEzJwvybwAR/oswtIH2n7gx+IhSWAEkrQBEnIhWcYQRi4wkQJtsITgmIQAQAIgVXwgFc411fghEf8lQgoh35bjuAgh1fZEXk1jnid10+1imnIgCMIh4CUhhJtgBB1CW/YhiPQBkrVCk/NV9LZgVJ4BzwYAQkANlxAgP85owAr4IEg0EvoqoFDMIE9G4RBAIAKyr1kvQHN+4MYcNKIFQQLgoNUyLxFgIEVWAEYMIIg8ATZUIHvc4IiEACRbZd4aTEyKzMrXYRleAcmwAIVoAQVeNqnzTcwegnwkikEEtXY+KKYMLuf4IrxqgekmIGvDduxTQqGNS+QCYNw2AalaIAMkAYRBQG2nYEsmFuFQIK3JciyXNizJZ1NMQcsiIIvIJ9apCHisp1HcAJUsARQCJX9QoUYGIEAiJBDyQErdYAOaKhVoMU+UADP3bmNkyIDcIIriIMdSAgsiwZdddJVkAUTmAWdRJTym4IPoF1cqAUEuAL84p/SnDtkcUT/A4oJvZuJklkOJkOv482J5O1bEOiGUdSGbggHgFQS4+zbXkFdlwAFQ+A1GKCAZcskecAAhikrTeAfKGG6KjiBEBiEeSiaC5iHPtg8HvCAJbA1TggCJViBRyCBHMikv9EQ9WRMI/gE4uuuhIAFLmABIzABPECBLPBMfAClOVXHx8ExxOAYBo2cfYMJS+zHflze5T3bbQhY5diVJKle6zWSHGMc2+CxA6o4XbCFLHiEQWBPHn0fClgGHACGJZARbOgCU/CA+pwDEaAhHVAaNnCHdwAGKlABaACLGiAfA6CAJ3iCCmoCPqgdEuAAtSEFYoiCIeAEjvUxH3Mg1SM6oqul/1F5DSKjBgSxrwwmqZUS2zCoB7BNirKlYzsO27OVhm4gyI8JZOrl2xQmlje2DSKsYC3jBmXJmY6RAjGwAWvkAAXoXzh4RgAwgGVohShQQQTpATBgAbmUgFDgwBxYABmggEVY5QGAgTqIgxU5BQ+ohwrQggnYg1rQgWDIvT24gGHIZA7gAAMYAR74Aiw4B9vgrgOhpcPok+DdYAYlqW9Qvp64V3tlFXy1ZkLmUCRI2z8OA71FEhQuZCSxqFGJBgY1EB4zhyVggjpYBnVwhQkADYQZBCNACIoBr2zQBA+I3EJhtHl4sAlZgEFwABb4Ak4IEWroBAboADuwA1moAA7YBv/WWoB5SB8P6gMrcAIjeEwWMFe9dJuZ4B/cyGAg+FNfalSXUGlDXdQUBgFwmAZvyIIG2FBx3mZy9pXhdZtKsTWXCCgfK+kKRqDaUIE4uAIWQAEASAM4wAA7eYHFY4BBCxWfSYQt2IIlmJvIzQMAm4JU0AAFiDkG0IRrCFUcw4IasIVIKIIQIq49KL9L1oCAnpNiOIJnOITFs4Eg8IJ1kK6myGDp0AVrYLVdQor2KuxyOOyRSeycholxbuznqK/9+R76QqORRtWIhM4Z4AY3cAIKIEnXojpamIL3oaJyDWnXcIkt4K/ITa15CISDEUwuxgEu2KJSsATEcFxQWIJXYAD/KNUC4NaCQhGNCag6XGwCIeAAFHgHD/iCdvCAZoCYmNAf1IwOIOioxcIVGbylOpZQ7q4H7x4vMmqAaUhbm75pyG5FaNiBGviCLygFFUIBKNgj/+2DZ4gFTPuKtnSJXPuEOoiEXh3aPcgBPtCwwpOA+RMADjACSTCMjqklTdCiUvgCG2AHGBgaHtWBAtcwMRyESRAA4WHa7sKYGVgri4KcGU2MR1TEBCCp7MZHDS0v4oBxnDadnUDFUQznE67x9EY4gyrNooOGLUgCFnAAAJAHcsqtCrCDf4JF5qQCD3iHKqgCOzCCEWClCZiAYcAAWiianpwEKxgDMV/yf+oUPOSG/wmkzA5wBFmICM8obgkoBLehBuyFI6lVPb06UFJB1Y2RDSWbAbD9hiMgqQgI9EEXDkMndDLaCbLslcfu8ffacyihBkuogmegAP6FAz4IBFTmABqIagZggh3ogp3BMQeiBhVIBBUYhVdwhlWoAAPASPWRB1z0QHh7BCOwgbxOAgbcFG74oi5IhC6Qg+zYaQSJKBKpFIvKbdhgTpkIgfJCHRkcGdGhQWoHjmn3KDJCgoH1lUeHdPeSNe/qqyX4AjsYg5LbuSM+4g9AgDh8hlVoB4hpZNrQsqIGheDbgV2ohxMgMOTh5T34ADgA6yOAAXbwgB2YK5g4h3PABgOhGBJ/kf86l6jZgJxKiag/NwrxVohcqWON9/gxYpmQcZJvB3eXwhnbQJDwAiIg544gePlPOAQacIBLyif+PMZFYAcw6AHSVKDWeeK9qlFj8ACiD4If4IHuVQAA8xZ4cwWnl4AiYIEGEL7gGwVKeMVC8zHJyqh1hQkg4CVrSDtysIaOaq+xL3uFOHttJyNRJMVp0HH0NvmrBCKOeePuMnPWhIkdMPcKILAJ6KZYSu4VQAHPNAEW4HU+r8daexFIAIYqqIAQUDHPVYD21XQP1IM7qCpqI/xlUBtYgAl9niwXDnqOCbutIBLMKTuXSH2zmwHWB/eSl3sy8t18e6vuko0ThIkW8ev/r4CE3o4BK6g8H6C6nfNAHUBuctWFJsbsaoCNO6SYi8EGdGB4QjAE3+5MFCgCeR7+qiOu/kQYOABBKJAFYOAEBkRkyVbKUQX6hNsGIGh7UoT7I4l92W8pFaSpg5qRBKX4iAOIGdFmELw2AxpCgtCuSRmFBdQQVJHGhAgwT8cHNfP6PHr2jgGDVqgsGSRIbaBBagRNrhTYshqWmKPc1HECw4oDByMk+FDzAUGTGxSOaPlFwcoLkEoZ/NBlToqKki2nUq1qtSqIEysbbJN2pOURadsarAwrDcnVtGqlTQMR5u1bEGrn0lUbIULdvHr38u3r9y/gwIIHEy48A4suBjHc/wUg0SRHDj189OxBsEDGiHcNOKkgmI3gwJUIoQ0MrbA0VSyvbMh6tggEiCKPFCyAnOPOncg6HmG7pkKly4Qrgc+Q2vdEhDDWCDbQFsY5EILenj+X/rxbGLmGtxe+y/07+PDix5MvL7jaDHOcruDA8cMWj2chACxAUIuPDxFacuZE4YyKQZ/NgN5KnyW00AzAUYNeQtxEM5A5XgTRXnuttIIDEypBU801pT2IzQwgjgbNQST2Zc1by82QQRjRhRMGEllUN902M7zVgDRhSPMdCODUaN5c3gE5JJFFGnkkkajNICBxCEFCjA1G7KTADTcoMIw8OSCgxgQBOKBEB+848v9DDVSQiKCABs6ADokEDgdaNCCWlM2DoBUnnIADTmXiXm6pmGN002TnljYz5LjjdOFoow1Z3LkVRjfeZIHkSkJSeimmmWqaqXGggeiZQNFQQ1wXKlCyRhI4xAADBzJooAMCscIBxwUYDMIBHjbUUIohxlBiGp0DdZGgQnwW2+ZUdPKoHEFIvDUNdnK9qM2LO7LoXDeTfodEBuDEdamlm4o7LrnlDmaiiQPlaZCHSxILXGmYEPMKvcCwUIE6AJBwgQYY+BsIAhqwscgmzgBjSS9iDAFKgQhxSBCIoWWj4EF6MiiYnytlIdaLzWbQbXYyTrNiGCNvm4Gg2YGLl7ktu/z/MsxWVUMgNgMRdxCb0JyzIYGftYtNQonEYoNS75hQBE96fKDDHXo4vUCXHEAxtR+taKISNcgW5O5K7Ha61wksigMCWdv02CJBR4CQY6HOdnPEdN4sC6k32lEabsx56733dl+rVeeACHFTFbyhjcqSni8hdDg6p0hShRG5GOGEA1rk4cMCC8xTGwI5zONDKPNM4EoR7HjQSQGihRoYinDJ9VY4OxIkaKSNbvNi7Tz6uCnefPv+O/B+CdeSaSoBTmyJb4o2PGrFJ+8uncPPAAkkoIACizMv4OGECU6gsMggryKgB+aZLyDEIzFI0gz7cXR2TvAu9x4//fXbTz9qKljy/wMeIVBAgRYo0JgmLMAHmIPVAhQgggUCYBEmYMArKlEsO5FrG0DIwjQymEFtIWl+9/sgCENIrjythEALOogUanCFKwThCh1wghWOAABBCAIAPsgB02olCAAKYAXDIhdbHuW6lYmwiEY8IrmkMpqtEW8g2EAH9mJgBS0AYAIY8MEjSIjEwXhwi178Ihj3cg1jIW5mBaqKm1J3PEhUAgsqMA25evSjTHUxjHa8Ix4P4qaqfOYzJ6QKetx0M4N8qlyPihQHO8iyPDKykWAkY/KgIaLEGcdDx6tY3rjlLZXdbZGO/CQo8UgiqTTpedFIl7pexq2U2e1IdQwlLGMZv9Asjv8ge0Rc4qhhkAO17JB1w9QrZSnMYRLTSHLknSeLqcxlMlM8SDgLMpspzWlSEzAyaiURq6nNbXJzKs2RBmzIls1ukrOczBTitzppznWyU5bPlAY8oanOdtKznnhsQDhh0yhF2rOf/kQiOjnJz38StKD1eydbtIGWeRq0oQ71nVsWOtCHUrSi48InbKaDzSIF06Ie/ah40NmNfboymSA9KUrBg1B5MjSlLn3pYPDZgI1JdKIwvSlO9XIEGGGnUOPMKVCDWpUg6igMiTRSR4WqVJRKQxs5aoBAS7rUqQZVRmEIh4yOylGTUrWrKEVZFroFTK56taxm5U5Sz6rWtdYlrWz/fWtFG5ABlq6kK/DUTlc2ahW3wrWvBp1GBo4QDpLOALCwQYs06qYNvVKFr359LDPZokGtUqUB4ZDOV1rSlpYodAYWpItjIStaYW4DLulMCwhMBs+pTEMb0/hRGAiSWtCSdbS2jaxR9TJbQ8luJWhBgja+EtsZ7Na38ZTGXSJgjdretrnDlBFh1YJBgkgjA1ZZbTdkC46prDS5y3UueJmZhW64doN0GekMtDEpEPxIO9P4Cji+AgTrBom54b1vIwPK2KlsY1HRMZTJwOFfgmShvNGtSmjxq+CHJnjBDgYhV7xCR/s+uMJGbA5c5PZTC3N4ixnohtlyRNkhNbjDJs4b/1tWElWkUvjELv7dTr3BljAcmMQtfjGO9Tadt8zRpjn+cfCQIM6xArnIfGPvSunKYiMzOWZENe1+zVPiJlN5PDHCaDhrDKQpV7nLKpUdjrQs5Rt7uczlcQtzVrxVM7OZUikz7Yi3TOY207kwQHCOBnvr4zrzWTwYFDORuNznQavFLVEO9JwJrWi9BDeai340YfS7YUhTmi8Y1OA04jzmSnPafoLuNKGz4I1pAAHQ5fk0qPmMBOy8xactTTWshxoOtBh60rG+taF8CtVDkwfVuC6zjMIBreza+tewvt1zNL1pYzNbXL5uNpWB0FNlnzrR0K5zaYXdDfS++tqcbiqB1f+MaG/DujkqrumSyQ3qgJ52zeru9KUxnek9v7ve33m2vV+MbPUSOd+Qdou2uU1vf/MZ3DPYdbEJTucMzJq4ue22wuu8ari4euARb7OoSW3qXlv74kB+Jroh7nEzX9PRI6/zN7Oc8JNXWdIiZ3mVkxzyccO85mnBt82dm4UXzXvCOS+zc56lKZz/3LZhsC6Lht7xoj/46CBgkT5XzvQXm3aIL5/6i+Vt3qtjnc9ZAMd7qYKy+BJkGxr8r12W3vUmY9Wy6M5AA1aNWD3Xd+2QBi5BgNBjzcpltXkhut0rvFu/cxe9CZ3GzBur9sD/ePB0P3ijWyLWlnT3Lt9lPKHxPgP/vXtTG3snrsmMG0/vLh7zOG57wz/bnB5nAAkNAAd90276UIM9s5+N92tncASwx172s7844H8/6OALn8/ELz6dj498Nit/+WVuvvO7DP3oU3n61Gey9a9f5Oxr/8fc7z6Ovw9+F4t//CYuv/k5jP70V3j97Hew+9+v4PjL/770rz9474//5up//7btv/+JFgAG4GMNIAH2lQEe4FsloAKuFQM24Fk9IASWlQROYFdVoAVOFQZmoFJtIAcGlQd+YE6FoAjeFAmW4EudIAqmlAqu4Em1oAt+FAzGoEXNIA1SlA3eoEPloA4aFA/2IEH9IBD6kxAOoT0VoRHSExImITst/yETmpMTPiE5RaEUchMVVqE2XSEWilAWMFYXUt6Q1d0WlhUQgMOdUUUZnqHuOVXDieEYdhWxgQM2xaFczNtc0dYbdpXjtcQeDldx3Vzp5aFD7eFK9KFshR4gCuJUEeIhUteO+CEiOlzVTSIlVqIlXiImZqImbiIndqInfiIohqIojiIplqIpniIqpmInghAdzkCMEEQr2uHjIVgg9omKEAkI3KKcuduQ5CIvAslw4aIuLhsSpaFPpdjmmaFPHQEbJt5UWJ8vFkk02tgvmsc07iKRBGMvDmO1fdEXNgsHfWOzhKHvAck1miM3clw1nlk6jkf2aSM6rmM1QWM7jsc5dv8jzW2jPI4HPFpjPYaHFgJkLerWP4bHPapjPsZjQppHP7LjPk4TPRpTQd7bQOpF9h2kO1ZkXjQkeWCkeAQkeESkNE4kWmlkW5kkXXikQBYJR9ojSW4HSH5HPdQDkeiCVhSJTRbJTOokTdbkTQ7JTuKikeQkkQSlIh4lUvqVLliDNYjDT4rHESRApYiDOJCDLoBHPYhDU0rlSugCOTzldpADVaJdBjAlrwXGCajIEWilU4aHLgBBUxLECWilNVzld6QlU1pDdEQAVVolQPalXc6AV4KlYcClOMReWVrDWfJFBPwkEFAlV65lUxImMWVAdBwBOZAHiizSTY5D7xlGPVz/ZT18Q0uIQzks5nEQxNjMQAJkJnlk5XB9w1ViZnh4ZkuQg3x95nckwDjMQGfqJmHMZd7Fnmmi5l4cgYqUg1a0JnjMJScJpy6Q5gzIpu65JjORg3ZIZ0aiIUpOhS4E4zgkgGKORz2Uw1WODQj0JHgs5QkMVzlYF2+u5zfUAwjYpXSCgHWuZzmo5+Z15wyMplyEJ0GE53hSJEF4B3ryp2EUaAawjDVoxXuyZm82U4G2pGHgjS7spzv+l3cUKHgkgDiwTBiMA18CJ2GMpx+WA1UqaGGAQDmQ6GnaiGy95F9EwIQSRIayaHdQpYp0qHHqljjogi6QqI2Q6GF+R4EKyXi6/+iKSlOF4iOOigNXhgeIXuVcwsZhBiZ4COhwRSd4ZMA4wEZ2ZOhVliV4RCNt+iGN9kV0qqcuSKlBLseQNiZ6ZumHWgM5kIN1dal2Lqh2KGl9mueKrGkjAYFUZiWUvumUfmiQEkQ9JNeL6mhh4oWGeimPJFcYRAAIiIOKYWU5pE1migNNJgDa3duNKupH/lcuPupdROp4aGil9mlhFOgRTKh5bmqnNtOmggCR2uM4hKlqhmlWgMcRfIPa1GdLeOh28CoIJICGiievlip4DFeIRmttAsGmfoWN7qpbzudKiIOwUuZglGcCZGuy/qhu4ed/Qes4SKtg6MKmZoBWZOgRmP/pDFRru04TCETAogqkkCQXv54pwPJnAkjqYBxBBGSAeu5rZrkjjiZABDTshzbmSkAsuurFCSwqwPYraDYoWBYslVJsIUYsd7BqwP5nwtqlLkCsxCaly74szMaszM4szdaszd4szuaszu4sz/YsqD3qxeJogwYtWg6rVezrTGqqeACtz/LFW0hldGZqXoinVriF2qGINZAqoRIEi4TBTbYOs4CtOGTWCZQDXHwqgmVHWnKsYaxt0+5FipCM1PpmwvZkViAH1I7D0Z2A1SKsdtRDg4LsSgDuXWhFe44NbKYnQUBsAlipXJyAlt7rW/zXCejtOGgFigSWOITBV3yD1/r/5jDqQoPqbX0qLuGKrOhmAGwIaXr6bVnwq10SbsHCa08irNK+7VWEgeeWrefiRQKEgWl+g1boLlxoKlwoJvHGBQh8QzlYwzd4UgQ0r+fmYvEW75t+A4pwavZGVXvqrXYmh4OqTHt+queGp4K+qXKYrZjiRfQ675hurjWor1t47rforfMG6fJKr/HiBTkox+bibu425eYCgdSWw6fWw4jaSJC253Ikh1y4RW+yyF2MaHryZz2Ejd7iBbPMAIosbqbip9eiiNpoKQGfQP9mFvgSBIpox1uwJv0mcMVKrQNb7X9icKZK8AzMcAJLMAL35u9CLAXPJA2HQTmUq8HirnL8/y6JSu0GM0sTN7DK0LDVLiVcLKrekkMG24iKdHAOA29epmVD9i6KuGYKc7DKfKd06sIRAMH0VorK6DBeXHEGO3AXr6/D7e8dU/HT0nAC0G+jAjBVKIcuNGYKi4NsukV0PHEXHwG8Sm3ffsXv6iLwsiYTb3EYCOlOjcNs1gMXt8Tv0qXn0mQZr/CQSq01fEWGhoF6/m4cDwoTcyors/IMkK4UZ+p3QvER5DIlIy/7zuQKA3Ig32IKn4AfX6UiPwov33HX6u5T6i3xanCPvgVeEDBcgDFV9G9P6m1ZHq8Zw8V/me1bfEO/bi7x2rEz9y76lnMt+y5cRDBcCC8Nv/CNAv9zIf4kfS7sTxqt0d4z7Qqm6cIGVpQuTRqtbyKrPyMr31IFQDvq3YaT4YaTltInY2UFfbKu3Qp0QYNwaCpuP/uzeko0jioucYk0Pf+TablrSQuVREduSre0S780TMe0TM80Tde0Td80Tue0Tu80T/e0T/80ULugkB1WeWDQ5xGGcm2ty1BtVcAlYLitkejlXwypVPsFvNqNRAM0365uS6xs4VqF21Z1eIi1WjC1WkB1XxC0V0sswjbu60aAjno1XL+uwmoMPGnLUBN1keRIhoFHjsjFMxFtWvwuOfjnkSBtVUAsYNCwlHHSBveF3hoqHe8FNaOwaXXz5MrlN2Cv+mL/hQyz7YWCdmOJ21QwLV8gxwaj7wAPKPBO8iwDbxs/4zvTJAEb8jegxU6Fw4t8BV+/xSySx6FYllGtTRaYje7xXtmB0zR4Q6OMne2dheoKijdsQ2BzLZ6icAKUpSb75jjgab9ipjVYFydTcEvwa1myzCBfN3E1ZrkOql7SJHjTF8N2d2YlJhDwJ3iHKdMyLb8iB3I8cGMiLcKOagR4Ncqu8eWZcGHPtUK3CH3r3lxDrJbyq3IlgILbZVni5uJGbJ6ewHhzaXhbw3ZXrne3RD10t17Cq9lqKooI6ImLeNWyNzaB841mjBnXZxaLcNo8JVX3L/tKJX4yJX1R9V3IhXmL/ziGqzd3l3jAviVTJpMJM2V27LemAm1UMi3LdviB6uXJrkTrqAiLRIfZXvAk661UvsUgzy0f0qSPozHJRIdzZIGMFEqO1A0IOKN4HEphZUeOYIdXhIEZoo10E/B2EXAZcu6eYwfDPQe26sjmtcgJ2wjwmu04IHCIjkN+7hQ5GHrZAu+i6i4Q9K91GTJfem1y9G5k8yUIaLqhdzH2vsWJt4iqx3BhF/Y62wj9InBmYrMD/651Ma8ZS6L7FuxmK5e4uUU5lHrGHt10oq2KwTYRb25vGnqko4iKEnGni0MiT/qIWrqN5mcu2uiI9nESm622j2aIbrarq7nuHZ3n2qWN//8yApOm9+qpgg5wFjOLjRq7VOI7E3P7tEM653o7pmvxDJTD8wKBs/9nsa/wOs+vctCwtW/upxJwYT92IW5wckSHw09yCuutiv5xVZh5xrjFyLSwpBvKVU2DNGwcd+QIqV2VymeWt5CFNmSXoBCEc8wAeR0coO95o/y1w+1IN3Dqd2Yms9zy+M6XlvbveZLmZKuYnCoHA4v7BGdW/9r6DDj9vUK9yhAwCGv9SohNwN66a5txdEJxfX6DU5pybNHwTk2wVEY9H0pt3Efn2DJ7S+i7yjAL2wtmGGQmF//vZCc91RMx008Fb2JtsNcxyZDoCidHy752rHNlvDt2bJVyOP//ZPfescGLrlh+cAIP8dQvx98f/dJngDGb/jeQKH+yyNy7Ml5YLSLLlturZmwRMUFgvO2rCAIrRxub+4qTzOYKr6Q/9uE63HKYfMqnvAVJw4ugNHCvvDcgFifl/J5nf/aXzO6PDPar/AM7uiIrMnJ6Lqd6+XB1MN0bvBb7SXLtKycNKTkjZ/rHFh07sPy/hcQae4sABIgwEWYIJBjG2gyFCcKMC5NgRoQwIGY4dFhvhrUwBQdyjCCRIkiFIxUa9FgxjLgwukjOQBhxosuEL2Vm3GgTJsWaNY9Y+5aSJJAwQAQm1KhQpMRxHyPUE0lSVxiE5YByTGiTYr0w5WawLKiR/2DJjiZfivuWIcNAk2SvvqT5sudPcTVPkKP6DSPSmCDXqu148ijOt1dJFh15IkICqgrroSU38cTLtAlBVD6x8Js4lpHnHgkDbka3MA0ahOlWOMy0lqtZt3bdWloYaSRj60wrzTPoaRPTggYX5kjsDDN2j4wtrbLsGb+PSBw+GMS4IyC+fSOZNoJncjlbpoweZnj1BCAyJHg6LgMIoWgHaucOEr168CMzEGVILvK3CGB3dpX6jSWRPKPpqL6yC4McEDSi6BvCOBoHBJUuEwjB1V4S6aXHmpsvsKMkioAi6KSjzrqRNDqCIaNu+hAEzqYDArGYrmvoI6pOaMw7mzI4Qv+lIzIaUSWduvqmHPkOmqlIoSKIKsmOBptBQ+eim666mqwZT6PLxEpwwfz28ysskzrcqMcUWzohLXFAYGm8x4BQaDqJ5tLqmyMsWi2tb4BIbAaqjnhsmxm8kS02b5bzRppwlHuN0UZdO442GWcAQjRwGiAuDEWnubSB37p5E9ORkFAUHIFma+AxPRUarB6VUtJyJCB+IidASVetbiiF6pKqnA11iuAnVSedtdaQJgI2DGHhpApBloQqx6EjSbqTuz4fUqjAsToSKjPIrh1JoGAhUshPCxPCMCFdUgV1zBnqoWo7Vl0VB9YZTvhJIxUZg3cGHqUSxylbZ1DJK6H2lEr/Kpv+9XGGDOZleKQE8HUyIYYQ6kjii6WtSd1k32z138sy5HXcWJMNctKtojUJsJuOOoGqfFvSCOEQtwrLpm/G8UqxZHdejWapEjpBJWE7lcrSGaQR7VNHnX4a6paKi5rqqlujyeqstd6aPhD81SUDrhplkuuyzT4b7YUq0zDttguLM1e35Z677anpPhvru/WOmllxfMzOUez2Hpxwqh26uXCuLdbZq8QdfxzyyCWfnPLKLb8c88w135zzzj3/HPTQRR/98QSsqdcaUEmP+oQ1u2qxNdPrbTT1lnQxL4LZJa+dNdndPuHK1YUfnninn1rVweJfW9Cq1kBoCqdG8763/0GqQkyepMDozpuk49Fm2VHulR+ffLSBsMaacSbMbhxrGK4LfVsR2o8gxCh6vl7TrSHnfXLI+Qgj9Wif+s7kPwA6xWsQOUH7gMCS52HkgU45wvkgtryYGOZ5dnJfQZoCAqqAqCDkSJ1X9uMQB50ITidgSDk6KEJrDMeDagnhCO3VPnKUzF3to6F5/oQfpKSPe/BjngDTdxnzKOhnM9DfcCKSgAykjyW6sGFHdLEf/rkrO+cjyAqhFyv0ERB/45lhA5WIviv2S4QQKt8aR8dCWXFFIg2SSj3qUZ0vCcklenpMBrSyncfkRSHk2BNV6GjHBdVRHMAqEWMMOZFwIQSRwP+aS1IceTMJ0e6CF0oWzQIGgoxdSTtC2Y4oJeIgh3yDHHxMWYMQsxSNJOCTCQglgrSSyHFsB1zWiMCdNFIOlXCFlHmro34OmRlF2mQcokwZEPbokpRQZRwDG0q0BqYfCVHIJw/h1ulI4kYiweQnBxJkhQQZAULeJwL/Y+M6P6eebHJHKOS5lvdeEhUV9bElTrGG9SQCEZCkxZWS6mdOBAKqtPhIKDEyVnII4hmcUegv2MrkuWIST5EE5jE12sg3+9OVwyVLZFcBGzlUQhCMDsScYYhMOYCQgcYtpH0vCYxKZsDRvKXFn7yh0YJmulEWlpJjCIlMNA0SGV2urCMO7Wj/Sc73E5gwLKMpxeI+dZpIHLITq5fTjr/ec6y9yK8tFUsJcEiCyAQ45HlfTetSADgSSjJULwt9q4FGoovKgACQWGneWy/qMpR+ZCd584qCKKYQs7DHpH5lSkOzOReTEUWmfg2sg/hKIwC262YfgQh0tAWi+X0ErmxpyVZp+hSwMMWsaI0IzVSXVddO7kNHWMxcEURYPHrHIcPRRbBaIhAuTUQ7tnWRemAV3AWxLDIJKod10pTS5EDokoySSIIy2tW0UuREaKqtnWyCorylbzoo2wpex6uk7mo3QXaaEomyBxwztetEZgJXbbuUkhcBT6d+VIt5JrvbJhFEPOQZT2dd/1IkQMZ2tjJKS3ohRF/e2KdCr5Vw5HTxywQvdJUoG0mypKI6h7RWIadEGbdQ5q+U5JXElcRZz+jVFY2I4zHJuctVXSMrj8U1JwL6yXBSWiGYXcxBDluYXlRqMf4cYccRYRY5QPYqktwLyNF7Wcy4l2KKmBhgvURIFMcRrI295JMd2dVWpkNgiai0rhbeyPF6vB0RA3fJL53wnMenkry6Jj1fY1SeCVY18NE5ctoD9KAJvTmjOq1vFWxNoq3250IXTtCPlvSkKV1pS18a05nW9KY53ekZNCBQq8kCOKbBsAZ4Yxqz8fSqWd1qdm5jGqpZTTiy0IBwIEFQwwFHqF3da/9f//pzWciArEmCBG0oBAiBCseljmAoYD8b2tGOHAiIDS5ZS2M2N6G2tLndbW+3bdu9vXa2S1LtGWQh1rFGH/pKRg1oUGMG2MDGt+ld72eHu9jHnpSyme3skTTgrgFfygwKMINzzJsa8Ia3vRnecE7jexugorWtce0NXfOaNdWARkQIAoqNRwPe2Pi4w0leckkDId1ZmEHEFTLqUivk1Kl2FDQ+coZ3LIEbCI9GNKphcp//PNrRQEoEuNCEEoBg4wpJOtCZ3vRV77waHwHGGOggCg0wId7RyMbSnd51r1ea5hFIwgsI0IIN6KAda6BGNLjxdbe/fdA9/0gDTECEMBD/QAu12AAzsuAJuP8d8OyERjSw8RFdtMICYRDGDWBwgTK0QBBmyMcC3OEBG8DCHArBxtpncA1uRAMag58BNKpB+NDPQOgKcffoqTHvkUBj3qEXeuo1jvrA3x73jUo4xy1RCieUwR4AEEIpktABJzThASlIhQZEcQAIqAMKUIgBE1KPjZ3PAN5CXzjCs7/z1KOjJdcYycJbI/7cnz/3IOc4JI4vgxKEYAChGAHo204FTezjEcW4gABKIApR1MIVCEAP5oAFjKAIYMAOdqAQSCLpCoAboKHtzG8koqHgJlAhzO8auE4heg79OvDt5C0bPgIaXmADHgAKVAAbfEEG4mEY/yLB9mYgG2agGsyBCezAClZgBAjgFg5ABOjgAIjgFngBAh4gEBahFd7hDT4PGsyh7ZRO81xPISLw44SuCT3QCv+uCT8iGs6gFnhwDOCNCZrgByfgD2xgB9ju80Zv8OYNFILgGGygCozgGSJBAT7gFoJhD4RhAyDAAOZgEkyAC7rAHOAt6TJv55Ju90YiBq+QEd0u4QBrB5ahDTQgACrgB57hHNxgBAxAAURABJ4AAByAAbqAENXP9gqOG2aQGmDBFBggBBRgDzjgA4QhDOxBAKaAFiQgBmIBFh7w+jJP9VAP9Egi9RrRGH0uGj6CGjIhGuDgA6ygD/iACNSAGD4PE/8YwQQW4ABEwQXm4BFeIApGbxhdD/zi7QFLz/qiARRwwAGsoAJw4RaEIRCYYQM24BYCAA7sgQ7ygB54QBJAgRuowRxO7xgLsuR6LhkjoAB6wRxOoAyK4BiEwB7C4AD6wA0QDhM8wAmsAAbmYAGKoQR0gA3wABIscOfg7Rw2zt2EbvBA7gw8wBCMQARoQQNgQBCmoAXoYBB+MAUAIATmwA+uABSUTgMN0iijre1CMAK6ABiGoBrgIB/koACs4AJEQfFu4AeuofTUDx0kgQb2oAWEIRgUgAIq4BU04fVeb+PajhpisAmFzhBZkhp2ABj8QAAW4BF8QBiA8AnggACGAQb/agAYdoD8hjEbtO8FsUH8zG/hFtP21E/kNk8hivH6jtIyi+cjusAJ7kATjKAMBmAGuIEJxgADyiAMiAAGUI8Dha4LoqEQJOELKmAWhAABUuABdKACYmAwWRIxCU8Gs6/zQs8XU28REcEDTAAKUCAU7CEFzAADDuAWLuERrAAKWIATNi4lYbAlFaICu6/z4q31TBH1CuD00IEDLxM9SSfpPkIKnMAenCAaLmAPEHMNdgEKFGEY5sAOWAAeqCDptO7dZqALqGAFbuADSiAAMKAf8gABSuAOtMADqCARo+EcJhP1Pm7ezlPjNm4NuSEJrsAOJAADCAAAEIAIhKEFtIAZ/0QgBOjhFHAO+0aPGzJvIGXwBRfO9AiyAtOTR0dH6DITFQggAGaACyjAFfxuA6NhC4xAAm6gFkQhBfQABVRgGKEhGwhx9LYAFF6BBWigD8zABUrgBvphEd4BGLYg3mTwATew56oBIatvJMSP/KABHeRADOxAHQLAAfROFKaABML0AlAAHlrhDWyP65KOQyezGGFQGHvUUTdnPSMgGmDBBxCgNVchBZihNWegRrHPA9hhEuDgAHRABqDgD97hFUZBJQkPCpWuB2rAFpZBBvKgDIDvCfDhEIKgB1TAUEePAZMuBmMQ9EQPAtcSGuTgC3xhHzaBBAggHlzBDIjgAPLhD/9EQAvwoBQiM/ZGrxpWz0Y3rueK8lHHNXIiNRqwAAoegBjOoRqgQBhkQAbZrgLZTiF6wRn+QB0cTxjwjgV6buuyD94YcwZUQBIowAfyoQ9uQAYw4AZagAB8AAUYoBeG8jxVDwJn4B6WruAWkQIVogsu9Bx2wAtkgRMVYBHigQhE4Q4UwAxoIQAYIAheoUK1b/ZSj/zIFWclR+4IAgtsIR6WAd6yIQCIoA+ErkLnDR2ELgazzxAowB6skgj+EgocQAnqgAUYoQok4QyolPY0Dh3iwBB+oALkoQRcQAFuQAiE4A7ooBhGoB3QUvNq1lc3EBhtlBAJ8hquj0tXgAYoAEz/N+AJXMAeaQE5I3YHwvVmc1ZxEyf1PoIbIGEHzAAARu8cuqAPRCEQECEuExU4se8cbCAAzMAqbwED8mAQ+iAABoEEACAPtGAEHOAKTuH6qkFYsUEOdiATPGAVjEABHmAD2qAP+kEIFqEP8kAUK6EciVFRCw5HoVD2LLQLAAEYjGEABgEBfAAAtlEUOnEKbsAKomAJFld8HQewEmEGFgAOuqD0FAIKDuASGADe1ndYR8L64pQBZoECkuAV3OAGXGAK2KAdDUACFIAEWrcDXkEOGFVR1RAaKoELWOAHjGAWFqEE9rIEhEACkjMExoABIIFjK/YFZ69RoS4dS6/gOAEJ/8agLPMAAqBzEh7ABXCBAuzgGQ7B7zSuQjcwGM0R5Lp15LaOOINz5ExxUcWvVcf3GAHrYw2gBLjgPNcBBfJBAUIAFmIUIQmyLVsi9BLOAXDBBYhgDkAPEmwBD1DAAAq4D7RgERyABb5gB1RgDVRABQpuIANWQKMgEpzgBKyAAgKgDERBGIbBdZ+BARgAbkeuTU+PG5JSGB8wfoGxCRshCd7BBiRgD+whGIoBkMsAdRVgBJSACkABFAhhFEaiAkWPQl2vGiQzTX1VhFOPQzfuY0EYiRkRsMRPCexhBXR48HZgBDbABULg3XzzbhV1aZ1Q6F7BBBhg8N7AAqZ1EpbhHf/8YAAE4AZuYAIUIAD6AAACQAE4YAVeQBZegAZWoR46gAFwgAVYIAbi4AdQQAsc4AgkQAaCQRgO4AEG4A/YwQZe4WMVzt1OD+EYlXazDjG3kxqwoAdIAQU4AAM4AAEOQA+foAUkGgEoAA5EYAA8YAikgOtak0Lj1gnFTzyVN3Fr2ZZxhgoIoGgVYhEVwgnoIGr/ICAbtZURU1ixL+TmLRoSYQyKwQzuuQSmQAI0ARSuAAecAA/8oAJwUAJcQQSE4AZIIKpJQBDyIA+adBCW4Qy64OOwoAM4QAEWgANkQAEEoWzzYRjY4R+MYRSOOTQ3jqeL1UYt1N0KLvY+thJ0IQb//OAF+mECQsEAoEAfNkAY2MACNoAAKGAo503ebHr0BnECRbglKhOlGxGwRiIUPqDgRG/81sAK+u8BioAS1K8yF/VKY/RjSWIgK4EFXOEDYvgVhI4RYkATzC8bVAASYEEMYgEYkgC4xcAYjCEOamARFnYWimAAisABXhcGYMAIeIAe6CEApsAeLngCmiAPHmAKFGAMnAEYYGEJVGAUtmAJTkETNEEMzmAIVEETzgAWNMEStuAQBy8Gk1bpAjIauiAJWCAWQkADSgACJIAAEOADKMAAFkAAKsASRHoJ41SL5fqyjTGz2dceuGDkFk4lIWEESqANJMAdevEFv3Mk4hIG/zPQs4dxBiphBwquGgLgAA7ABSigJaNgB1hZp38T+5IgEgCAAiRAAB5BAp6AnovhBrCXDW4AAG7gbOEgGFJAKuwhHwwcF/yhBD5ACBRACKAaAAQBA55aBARAARRAACRgBfDhDyoABv7gBFZgDFBgDLJgE5g6EmQBGHqAClChAsrOBdggAFzgBwWADkogFTaaBZJgDR7TshNxwlN6/FggHqwgLd+SOz0hRIkgBRRAEmJQAsnPjoUuXKEhby+UU9d0CGBACPQgBB4wHXJA+ULcQkfiHHxTClRADipBjilBBXYgCoLABNiBB2JAGXigHuiBHfjBFmIgF9DcAbRACMqAFv/VgAAWAAMmQAfyQB144B3soBWUYQxgIAACgAL6wRWKQQFcAQAAYA4A4BcEoBj8fAEUgA0WgA3yYAEkQBBGQA5pYAV+QAby4RYQgBckOh4MoAgowAQkQQ4eHMIb3QorfAaoQIqJdTJFzk2VTgU24QJinBmcQYttbzXFM1wTM0YVIodjsAIW4IvLoATUQACGoFFvNuS4del4TvVYMt5OLxET4QucoA5WwAEEoAmEQRjaYBLIwAF8gQc6QAwogRK6oAt0HRIgARR2ABK8ABSwgAqwYAe+ABneYQTG4NtXQADyIACYQQZ+wRVgwAScgAacwBV8wAKEIPHCIAWeYArgAAD/TAAWGqALJNDhz6/CB28CLEAKVLz8Tg8VbkCiNSAIsCDHQX01yY+nncb8NAEPhqHsHoAF1iEaZEEHvhwP0GD8Rjwt6VdRixXnNc9jqcADzNgBDAAAJABlhWEKQoDt24EUtmDmXTkaBnHwQi/pqmEHNAEMjKACHmEOBCHeT3cS5mAC+gAOIKAEasHuTtMeiKAF8uECrnkSVsAJYIEKhqAXXgELanoygfXduo+yeXrhZl77NBAb0J8BSZwkFm4RE7cawO+IAQLaDIEzChqccW1GtYMCEyYcSPCgxIkFCS6MaDAaxRkaEW70+FEitYMLQ5o0+PCkypUsW7p8STFCBIZ//9qY4IiR5MAZBQZ6uFGLlwsdFbrM4MYxGrZzO6EJHIlyYkqQHSEBw8KRXT4XRCy8MYcNhRYGSAtG65jwLMSkGhe6Pch0RtwZWDQZUSdDkAAJGniluGUPQAUkHkDJ4bYwW0WzaqEiVNHDBgNUDIIEYWCISwweUAQY6MdrmA5c9ixsCBNGFIQNZuypubFAQIgiKP6MiPHnD4pFY4rMsgIFioMQDlb8cQADihV3ixYNrwDjhy5NmgBFwdJlpFODiituX1tQcc+JIxc+VDuxu+KOHMO7V8hSY9ruTw1+pygwIsapM7AxrAZNSQVRwx9DiwE4UEL7eQdTgw4+CGFMM9kHSv8+fFQTjYD49dRYIodgwJU+T5iCDkjrsfeWVCoKdJZG5nDDjRRiSMahFsIIQ4AMf9gyhFEFoeMUhjOYA405GSlVEIDcaGQUVNo5ZU4XoPTizBwTWMCGAnkMc0M8dNyAhx94mFCBCVxU0t9IGq3ZUTXUQIUNN+tg4+RZ/o1SCBdOUADAIi0IE0YJH6SWwhQEpHDAFMWIYEAAi1AwCBQADKKFIFoYQMEkWuQxxy9s8EJBAAbI4AMbGCjwhAYCBEDBCSisYMIzz4wBwxhOjGECHiiQCUOsMLBwlQrcMMWeizMAaRZ8OeGnIUj+bYTesSANpJZGJe50zbL+dbfTRTsd5Fj/e2tyu1GzJym4bITqrsuuQTIxFA0U/ijBHkXjoYTUSJkMkI8wG9DCCCbQlLUTNs+GxN81jlmEWEXPYvFOAGYccAARt8TAEShKMLCERtq16N9C4bI3MDdvJjWDmhFF0wkwDKyQSgm3yDDBpxYQIUwJIyyyTB0d1ADNtQZBVWCL1BqUDkfVFCIJDf+gEEo+ZZDxABGixDPHAWXEM0kFIFTRQCLtCXnNGnKogHYXXUCyBAOMnGCEHSg4YUUeAPSDAS8T3EACBjcAQMIgMrAxyA0YsDFBE4NMkMemyziBBAMssGADEox44AwoPkq00MEPVQOgeSYJ+FBCB3eU32JCM9be/1oAsjhDNuMa5J/BQRaE7n8BTnuSfN+aJM02BmUAzjTeZNFu8sq7O2HrmpSAQbrJXvO6QkYq5V8XPMxzCRuXfKCFDdzAnhFFBXLOmNFBt3cNN5RIYoQWvNhQkA1lEFGGIm4UBMoQRsIXO/fsLlvY6Ih6FLKd9ZzjWdDYwhl2QIUd7MADfxDEDUbgigkEYAMHaEEo8BAJD+wAK6t7U5HGVw06DaSA1HAKUlikmHNoAhJncAMTUIGKSUyAAABogtVcIAAEPOABwaABCrASDahcCz1O2d0aQLEETkDQE1TgxBIgKMEr7kCKVBgCEzpQgWcEQBDF8IEEhICqGwgiABrIw/8T5kCBOQyCAgIAABTguIhfUOARANiLELQQxxFIYAR4UMIXmlGKRHqgGV8IAhO+UApdfOELrwDFewQiIGisKUkTMWAAFzSglD0EKrKbgY8IkrsAvuck5DoICDJQkG1MIwzTMAgtwxGGcCxvl+x6l0H+RwEX4KCVByEXm7jTHUwEQQjxuJE9bhCDHXxSeriTSOoI0gWkkGxgasrQQa4BiTEIwAcaEEN/HNCGeMBBBBxAQSu8sMBQgosaLxzJs/zTRI5wyD7T4wgaXqELBwBgChoAgAjmMYdbPEAPMMBBA6ggLjqppSRqStlTxkcNprxpWAUcGDRUAAwTGKAPA+ADAcz/sIBJWCwYf3jEHUIhAS44Ywn9CWABomUfULYHn0Ty6A7E4AxjJFKSwOACC57xB01RQAKPeEQAQnCpEVBACxwIwCPqyAFMFSFUgtgbG4ahAAws4AY36MsNihEAEpBABgqYBAc44ICdDecPy3hGEGrACU5QgTqayAR1hsAJ6ixBE1K0xCn4qokIUmevmoAFLBpL2LwyFhJHw6mKWqKLbWgjDEAoCBA2W8uCIKEgYegGL08LIV8G8BrZeMUDbiA9jNSrSJqMHUGoAQk7PGEKKRAFCaCwDMoSyCQpMRhPYpcW/5wsWduxZzToQ1tMokIGQuSgKIgwCI5kowOyYEIhWOSU/+cS5IXR6Mn/fpSygQCohYnBRoAI5JQuLOEVsogBMyzQgrAGoA8yyIcGAhCEV8ghG1JAQ4mSWFu1oKMj1XKLRx3Toi4YaQcOkIc9BKAACLigDFooQxkeIIQK7G0Cy4iDe6HRnYUw2HfVWrF7wkWSkmwSIRrpTkrqpQJNfOEddagCC+zAg3e84wU46EAdftABFlQBBoswgAj2AgAKCOIREsAABvIgAgk8QQEBEMEEZGA4g+ZhEjcIwCQWAIA+kMCCgpjD3yTA5RswTgQkkEAf2iwEEcyhAkZqCERKcsq1XBOABqkHEL7RDWmM1iAgoOVBNBuGI6B20jBRrbigIYgWeP/gJPmkyJKONLBPhGAEdCBCG5hhhSq8YnMbOV9NmzjRJLKOIHNp3bcgYdQVUMAEZ+HGBYhwABesYCQqOIYlUfwt8iEQLgPp5kFkXb3FUMcZLECBAMyQghRIYAEBmAMcDnALPqBgGT8wBCDomURqyHp3KGuPPZMUjXPUFhpYQEMidtAJDzBhERggwAIEIYwDCIMXBGiBCGBwhREMYAxBIDTncrKd79Srky3JT8RTZ+uJFwQLaMMO2nbwikPUwQmyYIcReOAEFMTABMuggRMioQQT8MAOFYiEEVDwgk28YBUmiIQsnMCDXEXCCXioLw3s4IQXLKKgDnjHKn78DltU4Qf/P2DHO6ogi0PwwBY/WEUd6iALBryAHUo2iDXCYA2KNDq0BQGBNLqhjQZQeu4rsfROosGFeKQiWSqLkFqSMAI9lOG6G5jCAKDwCYsSOi6+M+5RPhZP9LmkdAVhxAAAsAAanIULJSgDAfbQhxBEQu4FuV5bsKEhNvWkPN6Exom306LtVKMLb7hCEIyAHAkEAgF32HLeIGAPXATAER5QhQq0kyKJaOTE3zpvKK+BDXRIKQlJaIAXFqGIDhoAUWEIRD9KcIcAoOIdMciFMjQhTe0UMGXqZnCyTDkwi5JPI7SNKDXiBBFo+ycaEencsxb2O3Q3EUkAKWoFZnlgQa4wBz6Q/wcKMAEA4AMAYCUBkFYLyIAKsBOGhmiK5kqONgMNQHqbBQICSIIboVruhw1QcAAUMBJIESfE9BKOwRRM4AQDIAIAIAgClw8SUAVy4HpLAQ3DtX/p1SJtQjTgAhNToSQCgQ1eAAUaQAcukALCIAoEEAVn4Qx+YAc9ciTaYSRGskBKAWP8FEpqQXmgQyTVsFdXwAIi8AEtAAcKAIEBQABNIAEd8AoqYB8wYiRNohYcchbyJhDZQExnMTBXcAiW0AEdMAYvMAsW4A8pMAkuIAph0AKTUAb2EAxF0AHLgAql4AmG0AuyVkAyZoiqxF4tJE9HUVOb1BH7V0rvt4qqpHElmP8ynPAJwKCLTJAEpUB9XFADwPAFDfAFuvAK7fAKxOgGXMAFTAAM5JNZm9VZM7AN3pBLirZ2m9UNpGeL3Whp53EUN5ACuUANKaSK67Ie+4cgUmAHbFACN9ICC9ABN0U7lIdx6eU6qwQh11Bji0FvTMADIRACXqAQUIAzB8AG4+EGbiAHFIWPSlMfFbEk6IEg4FEvx9QfKrADXBAEJuAAUSgMJDABfEIBoTAIrvACz8AANWBJ3yI0RsNsywUVm6RJQbgEi/QM7jACKGAHN4ALbXADdxAGG+ACA3AJB2APC/ACBuAEQeAF2eBRSJIy3FAirndcCqFuTqGKrSQgDqZeGgL/g92YPgVxMPeifLRoa2oHSzMABNPgltOQBQ3QlsazaGJpi3ZHEIrRA3SgD0nAHgfjIM3FfjOpENWABbZgAAgAAWxgBmoABY7QCRJxDrWmGNsxFWH5ESlROs6WMtEwPtFiDuswA0NgAoswAQOAFNyAAcLgJfPwC1ZwCFjgMYtRPmtxDSkRce12EVBiDoTJJGfwA19gBGMwAMNQBrfQAhygACQAAJdgD4rQByzwDqagAh0BFRgBOirWHvEnOxqRNE2hSc81A4TlDDAASD+wCD7JBxRABO2JAQGAAI7iAUXAAQPAAF2gGMq1nfDRIg/RRM8SLeUVHkyiIeZSgn62HYAp/xHXgnE9kS3gYZcR2hKWhkkowQAtoAiwwH9p2SBW+aCchDIjQQ3msARBoAAtgDMp8AB0QAEx8AzNcBQ9hY/14motwR/3oXyydpE8EQN5IA9m4AIbQAQbkAswsgMDUAEitBjvlhCEGYBCAh+1Y5vpBQ3nQYhexASgQAWMYAMBsAf2QABWggEGQABwIAMVwAQ31A6HAAsMASUeMxI9ITIegS4iWhHFMhBLwA4OIAEOMAhBKgwG4A+iIAoW8AQlYAZmIABCEAwB4ADE0CNVKmtXqV0DMT7VlF4F5DsSShGkZBAlIqXiYobSkiTUxKmnyjwxhqnYsAwbUAI2YKqBCaC7U/8AAOJeahEFLwAFCqCYoaABonAAijALHrAGB6RKtGmjFEc78lQSCGKrdvItI1EJUWADeMABXwAgn3A/RFACZ8CPncAxUHEOG6pu3FGbrBOgExER+9cWCgEKsKAKnzAmihAPwUqB85AHwPYABlABjmADp3BsD6GfLohssbNP0DAXl+oQ1jIDlEAFV9ABsNAKVeAEsbIHuKAI6uAD/sBBT9ACLcCiLAADDMAFmhALpOAmGnGp7ep+RYiquFOjOXqsR/KyNWuCzTOI3dIeMdACLmACYwghTlJb5epudooT5yAHkBAEK1AMD3AjLvABRaAFMXAYu0MfyToVKRGLGIIeB2b/JCPxoOURSkByDuehAh3gB2NEkNdQBMLwYbWgAI/gBGfgGM3CbveIQC50WUAicS/UOpDgAVfAADZQDwzwCAqgCE9QDIMgBIJ3CRjAAzCwDL4wACOrCeWjFh7VpEdRW8c1tPe3HTCCsJk7EKBgA+xgA67ABxAgD30AbMIgCB9ABPGgCCYgAWwgA+7ACp64A5SACTsACjJ6rnZZlXyLhPgoEH1moLVos6hqaSjSbP4RBAQgDFBQax2ao2cBOgVhFASxfgRzY43wAtvGB0/QBldzAyNLU8xLXJhKhgh0qe1xIgHkXCuULBdRL9ywfjPABZMwDLjwALfQnjKgSV3wB+qw/4ULtqH8cRaAWFOteKfiwkkt5B8E4zAeEzSn0ACfMAIa4JwU8DcUYA9WcwkhwAEmwACHwAT3cp2dCyMVUVGdObQP6WcGwQ2F4AnGgAdaAAA0YAVCkAoWsAgBXAYL0A/t6QKJ2QYt8AEVMAkwYAOgELN0B7TuixDcUiDe0rxbPAN216lncQa0QAT9sAb2sX710TndeA1yYAMcAAdTeABtMAhWgAKZgFHt5l4Z4b0CQY8FgE8Dkq7awUtd4AbskGoVoQPteQtOsCSjwAJXAAqz2X+1qcVH8Zm9hjIOiR9BaBAAYkXotwM2IE4UAAUSQAIBgCguoAAr8AI2MASwYDAV9f866EF/+sseTfJpbmLDY5i5KhALu7ALmgAGMBAACrAnNxAKgfAIAkcEzCABcNAHUPAFvRC8nBSLEmdN3wF7oRTDGSUXR3O/7LF6rYNTygWAXFyzXnyWP3IP+YoAVzggLKIRZkmC3Skt5lAK1kYCBpAGolAGCCAEI2AHxAAfC2EUJdGdr1N/D9zJJHjQEREFSgAFecAACYEKbUAELbBQfeAO97mf6WW07WGW36EYhLjONQZh3+IiRTID6SAFUcAEA8AGasAGQhAAE2CcEKAIA0ABKxACfmAFDKAJLE3Ov7MmRA1AtYggJROERlMsiYAKKDAHViABqyEMAXAJt2AGMhD/uR1AkCfDXtxrqVepnfwJhPmREOsBv0uKGCXifKljJLosv60zDmwnDbjUDdMoEUeAS5zlSm6Jzg+izh8RJyNQBhBgBJtbFssXkXOXl/3YrtUQBEWAAfZAMURQC0+QD6EABTBqiEBipx1hFIrhn30Wq+uCFu5hiPeAOpjgB1VmAZZNBATwBgVBA3vGAAQpoC6Ul2ALvYpxXvk5hCCqcQ/BeFp5DTswBAxgAgowBQ8wCTIwAAKACzgTD1AwCWMQAwJwA30AA6/wComgkUsApccym+KsFBGRn70WF6HjTcYbDYUQBB0QBFBACyUAB5OwAcKgbajABIRACJXQBSo2HvyX/5sQkdZECJGCrGJocYr5YcGYCpX/AyAJUA6oYRDgAARA0A1hgDwSIQ3e8HZhIDwf2OFhENgOMthn2R3nQANOewOvYBYm1ERTvDzs1jorcxSjUAM0YAADsAgFB2wWMAkxEAX5lz5xAg1dkLPsu0vcgoLsZ6lOYTBLAAZkIgeeSQEVIwoAUFsmMAtQoA5/UAeX66byrLI4ChXNgsUCpNrytHyNoAJoUABdwAQowCd/IAFPNjE5AwAKwE4a1gKCgAd2wADAaxbGlXzQ0BPCLSTLt58N3n4GLiWc4ARQcAcA8AHBZg9zcAlm0ARa4AxV0KbLx64w2R9MYRHPUkoIMh70lP9R0BqA7WaVMwACEYDhErFZdTkR0hAG0lAQ4LBZKJ7ildY80JIs2XEWnNAHbisAlHBJTCiAmPQdCD3XVPFcsBADQvAAAicBikAABRXUojkkZ6EYnEmpp90uVsnJDB1AhlhKS1AHYyABeDAS5nABB5BtN/JhDCAQKpAE1Wngy+UeldluyUYRJSGwjWFKnGsu1SBFr8AFkoEDL2AFkSAEJKAIg9AHPcQGKfCxAdAPA2AFyzACHWAKKmSVZS0kJ4bq+jHP5Z4kTgBmMoAHPkAALmABvIA/LSABtOACLWAGI4CoCzAAXGACuRIE1WYCLwAIo1AftIpgQVPt57MO7c4THZH/622HGsA+A9IA9iVeELg0Wkfg4Vtf7BN67CFBDQftnyyAAERgBi+gqc/Gqd17W5uqEONzDoVAD3+gBDdQcAKXMwagCqdAaOeTLeqePMxHLjCyRAPTGOXYHs1QBzjwAyJFAlNgAxoBBm3gAgRwA8XqsgpCqqjOTxgRLnOaLP1oIKikzVlfJAVABbHACCagAR+gCBwwVXOQA4TqAlAgkCtwA3rACxVgCZqQn+7WyeqGIUbCLTBYijMgB4flAbOgAHDAAX1ABx8QCBUQDBaQAh9wA5UoCjeQD6mxARTwACUQnyOwB09wBSCtFkaBOh5xEdTQnR9KWgARZsbAGQ1AgAtz/2TGNIZABjbwFmbbwG7apIUJI43gRo4dPX4EGVLkyI0RIoikNiPawGwEq7H0E49IniXQCKYkmVPnwJUDsc34OeNlSpszcBJsuZIatChBaDwpkWNYini4JjwyESTRDHPQzM1oOaPoTrIvOYYdSA1btJ4DoXFTmfIlXGo4s0GDFq0atC4EvQTQQ4DAlhnnYLSAM8yACS6a0ADFW+1l22tFj258Cw2d2I52xdpsiTca3rFuB+7llndGFyxcTBgYZGUShRF8yhwo8UtGHgc3hk0YUUGWDSpdVtrsCe2aymjYNKfd2PLoaJ5Ao3F7xQSHAxgOftD48wdGhwkWSpB4BEGYsP8nFDAMC1ClyIsko0YB2rFDRf78lHZ46gGUlcLCiKBtGpgBIY04akCbbiYaiKFpMJqGLAsvxJAjk0T6CZrJVjrupQLOIIGIFjjAojm8MrxwrGt6MougtW7ibAa4BuIGrtGoYQsSTTYZBgEzbhOlDQ6aaIICFvpijkWysumJKJtegqauG4XCcoYCVHIrNdHAmmE5n7DxjyA7cDEjhQOI2GCDAMRKR4I7KKhgh+o+Aq2o5O40zTMs2WpLJW56as6oztiqhBJKVKDCBhY6MOERA1zY4IAJBpFBAxFcoMMHI3yBh4cKKvBglCxPVQqyL4EytJrjnDO0RrHOqeaeNbqAxI7/Xzgg4IANCKBgzQ0UmMDXFJ6wp00zoPCnTR/yqiYBayicCCOMukGiowmtrZCgAp0EN1yPNhTXiXxEgUALWE49qigqxYVXJykaUMYBLfDQ4ZY141lghCAoqaYuLu+8bDS80KGLoEI9Ki1eC68phIl3YAjAhzGoLPYAYSoYCBYt1HGCCUo22uusWHmibjK3YlwptencKiqsGVOi7iMVGjBEFyo0SQKHFVIpoQxXSJChGDpEOaCFER7ZZB8TxljBCU1SjLUyPWNFbmCgUmMLS5xWLAgMJsTQJIYBiiligAUwwKACITAIRZAYSAgllEV8AsEkaaQBYYYs9s4AwY622Xtv/wgH2tthsrIAZxqFNkKicGkm2kZCh0YiV1w5nvmAiFtu+GEl58Rsa0BZFUe9ayyr6eIUFh7RoQ1RNLihBDgU4MAEJoD6aq21vPISRKFsEpNPMNFCfScYVx6oizNYGEMXsZIogQgiDojHAh+sMC4aTZyRBBLTCOpKYUK1HoutVff8zMMsbcKpeIJI76mLXjQ5xhg3bIBBggmK6IMQAlCGMIiiBa7IwyRgAAAoOCEWlshEA0DRhb4gz11aqxE2lsKq5eTFYKz6DDdo1qRqXOkyyUPhR8KRhQaEI1sEMQgIQCANcMwgcTrJHLh0NAMnXEBjU0ABNEKDMuc0LIWpE16Y8P+SBBS8YBG1aEEZ1nOAD7AgFi3pyoq6JjCUGWWD5xiImJB3xJGsZEtNMgqgClAUdABDCQ4YxAVKsIF89CBHjziAryRQlAYAoy9TMl5HojFGs/RkRobakgXHtxz5MSdKKUkJOoRIiSjEwgljGMMLaOAHCmjBBdbDgAzmcINitMACzHDCH1DgB002QBOJAAUktuQ+lcBqOVsC1Mlakg1I8ihVxCNjMDuCBG0MBAiH48g0+nbDnOTQSS2b0hUA0AIiWIBjNDPHVxwZKGGyqGQK2wg1lhMUSACjCg5QwAcm4YJ4KOIGj0DBFXaQo6JU5jNhgg7JujmSlxRSeFnjSi2xsRz/KHXhFZKo4A8MEIALGMBVM2CGMCBABxLMIgbAUAHYUlK8cSLlhNEhIUfq6ZGv2ASYAeMSOixYlCqpwBCRcIcR2MECHsAgECVogRZEMIkAwOF6/ngCCfowiffQ5h2aDIIbtrBRQ2HDOdr8SQG6pqckFmafZARBt5i5kcohbhramMYLReJMFqWPS7B4hEwuAYUe4OSMH71qhiTDmZjdaaBgYl0NAsCHB9yCCMIQxTBEAIdBhEAJfuQlQaTaJLR8M67hlEs/uXQcI64uRl95kVjKNwMTCIEP9vCHMK5Hg7wkoRYECAUUpCC6rCWFVQGT0phOFRLS0Uig0VjOZW6UsOIl//Eaa4hCfrywAwacTQTLsMIzrKCIFBDBHk9QgA/6kIIWlEABWjDAEypAgRXggQGMiIUm7mIOyl6nSgPZzAx0kYAISOOFWZChDAUHOcJlQKwFkeFjB5JVxC2II+Ho20YyUMONZEFC07BGgstxEnGlihtgpMZLNMEBMxDBBQpgwEDOWA1t6hdcpOHGT4Ly0ZT8RA5JsIMf5lABNugjBVOMxwd80Yo13KguXdulh/nZYc5ECUTqk9+Pu+iqLjRACVZwBReqUYA3YMAM/tAHJ6JBDSdYAHc8cIYNGOCG8a1lqtUxyxhF4pXIQOccXQuKBguDF+lA54wD+Qqg1CdCFRCDBf8MsIQuglAHQWhADWT4wwgAUAykbSAUJGCDAkjwgHzAoQgCqIAdGPAJLFwjLNSIgLWwtRBrhSHAG9lWGLox34gIRL/ENCYyB9JVjvB3IzGMrwzHweBwtaR4b9kIJJahA42VIAA/0JKOM5Rj860uTGBMS0pu5FTodMELXIhBCAAgjz08YQMtuIoRvqCCrvBY2B1BCzcwaxpYkWYjyyPNVLV5a44Y1AN9iYYJ9FGGv4qCCGHQAE6sIIGsqKBrcU5NjMC2ETEKOUrwU4056JIa5owlYOrm0ptlNL/xfUZMctDEO5axDAY44x0mmIMZIECARUhAAa6wh4XVgIpstAQE9Uj/UEY4nQH5duQIDWiQpwdyBGvpeIUtzNY2LjcDABPEvg0ARwZIQtay9hhQRXTLDyTQK2EowgTk/fZOxlKagom0StRpl5ebR5A4zAIX+hLGAfyhBQqIYAQdeAWThL2iGE32IxEGp1fQ2CqefGglHbzgRijBBCWMQAAUeIIT4uKDvx7AASqBhBb60Yc5LMMDSyBIZTnDsinjyPN3Gs2UV/KhpZiUS1QKCkFCfBqVDWwvnT8dNs6hAjl0wRyWIMYCF7AABoxsLBGZyITAqmqCRK4b3WpANy5ianCBoNNhCAfxO8I4x636ciDwxkaO0DilL53WV6XEDwJATToUoQ5RyDwa/23iZbRoPuvwWmIHKJaDRchDY2zK3iBw8Axb7ICb67cRgtiMpfigjXIqERKKEuMRjqi79yMJQNEEJPgDCagDtniDS0g70RKGMlCDN1AJTgAGdBg90ti6h9sLD1qjjeImq+ESL/mQukKZgYOMIzqBMCimGQACaQCCbkiIGeCWgTCw40MQcCimb2m+4/uqbgiHUfMwpgsmtiiATBAA9djAFkAAE6iLQmqeE0S2ZOOIRnLAC/mnt6CGHUCFGIACNkCAElAELdgAYfCHB9ADAPiDZtAPeIMMuNiSczivKesl37GJc2A4QfrCMBSJ5ZirXWKCK+ACnxGABZiAN7AJDqAuAv+AAraohiCIAR5ABS/Qkc3ALcugpWv4iQ1KIti7hpc4hzNjC7nDib8LpHhJgG/QhvlCHJmLryzYiIvQiOdjPhZhtQbwNJ3TLyc8Ij6kmWiAhdcQAgRwAVGgAxQQC0marILxnY4AQ0NUHkCRDmhwKnLamU2ggGGwgHg4AFEohmBwAQtYAAmoAFQAhQ4BE2g4B6c6BzGhhktLwLE7N5+gOG3ERp54K4EylJKaARsQBKCRAdXQgAKCQwLQg0CwA5WghBjAAf9DI6KIMzgbFDGhqrpYDjBCqYGRu5ESlwwIg2/IwYkIByDYQWLciJaUBh6ciPjCiE9jkZnURefjySY8Cbn/26dXdKQZiAItkIl4mAcHqIGf+KPTMBQuCiOAxJATxCcwqcqGC7aVAIUrQIFWMIAcIAB9+at8CIELmAAOiIFSIIxC1BoQcS3X4iapDCewyKV7miuPGJAukAK6sIMBMDwNMI8SMAGxiIJ42EACSAKV+AIhAAAHQIIzQI5wM5SxCAv10Rr5cb9/3Ilp+UGEgD7p80zl4wgjdBIk6LRuyIIw0MViPImtuCq35IrUELeBsAQOgAO/OoA2DAK7wyWCi0q5tBCq7CIsUbjTMz3laB5NYIBneAIJcAAzeEM2WUcHQIFnYAD/q7uqcgngxJNz80PmCIp+yhq9CJOuKRkwagk5/wCFHegeOXAC91iAV1gJJUA7IkgBe/gADtCSaECCEIgBQ1CBtCihQeQJ+HEklSE27nSSg5gGb2AhnIyrDQGFq8KLzQqUrpkyN6gABUi5AzCDBaCAZQCGWsK131TQnIjL4QkxDBUyDCqZyugKbAAFJrADdwgAeSgBCfgAUdiAFIAABLgBB0gCN5ADp/RH3zxRQQImnPgJMSmepWC4lvCSofyJuhSKrpECJkAFE1CHG0AAexiG8xIE60mBR4CGAiiE8iCBRciFIFgCV2kLb+QTxzLRJLVTgpBQCgUnREqLLqDHVYSGHeABNsgHF1iTAyCAQXgBOegJRrrTMuITbpIqWP98PWpYUejAOgJdikZQAWeAAS0gAQR4gAOwB14ogxb4AAygABhgAAF5ytl6VHqckrtUiUZiiw6aS7f4ivjJDFqSU7nYAkgAlFeIhCKQACfokT54ACLp0SngAptggAkIAAdoBZcAG1tzknoAgdV0wAYINZhkzRnAgsdii6OIsPJ5JOiIhk5IhhXogxLQmBYYhiywE818VAaUQeg4qT31IhzZIbgAm7y4DLygBi/wAEbAAQBIhWU91H64gSlgg0WIgU+ABLiyU7ZgNtY6tytJH8pKP9Vpy8xjH3LjCrNAAyZ4ASuYA2Zogt2EBjuIhw0QBTgIUGhgB3WgAV3gBCrg2QD/xRBysJYb/FYIJQiE6JaBQMlfZBGUDAcJ4dZwndB7nYE1sAEO0IHmcoE7gAJJ4BJzK52g8JB8lVphUoEhaIUK0IIKKIZ4oLfrKQMEqAABgAEbEJ+wIFAsGUBf6iK1YLagAFkAlEexuJKxzYmBuwblXIZI2AxoeAJ7a5MU6NFF8CAWsIEd0EKrSb3jiIAjOIJw0LkJ8Ya9uS+joxCCSE3SXNowsEVh25B6tVOz6gIuGIFAoKYDeIALmFYuuIz0yqXjEFwSPBmxaEDCZREhWwIuoAEHeAJm0AAKoDdhSAHbkQEe8AAPGNdD8sbR+InEqpHcAqEu4Ys9hRLixRC5MJ9r/+gBGhgBNpiAYXgPHkgJUKiwDbCAIGiJJICCKwCU7O0JXQCBJUQQ0HUvj0CCbjBagtAGzxSXAh5dHWvdsU2KH4OFGAAARYhZNrEACrgCbhATs4CVdqksiyVfDKmS0quLvODDGUADG0ABCpiAD4CAFCgGn2oBAmAGCbCCOqCEtpjSsNgSLnoJKJGz0aASJx1hueoI1FiHr8NYExCAYViATxCLDsgjM1CED1CEfigEgnC+MLgchtAGjNBFy1kIZQoDrRo11M2QLrYWor2qB75TiasMNfOaHmBhNniAvyqBYjABOzG9HwsLDmsYXD3isgo8jVQJvHgwbFiCdniFGAgADf8oAUMVhQcwgAewACHgABoAg+7J3CaBETKLmSgpZAtJveGZLMs0FNfKmjV4ATYogXiIhxZogi1GCyAIg+4zJpkrnG1wPm0I425wCOjblqNlEQM7sKd9LDi+02ygEkmyDA3LNSUQBEXYAAszAw1wBSPYAZvYrPFN0cwsZZGoS+8Fp8X1O55QThN4Bl/IgaCBMQowALSpgzPYLEXOMVgJI+ANyHH2zb8VCvnZrOHpilzKxynDAizYAingknE4AhAIY6XzBs4NY1WLHGmIiOizob3BCP8a5w0ZV6lNL6k6ZbFQs65ZhyCwAgwgAMMkgrc1ADs4g4daDSP1Z3Cxi6JIDWb/Y4kgFsDrsBFIggYscKMi4IUc4AANWA82gQBFcAUb4DgBwdgaGVl7veks4Saz6C1D4pJ8vBMAvIxv4BYE4UGMyL6PcD5j9kGlvRChQ2anZd2flFqz6E0vOmG4GArO4ENo4AQbGIFQcOlb0AcdWITELADJysarBolbw4ufqMchhlVAcovmuAuK24trMMMYUAcRwAVGEwCNcYESkAdXWIFmwIQ1MJTlAFnFxkvfxNaJ6wJISpU4UxHbwhIZeloZauBX29ZWc2OykAYz7rTf7qYNSWzuHDiWOiQugbqXGY0lsAMoKIYPqN0PAIAiYIcayCfW3okoTYuigJXQS7cvA1/z/6lMbuAlagCFTniF7cKAfDBHIlCAO7gFRRgGBVCAGxAEBogBD/BZ7iaJq6nSlRBE9RuYAYc9ABcXY1RwkFgCJ+DQPHppU1JVFGCAN+iQlOjCWiWiijOrBo8XuVgCqH4HdYADAvAHXzkACKCA63EBAtAAQaiALyjSkYyLmRmYmvFdc80nLdrTo6DVGskxMQNxFjkI6QvXIheJHKkOO46BERAEPjADsbRPe8AAPKjLvJaOyyAKpxwkJY+XDmJyKYiCJGACJniFBoCBJ1iAfGiBc9QAeYgHPrgBDliBMcCDUqiCV1iO1Oiw9OIJv3WLc9iSWQpAnvbx4WSJOgVzI78WB//9NgYH89IIi7CABuCqAz/Qgj7ABSlqAQ3wg1OI0xUhxW9cQeFs9HDR6a41KX3OBBvwAzuggA8ImtsgAn8wgDIogxffAzr8AobOJdVAKQLMkb0wh3YJNrEwGLFNdYdBggG7ybhu9tbeTg1TCi7yEClAAWYgICoaBCjgATGADrAVobcwh0NK0WlHYiWiOMv4Giz4gkepg04wAS3AAFwwR3zjAxf4gBswADwAhiWQgh2YULzujNIo4axc9EI8bnUfiWffFuIWJkkHc6tBDvJkFZM6M2z4inMAhVwggTe3npc2A1pYBBvAiQ2qjvhx+J14CUdlQKQI9H7+E2wYlCl7BXj/YIBFgIN4aC57cwEtWJM2uAQdkIA/4AJ/kzMsQYvzMTfjafiW94gu7gZvkPiJ/z6Hb0DL3Iw2893RGJSAyYQfGIM5mIewFAVRiIcJ8AMPaAQPKoo1YnSpD4nhNYp3mS3Z2zyFYXLKoobNogIPqPc5cIQAEAJmIAAXEIYwWABaQNViGIB3gIVVNAqXoXZ8Eme674gjd0CKB/NeMpSRVRluCJhPNpRROAQKUIRzRJofbUxUMEnNHwkjZg7kwSVYhKRU/royszsxqVJvLj0VOAYeaIVFUIQ3tzdR0IcR8AF3/IE3oGswqWrZH1vPB3ERS72tyxJqEMkWTL++6wlOUAIO/7gBGF58AwqFCtAEmKf+j2ASXCVBrjOKFUF4lIEmDcp9zPhHblhcgOA2pA4MQXkc2BOl8ECLSwMe3dEgw4ENTVRUUAE1YyPHjh4/ggwpciTJkiZPhtwGJMu0li2zoIwZM0IEmTZv4sypUyc1OUzsPPqwQRQRF/lErNCEbSO1jdE4QtuYbQY3qFGpVm0K7erGrV6jPd0pdizZsh2nYuFCY8AgBBAAkGjRQhgRUWGECdhApMUHIa4AwFihjt2rGVHBgrzmsalhp9DOKY5GrRo2xI2jLnUa1ixZadNAhAkdGgRnmzRLo06t2iQ6w1uv7UDhKlCJA6KEERBkpEGXajOmUv89Zw7b0mjYzkVlPCMaNMW+z4XdzHU19eo6KyOGxq1qtmjXzJk702GRhCetHslA8MC2qD3ywtx2IV/fIh8THvF4Va3q9hnnqEYV1X/UROXbch8BN0NrH9UDAkwzZAGChCA08FGEE1a4UQMSWtehR6d5GKKIOE01FVhNYZOJEUI8IIxCG5SwgAAo2DDKDJkVgM10lkV2Izf/caQjUyMSWWRHiFXDmHbQWMbUZFEwwQQVmvwwhgQkYDDBDWNYcAAR8JXhggJPtGBGKBTg4cE9iHUBVjWHzUANY9goRo1iM9wZli7ihDHNRtOIFgZpHgEq2qAzeBMaWSCAs42RH4H4qKT/RTalpIGVGobNLssIgIEFbdQlygYu0IGBAXa8Qsk53EAj5wzmtLqVU13B6lR3k+KamoHAZRMVcMU9FQ105iz3FIHE+hbgY9B44sEYT4SSjysc5JNPGaHGA4UCChRhSwNRRKFJAR0JKeS4TY07FRCh+TkDoBlImGFH78a70RGiLRpaN948+GikuQJMXTTjKhYgc72ee+BWkHxBwyJCfFDbl0SkYM8efRTRwQ5OYedkwB+jplySHAW70bjQ+AacV9OhTHKTM+zHlRftGPGIAiOUUFcYRBwgzBQkbFDLBMUIIUQA73ChCRagQIIFR6BF0OefYWgzjaMfAVr11Q10I42i/2QhkQE4o0n6L8hnk5XygWA1F+dyyE0GlTncEDcDFjbAIMAEH8y1kAsfkOCAG9AMF+zLaCNuk3RXFbiRb8o9lU1VxY7rGrGNwRyVcxtd3lQ0XVhiRxEUUEDGMg7oUIJeRBCxARvxCLNBCgdMscQMupQDBGjtAiENEN2EccQMovnZ++/BzwCONsOHUVbYhR5apNmJUy/TpUO6rWNyQWbmVAFP+fYU6Dg40AcC9rD3QB8mWLKVOQZ2Vb38JIW1I2L/tVZg9zCTDKysUaEDGpWLTLC4QSDJfE5hMwBEFM4Arjj4QQKuEIQgQrAGaIAmUO3aiNekMYMJ9WsGHWReoMaSwf99RU96NZkfC01iGa9Qpm0bqQzKuoA9lsVvVtvpATskQAAXxY4AF5jDGOqQicO1kHpvGkn9EEgsbFAjGgkCUBQ7IisDGosak9vIFqGxFM8hByqu4cpXbiehDFANJuEAwvFSOIM1tvGDEiKbWBh1NVxNL4l6fJQxTDCJC1yiDAcITVEUcQMo8OAUKkCDChJRLMwd6EZ40gxHmlKNbGjlQNXYzEjutMdP2mR3GxlbGMJxx46Q0pQe+ZpYkCANJAAsj6CcZYfeRKwu1IAHVhBEICAwlNsII5hEeAsD5FQgVslpKlCcDHicJKyncAWa/1nKdCbpSVpik4VZEFQsV5jNb6r/BiwDMwwnX9WDK4xBEDdQwDrp8CUX1OIGj4iEJiSjGSaNsTJuk1NTgKOcSX7kmuAc6NkaoA1pYKhs3iQoQ3MiK4CyjUmGi2Q6HoeNL3BgDy74JcVKoIcnVOAHZwiLch7KRUn+JpJPEWhDWwqwDBpKoS6dqU284kkkxY8ayuyK51qzgyAsQwKhIIALvkQUCFiABFqIxBA4wqoD9eoaT0GODGlqVVy5UhpafaVMr+pVkIjTIyqL5FUShJkhCWs52FDBJ2hghbZAIAVEEUXFciABGOBgCAaiW0pnxdKvAnY1G5oQhboa2MBOlCMEbMw5uoeiqmRGWNsJq/Y2soN24EEC/xjIRzx0JowW5GMYFMjPsbgRFsX89bCqrWOguOmvha6Wpl7xiG+ERNKuLGhWD61U+M4iRm7IwRCic8X5fimqeAQiAA5gRGyby5msekYbsHytc6s7InSoAAzLmAQJLNBZu7hgArKQQjr0WSBZNXGL5AJonDRH1i9CEizAKSd7rYs40EzXSLK0L385I1XHzYAShnjHCOAgjDAc4G8KmEUMkiDfqzAmO3wF8CMrWayOlXRliekvyAYLgkS5UUT75TCJdwLhGYwLOunghBVEgIsSuGhnZTADH/rxhxWswA8dsCFYvkg4sep2Bl1oyjWScxjUBrTEH4NpGLohLxUqOcpmcf8vnKRyI1gEwQQUSAUB/EEX1n1pA8MYgx1owANZiKFjD3Vfqx4ZxZX6Vspngy5XDSvnO9+kSQQaF3OYw7+OWKIVymABK6xwgUGK5jZlIAAtKGCCK3CiR9eA7CTt6T5uEGuKeJ7UhhqQhTpTd9OiNglj/nm5qhQshuhYyqWkCg1YRGIMFajAMySAADNs4MA7cwEuivGLX0iAAn/AwRaMZSBx0nfURboXEoC3PDsrO9pWDOCBGmucGcbpTXeqFDUy4znfPDVyXWiGE0LACz7E4wAbWPeBb+OPfPhgALL4AigC+GPFSltEngGN10JIpBHnG8/JVg5xNmlwiZqWf9T0yJL/ImmYa2jiFRI3Bvn6sIcHbCA0R4WDEEIgC1vQgx66wHbAqSONg4ahAa7VL2xL7nJJXQMLragAFIqhAxewh3V0EYY9LKAAK7zDDcSQuBiygxko/pcp+IyknKrCOOw5DtnZmZXDl6MykzZ0m6Xcpr9HBPCXg71DUo1oNDTBABQsY9aPGAYufNna0NwiHxjQQgx2kEkDbdI7HEFOY3mlrGr+cySBP9JMMzCNLIhtUl8PO+OrM5UMCzkqrFrCO/xAAQEIgAISYMYD5KqQMtgDAQEoggNKbwIGaKJxi0lOVZ6iozcd2zjQ5IpZt+IbvDeeJIvPPe/LcpWCbSSMEY6Gaa9d/w1qQwMSSXDC5gnQAkQHai+hNUAkfnCIQ0iiTd6uYtS1cpVkdyU6YRUJksO++96jXywl8wg0q9FbzG3PVYYxhzFYUI93sIAHI+CFHvQxFDDXBRH4QwlMgAEYQRD0RvEVAONwBbGU2kb0SGYsUX81QAaAGkdsw1YNSgaGGEicX/qBYE7cnkjIF9RJkX88lft9kTEtBTesQSmYwKxVwCL0gR6YwS2IRgpAwAfcwCzgACZ0BI8B1FVE1grKRGoR1DRkwBGEw5O5C7yAACxJgzeAgDZ04Ie0XAhqoU78nmssR+UcW9zcCGL0kyR5X2ZsReRgm2IQS7BAAirEgLbkw/MphP8olMEtlEGYTEExQEHp+aEVOMAYIAEo3BsS4RsteYZLdN1HNEA4bIQ3CM+8RI90zYBKmMQHbmEmioT8PaAkRQfnpNRWsIqvYE5T9IefmRQ1ZdLSRYUKeIADBMANZMANTMCLuQgAgpldMAQu3IA74IAN/EAwCmMwMgADbAwobUNrXeHTtItWEYrWbETzfNAGjQQmauI10pJ2mIIHDCMyBGM9wEAe0AHs2MXbtRYRKMIAnEI2HMdJkVMEJMDIEYpLtAs9UmNq9FtMgEAzelBHwBISaIPwSOM+eoSHEdY4ZCE2KqRsZY5h3N41SAEL/IEVFEFFWmRFUqQItMDOEAAUaEL/b31RBHxDGDSKvLBLS0Rjn6AkdWyTE5IES3BQBoSEM3bDRjCKR7CES1jDTpZDQi7kT34TSylH5XRFGH2EAEEDOuCADLhAaJiBK9jBOpgWYxyBN4RDGABBSjoIR4zGIpZGFnRD1byESTjZDGgDTIDA1QzKNAgPOAgPEMhkSVgjUNKl/PxVZtjQ44hEdwQLNnQBCwTAJdhFPsACgdiLVWJlSoYGOCgmSVYHk63cSGyDNmhDVopQuyhPZW5EFoilS3qgT9ZlaFLPX/2PstjQgeiIenWEgayDTvkHNpgDMfzBHNiOOYgkSW6DvMAEElwlaexmbwbWXIrmcM6PvZXEVCET/3Q8BToUAJHNADzKI0cggfDwZhhkwXTOQHV6pVk0QAZGIrQRZ3jSkvw5TjWRzD61WTXUSjQ8DhDspEtkJZN5wwcFynxSh0GJhn2Gmnjy5ywFiEk8RkqdCFkFXwLQxFZdzRFo1XcqqDR852pkQDdsAwjk437254Vi6GVy5TJah3Bm6IeG4L14g2ekHHiC6InSZaKExilBGYq6aGgiQWEpHmi+aI32XlrS2QX+G43aaI+G3b4po4n66JCGHRJkgUHKKMsR6ZL2nitpiDR4Zoh4KJNSKYmBhoZE5o5W6ZaWXKEEynZ2yJRy6ZiuFhBog0pOQz9aKJmyqZyxRJRqaZvKqf+UgQaHSimPzmmerlZAdpOe+il/QaadUoeY/mmhYlNOKqKQGuqiYiOhMuqjtlAWeMM0AAGceoijQmqmJk6zicazrammguo3SUM4wFKdKmqooqoenRyWCupqYGqqwqqRbFM4TEM31OSpxmquJs42XOVZzqiuAmvAvWqwEqtqHI+v4mqxKmuRJCOt2qqldiieLuu0dsiqQkiWep20Uuu2qoZBcWV+tSi3iquIQCYdxem4oqt1ICo9gumgamu6wus3DWu80mtH8Goa/Wq96mu+OGtZfuq+AqxMWKvKtapqzGvAomsGkCp9tmt1HCzCiiunhoanKinEWixKSCqlQmu0Xmz/x5KEK4FrsnosxG5TwTrsu46svhoUQtXLv6ZsxwaqyL7svuZoyGbrzOLsxzxszsZqFlzl4eXKzvJsqp4puwQtyg4tt4aBTKLR0SbtxS4tCKBRy1bs0yKsOZosagit1WaqPY6ly3Lt0GYBOLDlRxieW27ENsDnJSJt2FpsOBzpwnZEBjRAs0mhmrKt24YtQG4EELAoR3yGCOGtXLat3gIsQQouSDRbhUTXNNjsZxqu1SKuMxYkn84tY/rjVkkDTUSANRRu5NYr386A31bu3yKudGou53ou6D4t3DYiLFmiQZ1SBiBBA4BDXOre57JuvI5t2VZiVq6roxwB2eJu7u7u//HmxNYib84q7/LObPM6b8pCb/R67PRS78Va7/VCbPZqb8Byb/fu6/eCb72K7/jGa/mab7qib/qO6/qyL7e67/tSa/zK77LSb/0W6/3ib7Dq7/7qav/6b6wCcACn6gATcKga8AFragIrMKQycAMz6gNDsKFK8AT/aQVbsJ5icAbP6QZzcJt68AeTaQiLMJeScAlX6QmjMJOq8AoTaQu7sI/CcAzb6AzT8Iva8A2jaA7rMIjycA9n6A8D8YUK8RDzZxEbcXgicRIP5xIzcWg68RPjWYSEBBVLZ5IarxQvKhCAg5l+BBd78QwcwUHJbRZrcaHeKjikUBqTBtBaYN6e8f+fTi7ezvHw2OQ9hkQUx7GV8mNH1PFA4jHk7rGe1jEzcpAHAbJHlGto6O4guygbZ+eDQLIbD24eN7IjnygYP5tn9G0XP9sYj+rjQsolYzKIWnEkc8QpZycWVyMpl/Kj6vErg2AsyzL6WYM54nIu6/Iu83Iv+/IvA3MwC/MwE3MxG/MxI3MyK/MyMzMxg500hgg0W4c0T3M0W/M1WwcIWEOIWEPWlgUtfww1V7OHiDN1lLNqnHNqpLM6e4g2c7M3kwU4B8w6szM5iwg9cwY+m4U+73M7b7OHdHO4biE/97M9Y/M4dwhBk4VC74Q7AzQ8j4U8AwxDjwVF64RFX/RBVwf/RucER4dSIKtG4BIJ5WaiR+OEScsESqe0RpvzPbczSKeGSI8ISQ/0iKg0Stw0TrP0auT0SfQ0SZyudci0vlUyCBY1dUA0TiS1UofIUocSuXqIp4XIkRYJEohyLWN1VrvtZGpmdWBudlaNNvytWIzxNCBr2lomZ5Q1siIB2epnaZBuA3gDZaa1WeyjEvYtZY61WAABuwKkWe+1TpycNoDDk5EuZyDqdDVAX1NsaXz16Oo1B1FmYfdeWZ41atyrdFZIs31l2n41E8K0TjzIEbQL3K4GEISDB2WAZV72WPCmbi4P11AHqdZudt5qWXBm3+Iuah+1TlhhJWKuNxRvaWT2/2bGdk3m9ugON9jBpAgtd2mIs8qpBmlvJluGNl970PCqsllsw4h60GTCUhmTBVxu5Qy8sbs0bE5kwFtLt1k0G2l4w9V0N00vNFfOANfE6MZm9Eac9+G9N6IEdsAVMk9/hO+EtPA04oZct06M5cmxURNyBkFSrlkfVGm0hDSAA2NOuFOLBH53hIFzxmC3i4T3dk5YzbV+UDiMaDhwuEhA84aLEGUuuLQNODp7xGTq9014g33ertS2tns7IuXCJWeEwxF8mDdkFVi3uCRuxFnCOGpMob1qQ46jBEHKtQcV+ZFfNU4gwaRKQ00i7vDa+CH/iYT4yZXzXiM+4oPWc9pOef9q7DgGapVVBvhOSHd363aIa1VL7GMk0rdYxHeTZ0FVbgSEl4aHuzmVowSIk3giLvlH4Dlv2stj5zNHEPobNQCjz3i0KSETKrpNxKigwNIRdIORszJfWyGHGHJpxDejZKXsMuGWC3Z2B2SsI3ZAZkBsF7nh4aN+krqpf/rHmlIVPuift1Jayq036I7lPledwlIjHgGv8+aEMnvjVaCOlgaFahVpaLtWybpNZOBW+WOdc7kFfmcF0q5qqPqnpXtpuFJuboQr0W1qtPsHae63y0TYSIO/qbp7SwO8y3l630S3D4q8Z4i+C7xWK/zCM3zDO/zDQ3zES/zEU3zFW/zFY3z/xmt80rpSUl/7o8dEhGwnhVo1Qq1Gx2/8NIeBo3BNGJT4jQMtv5l4n6jEpnsEGlnn1Bitl1quz4qGI4KE1zjIiasGS5B7youF0eJ8P7L7dDnIp7F8omRAhLi8gha8BW4DuOr7vl+rFQKkqKftv1cIFVN1RxStZUpqGPCLuyztGCMP8MBEc3PEtYPYhvyjBXL9fWcAFDaA3Vu9pYt9vGN97UahvWw70ucz3IcD8Hw31Sw+TDSZaCAU8YAG8IwGCHSDs+LtqNaqoHip14QGlGpDN2QN259p9GxTotz2CLG9b5bSDABPfIcsfk5Db8o85wMPhZxp7QtK5cdUotTqlGO+/+bL/NiY9U8jfZ9QJla6/Bs5IhKo/fBM+Tb5idDT53yikVapfRRqPeIlCiLXozQmI0KNDUsEDxavy9gijwg1f+unZCVafvRjYPMLvcwb6Xq7fPaz/xxhP0CEkYYkjLcZ28Jsk1YQBBIkIATOCBNuW8MZFzFm1LiRY0ePH0GGFDmSZEmTJ1GmVLmSZUuXLzeGmYbQ20JpEqddlIlTZ86FIGZAvCm0wbQwR7dl9BYG3NKbO2cYvbhQ2zSrWaRu7CbQKLipEaOGAdogTLeLDY4A2Qr0K9CfQmcsbSrw54y3EYXCJWoUKdxtW8NoawCTcGHDhxEnVryYceOMMhtIy2Jzhv+2bg0gAuHJc+ERzHgFHjlyEKpObaSf5gzbAG3BwUeQZM2IsOq0rUjsgjUKooHTqKMbhAuD+yLCm0tBwA2M2nhcsXoFkvUZRvRohNPgDowt1nF379/Bhxc/vmVpylkAC968E6JM6NIyHC2bRenRram/RgQiPwzWMBvBGe6ipTLgaycDw9BsBuHsSyojbex7LqKlyooOwgqTA+0mhI4yKD77soALsILIK9HEE1FMUcWRQKDvooeIC8pFGS9q8cWGMMMtxxkeYkuj5Ha08aIQB5sBM95mCHGj5DB6KIsQk6MPSiSbZJKjFh9izaKgeLMIygCR2HFHI7fk0coxk4txxTWB2WzTzTfhjBMm/hSU08478cxTzz3l7LFIPgENVNBBCS3U0EMRTVTRRRlt1NFHIY1U0kkprdTSSzHNVNNNOe3U009BDVXUUUkt1dRTUU1V1VVZbdXVV2GNVdZZaa3V1ltxzVXXXXnt1ddfgQ1W2GGJLdbYY5FNVtllmW3W2WehDTQgADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2009:[30]. file://www.cdc.gov/hiv/topics/surveillance/resources/reports.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35333=[""].join("\n");
var outline_f34_32_35333=null;
var title_f34_32_35334="Epidemiology and pathogenesis of primary sclerosing cholangitis";
var content_f34_32_35334=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of primary sclerosing cholangitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35334/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35334/contributors\">",
"     Kris V Kowdley, MD, FACP, FACG, FASGE, AGAF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35334/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35334/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35334/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35334/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/32/35334/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of the liver and bile ducts that is frequently progressive and can lead to end-stage liver disease. The disease is characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts (",
"    <a class=\"graphic graphic_picture graphicRef70795 \" href=\"mobipreview.htm?16/12/16583\">",
"     picture 1",
"    </a>",
"    ). The diagnosis is best established by contrast cholangiography, which reveals a characteristic picture of diffuse, multifocal strictures and focal dilation of the bile ducts, leading to a beaded appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"primary\" is used to distinguish PSC from other conditions that may lead to a similar clinical and cholangiographic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"     1",
"    </a>",
"    ]. These include choledocholithiasis, bacterial cholangitis, prior biliary surgery, intra-arterial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    , and acquired immunodeficiency syndrome associated with cholangiopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of PSC will be reviewed here. The clinical manifestations, diagnosis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of PSC in the general population has not been well-established. A systematic review that focused on eight studies (from North America and Europe) estimated that the overall incidence rate was 0.77 per 100,000 person-years, although there were substantial differences among individual studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/4\">",
"     4",
"    </a>",
"    ]. When focusing only on population-based studies, the incidence was estimated to be 1 per 100,000 person-years. The incidence was higher in males, and the median age at diagnosis was 41. All individual studies observed an overall increase in incidence during the time period examined.",
"   </p>",
"   <p>",
"    In an illustrative, population-based study (from Olmsted County, Minnesota), the age-adjusted incidence in men was 1.25 per 100,000 person-years (95% CI, 0.70 to 2.06) compared with 0.54 per 100,000 person-years in women (95% CI, 0.22 to 1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence in the year 2000 was 20.9 cases per 100,000 men, and only 6.3 cases per 100,000 women. Inflammatory bowel disease (mostly ulcerative colitis) was present in 73 percent. Overall survival was significantly reduced compared with age and gender-matched population norms. In another population-based study (from Calgary, Alberta, Canada), the annual incidence rate adjusted for age was 1.01 per 100,000 person-years in men and 0.84 per 100,000 person-years in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/6\">",
"     6",
"    </a>",
"    ]. A third population-based study (from a region in southern Sweden) estimated that the annual incidence was 1.22 per 100,000 person-years in adults, which represented an increase of more than three-fold from 1992 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of PSC appears to be increased among first-degree relatives of patients with PSC. In one report, the prevalence of PSC among first-degree relatives was estimated to be 0.7 percent; among siblings, the prevalence was 1.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     PSC and inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;UC has been reported in 25 to 90 percent of patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1,2,5,9\">",
"     1,2,5,9",
"    </a>",
"    ]. A survey of 23 hospitals in Spain, for example, examined the reported cases of PSC from 1984 to 1988; UC was present in 44 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/9\">",
"     9",
"    </a>",
"    ]. It is likely that this figure is an underestimate, since the colonic mucosa may be grossly normal in appearance despite the presence of histologic colitis. The true prevalence of UC in PSC is probably closer to 90 percent when rectal and sigmoid biopsies are routinely obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are varying reports of the prevalence of PSC in UC. A survey of 1500 patients with UC in Sweden, for example, found that 72 (5 percent) had an elevated serum alkaline phosphatase; endoscopic retrograde cholangiopancreatography (ERCP) was performed in 65, of whom 55 (85 percent) had evidence of PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/11\">",
"     11",
"    </a>",
"    ]. PSC was more prevalent in patients with pancolitis than in those with distal colitis (5.5 versus 0.5 percent). It was also more common in men than women. Another report found that more than 7 percent of patients with UC may have PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, estimates of the prevalence of PSC can be made based upon the prevalence of UC. The prevalence of UC in the United States has been estimated to range from 40 to 225 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, if 5 percent of patients with UC have PSC and if apparent UC is present in 50 percent of patients with PSC, the approximate prevalence of PSC is 1 to 6 per 100,000 in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported prevalence of PSC in Spain increased from 0.78 cases per million in 1984 to 2.24 cases per million in 1988 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/9\">",
"     9",
"    </a>",
"    ]. Approximately 16 percent of patients were asymptomatic and were detected by increased screening with serum alkaline phosphatase. This factor plus the use of ERCP to diagnose PSC could account for enhanced detection of the disease without a true rise in prevalence. On the other hand, these data may represent an underestimate of the true prevalence since some patients with PSC have normal serum alkaline phosphatase levels.",
"   </p>",
"   <p>",
"    PSC also occurs in patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/6\">",
"     6",
"    </a>",
"    ]. In one report of 262 patients with Crohn's disease, 38 (15 percent) had long-standing abnormal liver biochemical tests and underwent endoscopic cholangiography and liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/13\">",
"     13",
"    </a>",
"    ]. Nine of these patients (3.4 percent) were diagnosed with PSC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of patients with PSC are men, with a mean age at diagnosis of 40 years, even though the sex distribution is equal between men and women in the overall UC population. However, in the small subset of patients without UC, the male:female ratio is lower (0.8:1) and patients are diagnosed at an older age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/14\">",
"     14",
"    </a>",
"    ]. Women with PSC are generally diagnosed at an older age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of PSC is unknown, and multiple mechanisms are likely to play a role. The following etiologies have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tight association between PSC and UC (a known autoimmune disease) suggests an autoimmune process. However, other mechanisms are likely to be important since only a minority of patients with UC have PSC.",
"     </li>",
"     <li>",
"      An inflammatory reaction in the liver and bile ducts may be induced by chronic or recurrent entry of bacteria into the portal circulation. Liver damage may also result from the accumulation of toxic bile acids that are abnormally produced by colonic bacteria or chronic viral infection.",
"     </li>",
"     <li>",
"      Ischemic damage to the bile ducts may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the relationship between PSC and UC suggests a possible common pathogenesis, the two disorders may occur at different times. PSC may develop years after colectomy for UC, and UC may first present after liver transplantation has been performed for PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is likely that immunologically-mediated bile duct injury is a major mechanism leading to PSC. However, the putative antigen which elicits the aberrant immune response and the mechanism by which autoantibodies or abnormally activated T cells lead to clinical expression of the disease are unknown. The most plausible explanations are that PSC is a multifactorial disorder, possibly developing in individuals with a genetic predisposition when exposed to the appropriate environmental stimulus, or that PSC represents multiple diseases with a similar clinical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immune activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple lines of evidence supporting an immunopathogenic cause for PSC. A number of abnormalities in humoral immunity have been described in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 50 percent have an elevated IgM level, and some may also have an increased IgG fraction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoantibodies are frequently present in patients with PSC, with titers in the range associated with autoimmune hepatitis. The most common are antismooth muscle antibodies and antinuclear antibodies, which are found in approximately 75 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"       \"Classification of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibodies directed against cytoplasmic and nuclear antigens of neutrophils with a characteristic perinuclear staining pattern (P-ANCA) are found in up to 80 percent of adults with PSC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"       15",
"      </a>",
"      ]. The antibodies appear to be directed against a myeloid 50 kilodalton nuclear envelope protein, not myeloperoxidase as in typical P-ANCA antibodies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/17\">",
"       17",
"      </a>",
"      ]. In one report, P-ANCA had a 100 percent specificity for PSC compared to controls with other liver diseases; P-ANCA is also found in 25 to 30 percent of unaffected first degree family members of patients with PSC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"       15",
"      </a>",
"      ]. P-ANCA has also been identified in children with PSC but not in those with UC alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/18\">",
"       18",
"      </a>",
"      ]. These antibodies are not related to the presence or absence of UC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormalities of the cellular immune response have also been described in patients with PSC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are conflicting data reporting either an increase or decrease in the total number of circulating T cells; however, the number of CD4 positive T-cells in the liver is increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bile duct epithelial cells in PSC may be targets for immune-mediated attack by T cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The bile duct cells in PSC express antigens which cross-react with colonic epithelial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bile duct cells aberrantly express HLA class II antigens, and ICAM (intercellular adhesion molecule)-1 is expressed by ductular epithelial cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-degree relatives of patients with PSC have an increased risk of PSC and ulcerative colitis, supporting a genetic predisposition to these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/22\">",
"     22",
"    </a>",
"    ]. The basis for the genetic predisposition is not well understood. Patients have an increased prevalence of HLA-B8, -DR3, and -DRw52a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"     15",
"    </a>",
"    ]. One study, for example found that HLA DRw52a was present in 100 percent of patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/23\">",
"     23",
"    </a>",
"    ]. Subsequent reports, however, have only found a 50 percent prevalence of this haplotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/24\">",
"     24",
"    </a>",
"    ]. Both HLA-DRw52a and -DR4, which occurs less frequently, appear to increase the risk for severe or progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLA-B8 is present in 60 to 80 percent of patients with PSC, compared to only 25 percent of control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, the",
"    <span class=\"nowrap\">",
"     HLA-B8/DR3",
"    </span>",
"    haplotype is infrequent in patients with UC who do not have PSC. This haplotype is also associated with a number of other autoimmune diseases, such as celiac disease, myasthenia gravis, and diabetes mellitus.",
"   </p>",
"   <p>",
"    A specific polymorphism of MICA (an MHC class I related molecule located between tumor necrosis factor-alpha and HLA-B) may also be strongly associated with PSC. In one study, the homozygous MICA008 allele was present significantly more often in 112 patients with PSC compared to 118 controls (58 versus 22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/25\">",
"     25",
"    </a>",
"    ]. Other reports have identified additional loci that confer susceptibility to ulcerative colitis and PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strong association between PSC and UC has led to speculation that increased permeability of bacteria into the portal circulation across an inflamed colonic wall may lead to chronic or recurrent cholangitis, or that bacterial products may cause liver and biliary tract inflammation, leading to the characteristic pathologic and cholangiographic appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"     1",
"    </a>",
"    ]. The evidence in support of these hypotheses has been contradictory. Early studies, for example, found that patients with PSC had an increased risk of portal venous bacteremia; subsequent reviews, however, did not confirm portal vein phlebitis in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. On the other hand, an animal model of small intestinal bacterial overgrowth noted changes in the appearance of the bile ducts similar to those seen in patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ischemic ductal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic injury to the bile ducts results in a clinical, biochemical, and cholangiographic picture similar to PSC. Intra-arterial infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    also results in a comparable appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, it is possible that ischemic injury to peribiliary arterioles and capillaries may be involved in the pathogenesis of PSC. However, there are no data to support this hypothesis, or to demonstrate that hepatic or biliary blood flow is deficient in patients with this disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cystic fibrosis transmembrane conductance regulator mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the radiologic and histologic similarities between PSC and cystic fibrosis, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) have been sought in patients with PSC. One preliminary study suggested that a subset of patients with PSC had evidence of CFTR-mediated ion transport dysfunction; affected patients had a chloride secretory response intermediate between patients with cystic fibrosis and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent report from the same authors compared the genotypic and phenotypic expression of CFTR mutation in 18 patients with PSC with 35 disease controls (inflammatory bowel disease without PSC or primary biliary cirrhosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35334/abstract/33\">",
"     33",
"    </a>",
"    ]. CFTR mutations were present significantly more often in patients with PSC (33 versus 6 percent). All mutations were on one allele, thus representing a carrier state. A reduced chloride response on nasal potential testing was also more common in patients with PSC (50 versus 9 percent). Combining genotype and phenotype data, significantly more patients with PSC had abnormalities in CFTR (67 versus 17 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H237971424\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of the liver and bile ducts that is frequently progressive and can lead to end-stage liver disease. The disease is characterized by progressive inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts (",
"      <a class=\"graphic graphic_picture graphicRef70795 \" href=\"mobipreview.htm?16/12/16583\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PSC has an incidence of approximately 1 case per 100,000 person years. Approximately 70 percent of patients with PSC are men, with a mean age at diagnosis of 40 years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-degree relatives of patients with PSC have an increased risk of PSC and ulcerative colitis, supporting a genetic predisposition to these conditions.",
"     </li>",
"     <li>",
"      Up to 90 percent of patients with PSC also have ulcerative colitis (UC), but less than 10 percent of patients with UC have PSC. Although the relationship between PSC and UC suggests a possible common pathogenesis, the two disorders may occur at different times. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'PSC and inflammatory bowel disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of PSC is unknown, and multiple mechanisms are likely to play a role. The following etiologies have been proposed (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The tight association between PSC and UC (a known autoimmune disease) suggests an autoimmune process. However, other mechanisms are likely to be important since only a minority of patients with UC have PSC.",
"     </li>",
"     <li>",
"      An inflammatory reaction in the liver and bile ducts may be induced by chronic or recurrent entry of bacteria into the portal circulation. Liver damage may also result from the accumulation of toxic bile acids that are abnormally produced by colonic bacteria or chronic viral infection.",
"     </li>",
"     <li>",
"      Ischemic damage to the bile ducts may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is likely that immunologically-mediated bile duct injury is a major mechanism leading to PSC. However, the putative antigen which elicits the aberrant immune response and the mechanism by which autoantibodies or abnormally activated T cells lead to clinical expression of the disease are unknown. The most plausible explanations are that PSC is a multifactorial disorder, possibly developing in individuals with a genetic predisposition when exposed to the appropriate environmental stimulus, or that PSC represents multiple diseases with a similar clinical presentation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/1\">",
"      Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/2\">",
"      Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/3\">",
"      Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepatology 1999; 30:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/4\">",
"      Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/5\">",
"      Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/6\">",
"      Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007; 102:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/7\">",
"      Lindkvist B, Benito de Valle M, Gullberg B, Bj&ouml;rnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010; 52:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/8\">",
"      Bergquist A, Lindberg G, Saarinen S, Broom&eacute; U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/9\">",
"      Escorsell A, Par&eacute;s A, Rod&eacute;s J, et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/10\">",
"      Tung BY, Brentnall T, Kowdley KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/11\">",
"      Olsson R, Danielsson A, J&auml;rnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/12\">",
"      Schrumpf E, Elgjo K, Fausa O, et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/13\">",
"      Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/14\">",
"      Rabinovitz M, Gavaler JS, Schade RR, et al. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990; 11:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/15\">",
"      van Milligen de Wit AW, van Deventer SJ, Tytgat GN. Immunogenetic aspects of primary sclerosing cholangitis: implications for therapeutic strategies. Am J Gastroenterol 1995; 90:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/16\">",
"      Woolf GM, Vierling JM. Disappearing intrahepatic bile ducts: the syndromes and their mechanisms. Semin Liver Dis 1993; 13:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/17\">",
"      Terjung B, Spengler U, Sauerbruch T, Worman HJ. \"Atypical p-ANCA\" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/18\">",
"      Lo SK, Chapman RW, Cheeseman P, et al. Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood? Gut 1993; 34:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/19\">",
"      Broom&eacute; U, Hultcrantz R, Scheynius A. Lack of concomitant expression of ICAM-1 and HLA-DR on bile duct cells from patients with primary sclerosing cholangitis and primary biliary cirrhosis. Scand J Gastroenterol 1993; 28:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/20\">",
"      Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/21\">",
"      Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 1995; 36:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/22\">",
"      Bergquist A, Montgomery SM, Bahmanyar S, et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008; 6:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/23\">",
"      Prochazka EJ, Terasaki PI, Park MS, et al. Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med 1990; 322:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/24\">",
"      Zetterquist H, Broom&eacute; U, Einarsson K, Olerup O. HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis. Gut 1992; 33:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/25\">",
"      Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology 2001; 120:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/26\">",
"      Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology 2011; 53:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/27\">",
"      Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/28\">",
"      Hov JR, Keitel V, Laerdahl JK, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010; 5:e12403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/29\">",
"      Palmer KR, Duerden BI, Holdsworth CD. Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut 1980; 21:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/30\">",
"      VINNIK IE, KERN F Jr, STRUTHERS JE Jr, et al. EXPERIMENTAL CHRONIC PORTAL VEIN BACTEREMIA. Proc Soc Exp Biol Med 1964; 115:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/31\">",
"      Lichtman SN, Sartor RB, Keku J, Schwab JH. Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology 1990; 98:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/32\">",
"      Sheth SG, Bishop MD, Shea JC, et al. Primary sclerosing cholangitis is associated with abnormalties in cystic fibrosis-mediated chloride channel function (abstract). Gastroenterology 2000; 118:A958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35334/abstract/33\">",
"      Sheth SG, Bishop MD, Shea JC, et al. Association of primary sclerosing cholangitis (PSC) with the cystic fibrosis carrier state: Results of extensive genotypic and phenotypic analysis (abstract). Gastroenterology 2001; 120:A75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 659 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35334=[""].join("\n");
var outline_f34_32_35334=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H237971424\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PSC and inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immune activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ischemic ductal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cystic fibrosis transmembrane conductance regulator mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H237971424\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/659|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/12/16583\" title=\"picture 1\">",
"      Bile duct injury PSC Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=related_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_32_35335="Risk factors for and pathogenesis of analgesic nephropathy";
var content_f34_32_35335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for and pathogenesis of analgesic nephropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35335/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35335/contributors\">",
"     Marc E De Broe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35335/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35335/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/32/35335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic analgesic nephropathy is a slowly progressive renal disease resulting from daily use for many years of mixtures containing at least two analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , paracetamol, pyrozolones, phenacetin) and caffeine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    barbiturates, which may lead to psychological dependence and overuse. In the past, analgesic nephropathy was an important cause of chronic kidney disease, particularly in Australia and parts of Europe and the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Previous estimates, obtained before phenacetin was removed from over-the-counter analgesics and before legislation was enacted making combined analgesics only available by prescription (in Sweden, Canada, Belgium, and Australia), suggested that analgesic nephropathy was responsible for 1 to 3 percent of cases of end-stage renal disease in the United States as a whole, up to 10 percent in areas of North Carolina, and 13 to 20 percent in Australia and some countries in Europe (such as Belgium and Switzerland).",
"   </p>",
"   <p>",
"    The decrease in availability of phenacetin-containing analgesic mixtures and other combined analgesics once the risk of analgesic nephropathy was clearly established has led to a marked reduction in the number of new cases of analgesic nephropathy. In an autopsy study of 616 adults in Basle, Switzerland, the rate of analgesic nephropathy fell progressively from 3 percent in 1980 to 0.2 percent in 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk factors for and pathogenesis of analgesic nephropathy will be reviewed here. The clinical manifestations and diagnosis of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/43/27318?source=see_link\">",
"     \"Clinical manifestations and diagnosis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF PHENACETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analgesic nephropathy is characterized by renal papillary necrosis and chronic interstitial nephritis that is caused by prolonged and excessive consumption of analgesic combination medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. It is invariably due to popular proprietary mixtures containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or antipyrine in combination with phenacetin, paracetamol, or salicylamide, and caffeine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    . Two studies illustrate this relationship:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, 10-year study of women found that the incidence of a rise in the plasma creatinine concentration was 12 percent in those with heavy use of analgesic mixtures versus only 1.4 percent in nonusers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case control study compared 554 adults with newly diagnosed chronic renal insufficiency (plasma creatinine concentration greater than 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 132",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      to 516 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/7\">",
"       7",
"      </a>",
"      ]. The relative risk for the development of renal disease was 5.1 times control in those with daily ingestion of phenacetin-containing analgesic mixtures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Death from renal disease is also much more likely in analgesic abusers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decrease in availability of phenacetin-containing analgesic mixtures and other combined analgesics over the past 10 to 15 years has led to a reduction in the number of new cases of analgesic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/1,2,9,10\">",
"     1,2,9,10",
"    </a>",
"    ]. In Europe, analgesic nephropathy as a cause of end-stage renal disease virtually disappeared in Sweden and Denmark between 1980 and 1990, while the incidence in Switzerland fell from 28 to 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The latter figure undoubtedly includes many patients who already had renal disease before phenacetin was removed from over-the-counter analgesic preparations. In Australia, the decrease in incidence of analgesic nephropathy started in 1985, which was five years after over-the-counter sales of analgesic mixtures were banned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, in Belgium where analgesic mixtures (including addictive substances such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ) are more easily available, analgesic abuse still accounted for over 15 percent of cases of end-stage renal disease in 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/10\">",
"     10",
"    </a>",
"    ]. In the northern part of the country where analgesic nephropathy was most prevalent, the incidence was 12.0 in 1993 and decreased towards 4.5 in 2008 (NBVN registry data). In 1999, phenacetin-containing analgesic mixtures were banned and manufacturers substituted single analgesics for analgesic mixtures, and in 2001 analgesic mixtures became available only by prescription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question that remains incompletely resolved is the renal risk of chronic monotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen (paracetamol)",
"    </a>",
"    , which is the primary metabolite of phenacetin and which is now widely used as a minor analgesic. Multiple [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/7,12-14\">",
"     7,12-14",
"    </a>",
"    ], though not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/15\">",
"     15",
"    </a>",
"    ], small studies have suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    alone is nephrotoxic, although the risk is probably less than that of phenacetin-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/7,12-15\">",
"     7,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observed difference in risk may be due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    having less intrinsic nephrotoxicity than phenacetin. Alternatively, if acetaminophen and phenacetin had the same risk when used in combination with other analgesics, but less risk when used alone, case control studies would show a lower risk for acetaminophen relative to phenacetin. This finding would occur because acetaminophen is used both alone and in combination therapy, whereas phenacetin was always used in combination mixtures, but never as a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/16\">",
"     16",
"    </a>",
"    ]. This hypothesis is supported by the results of one study, which found similar risks with combination medication containing phenacetin or acetaminophen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    That",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    alone is nephrotoxic was suggested in a case-control study of patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/13\">",
"     13",
"    </a>",
"    ]. In this report, there was an association between the cumulative intake of acetaminophen and the relative risk of renal failure: when compared to a relative risk of 1.0 in patients ingesting fewer than 1000 pills during their lifetime, the relative risk was 2.0 if between 1000 and 4999 pills were taken and 2.4 if more than 5000 pills were taken [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, interpretation of these results is confounded by the possibility that patients with renal disease are more likely to: 1) have symptoms requiring analgesics; and 2) preferentially use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    because they are told to avoid",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and nonsteroidal antiinflammatory drugs.",
"   </p>",
"   <p>",
"    The latter issues may have been less important in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report looked at analgesic use in 554 adults presenting with new renal insufficiency (plasma creatinine concentration of 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [130",
"      <span class=\"nowrap\">",
"       &micro;mol/L]),",
"      </span>",
"      rather than end-stage renal disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/7\">",
"       7",
"      </a>",
"      ]. It was estimated that the adjusted odds ratio for renal disease was 3.2 in patients taking",
"      <strong>",
"       daily",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . There was no increase in risk with weekly or less frequent use.",
"     </li>",
"     <li>",
"      In a case-control Swedish study of 926 patients with newly diagnosed renal dysfunction (plasma creatinine concentration of 2.8 and 3.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [250 and 300",
"      <span class=\"nowrap\">",
"       &micro;mol/L]",
"      </span>",
"      for women and men, respectively) and 998 control subjects, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      was associated with an odds ratio of 2.5 (95% CI 1.7-3.6) for the development of chronic kidney disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/14\">",
"       14",
"      </a>",
"      ]. There was a progressive increase in risk with increasing cumulative dose (odds ratio of 1.2, 1.3, and 3.3 with a cumulative dose of 1 to 99 grams, 100 to 499 grams, and greater than 500 grams, respectively).",
"     </li>",
"     <li>",
"      Among nearly 1700 healthy women participating in the Nurses' Health Study in the United States, increased",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      use was associated with an increased risk of reduced renal function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/18\">",
"       18",
"      </a>",
"      ]. Compared to those consuming less than 100 grams of acetaminophen, women consuming more than 3000 grams of acetaminophen had a multivariate odds ratio of 2.0 (95% CI 1.3-3.2) for a decrease in the glomerular filtration rate (GFR) of at least 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 over an eleven year period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there is suggestive but not definitive evidence that chronic, especially daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use has dose-dependent, long-term nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/19\">",
"     19",
"    </a>",
"    ]. The greater frequency with which acetaminophen is taken alone rather than in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may explain the apparently greater risk seen with phenacetin. Papillary necrosis, similar to that seen with analgesic mixtures, is present in at least some affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/12\">",
"     12",
"    </a>",
"    ]. This is in contrast to the tubular injury and acute, reversible renal failure that can be induced by an acute, acetaminophen overdose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=see_link&amp;anchor=H1984922420#H1984922420\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Acute kidney injury (acute renal failure)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/13,15,18,20-22\">",
"     13,15,18,20-22",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/14,23\">",
"     14,23",
"    </a>",
"    ] studies, the long term administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone (in therapeutic doses) did not appear to induce renal injury. However, it may potentiate the toxicity of phenacetin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Analgesic mixtures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients taking analgesic mixtures (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) appear to be at particular risk for analgesic nephropathy. This appears to be true even in the absence of phenacetin (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathogenesis'",
"    </a>",
"    below), although some investigators feel that there is insufficient evidence to support this association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/10,24-26\">",
"     10,24-26",
"    </a>",
"    ]. One report, for example, prospectively followed 200 active analgesic abusers and a similar number of matched controls for seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/24\">",
"     24",
"    </a>",
"    ]. Renal function deteriorated in 12 (6.2 percent) of the patients, a relative risk of 6.1 compared to controls. All of the patients were taking analgesic mixtures (including analgesics such as phenacetin, acetaminophen and aspirin combined with potentially addicting compounds such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    and caffeine). Six of 10 patients who were evaluated had evidence of analgesic nephropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic use of nonsteroidal antiinflammatory drugs (NSAIDs) is generally safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/27\">",
"     27",
"    </a>",
"    ]. However, papillary necrosis can occur with these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/10,28,29\">",
"     10,28,29",
"    </a>",
"    ], particularly in patients consuming excessive amounts over many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. An increased incidence of urinary tract malignancies is unlikely in patients with a history of prolonged use of NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=see_link\">",
"     \"Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This effect of NSAIDs on kidney function was examined in a review of 8000 patients with normal kidney function (serum creatinine &lt;1.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    enrolled in a randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    for the treatment of a rheumatologic condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients treated with celecoxib, diclofenac or ibuprofen had a mean change in creatinine clearance of 0.08, -2.8 and -0.9",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively, over a period of 9 months. The incidence of a &ge;30 percent reduction in creatinine clearance was only slightly higher among patients treated with diclofenac or ibuprofen (3.5 to 4 percent) compared with celecoxib (2.5 percent).",
"   </p>",
"   <p>",
"    The possible role of NSAIDs in the development of chronic kidney disease is uncertain, although some patients do appear to be at risk. As an example, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    case-control trial noted above found an increased incidence of end-stage renal disease only in those NSAID users who had taken more than 5000 pills during their lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/13\">",
"     13",
"    </a>",
"    ]. Another large case-control study suggested that daily NSAID use for over one year may be associated with an increased risk of an otherwise unexplained and newly diagnosed plasma creatinine concentration above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/31\">",
"     31",
"    </a>",
"    ]. However, two observations lead to doubting the significance of these findings: there was no obvious dose-dependence; and the decline in renal function was essentially confined to men over the age of 64 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    None of these studies determined what type of renal disease might be present. However, a third report evaluated 259 patients over a ten year period who satisfied the clinical criteria for analgesic nephropathy (including the presence of papillary necrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/29\">",
"     29",
"    </a>",
"    ]. Twenty-nine had consumed only NSAIDs (primarily for rheumatologic disease), and varying degrees of renal insufficiency were noted in many of these patients.",
"   </p>",
"   <p>",
"    In summary, exposure to large quantities of NSAIDs can probably induce chronic kidney disease in some cases. The percentage of patients affected is small relative to the number of prescriptions written; it is possible, however, that the incidence of renal disease will rise due to the increasing availability of over-the-counter NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/27\">",
"     27",
"    </a>",
"    ]. The effect of long-term use of selective COX-2 inhibitors on kidney function is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epidemiologic concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been a number of extensive reviews of the epidemiologic literature concerning the possible relationship between analgesic use and the development of chronic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. All emphasize that the trials and studies examining this correlation are methodologically flawed. As a result, despite the collective evidence suggesting that chronic analgesic use is associated with renal disease, causality, particularly that due to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , has not yet been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the flaws in previously performed studies, suggested improvements in study design include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with early stage disease should be included.",
"     </li>",
"     <li>",
"      Explicit knowledge of both the time in which the drug was started and stopped, and the amount of drug ingested should be obtained.",
"     </li>",
"     <li>",
"      Personal, not telephone, interviews should be performed, and must include visual aids to obtain accurate information concerning the type of drug ingested.",
"     </li>",
"     <li>",
"      Patients and control individuals should be drawn from the same population source, and should be of adequate number to determine statistical significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an attempt to address some of these concerns, the correlation between renal disease and analgesic use was evaluated in over 11,000 initially healthy men enrolled in the Physicians' Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/22\">",
"     22",
"    </a>",
"    ]. The quantitative exposure to analgesics was determined retrospectively via a questionnaire administered at the end of the 14 year study period. Based upon a multivariate analysis, an increased relative risk of an elevated serum creatinine (defined as greater than 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    with ingestion of at least 2500 or more pills was",
"    <strong>",
"     not",
"    </strong>",
"    associated with exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or NSAIDs. Some limitations with this study include the inability to extend this conclusion to women, minorities, or patients with preexisting renal disease, reliance upon a retrospective questionnaire, lack of knowledge concerning exact dosing of analgesics, and the use of a single serum creatinine measurement.",
"   </p>",
"   <p>",
"    To better assess a possible change in renal function with analgesic use, a comparative evaluation of baseline (1982) and subsequent serum creatinine measurements (1996) was performed among 4494 initially healthy men enrolled in the previously described Physicians' Health Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/38\">",
"     38",
"    </a>",
"    ]. Based upon a multivariate analysis, an increased serum creatinine concentration with ingestion of at least 2500 or more pills was not associated with exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or other NSAIDs. Other than the ability to measure the change in renal function over time, this study has similar limitations to the previously report from the Physicians' Health Study.",
"   </p>",
"   <p>",
"    Somewhat similar strengths and limitations were observed in a study derived from nearly 1697 women participating in the Nurses' Health Study in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/18\">",
"     18",
"    </a>",
"    ]. A possible correlation was assessed between change in GFR over an eleven year period (1989 to 2000) and lifetime use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or other NSAIDs. Although the use of aspirin and other NSAIDs was not associated with a decline in renal function, consumption of acetaminophen increased the risk of a decline in GFR. Compared to those consuming less than 100 grams of acetaminophen, women consuming more than 3000 grams of acetaminophen had a multivariate odds ratio of 2.04 (95% CI 1.28-3.24) for a decrease in the GFR of at least 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 over the 11 year period. However, most women with this decline in renal function do not have clinically significant renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotoxicity of analgesics is dose-dependent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. Decreased concentrating ability or a mild reduction in GFR can be seen after cumulative phenacetin intake of as little as 1 kg. In comparison, clinically evident renal disease requires a minimum intake of 2 to 3 kg each of phenacetin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . This will take six to eight years in a patient ingesting six to eight tablets (or about 1 gram) of phenacetin-containing compounds per day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/43/27318?source=see_link\">",
"     \"Clinical manifestations and diagnosis of analgesic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The renal damage induced by analgesics is most prominent in the medulla. The earliest changes consist of prominent thickening of the vasa recta capillaries (capillary sclerosis) and patchy areas of tubular necrosis; similar vascular lesions can be found in the renal pelvis and ureter, suggesting that the primary effect is damage to the vascular endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/39\">",
"     39",
"    </a>",
"    ]. Later changes include areas of papillary necrosis and secondary cortical injury with focal segmental glomerulosclerosis and interstitial infiltration and fibrosis.",
"   </p>",
"   <p>",
"    The mechanisms responsible for the renal injury are incompletely understood. Phenacetin is metabolized to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and to reactive intermediates that can injure cells, in part by lipid peroxidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/40\">",
"     40",
"    </a>",
"    ]. These metabolites tend to accumulate in the medulla along the medullary osmotic gradient (created by the countercurrent system). As a result, the highest concentrations are seen at the papillary tip, the site of the initial vascular lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potentiating effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    with both phenacetin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may be related to two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      undergoes oxidative metabolism by prostaglandin H synthase to reactive quinoneimine that is conjugated to glutathione. If acetaminophen is present alone, there is sufficient glutathione generated in the papillae to detoxify the reactive intermediate. However, if acetaminophen is ingested with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , the aspirin is converted to salicylate, which becomes highly concentrated and depletes glutathione in both the cortex and papillae of the kidney. With the cellular glutathione depleted, the reactive metabolite of acetaminophen then produces lipid peroxides and arylation of tissue proteins, ultimately resulting in necrosis of the papillae (",
"      <a class=\"graphic graphic_figure graphicRef50465 \" href=\"mobipreview.htm?12/12/12495\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35335/abstract/2,25\">",
"       2,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and NSAID suppress prostaglandin production by inhibiting cyclooxygenase enzymes. Renal blood flow, particularly within the renal medulla, is highly dependent upon systemic and local production of vasodilatory prostaglandins. Thus, this region, in the setting of combined aspirin and NSAID use, is more prone to ischemic damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analgesic nephropathy is characterized by renal papillary necrosis and chronic interstitial nephritis. It is caused by prolonged and excessive consumption of analgesic combination medications that contain phenacetin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , nonsteroidal antiinflammatory agents (NSAIDs), or salicylamide, and addictive substances such as caffeine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Importance of phenacetin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analgesic nephropathy used to be an important cause of chronic kidney disease, particularly in Australia, parts of Europe and the United States. The decrease in availability of analgesic combined medications with or without phenacetin has led to a marked reduction in the number of new cases. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Importance of phenacetin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many small studies have suggested that chronic, especially daily,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      use has dose-dependent, long-term nephrotoxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acetaminophen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      alone (in therapeutic doses) does not appear to induce renal injury but may potentiate the toxicity of phenacetin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of NSAIDs in the development of chronic kidney disease is uncertain. The exposure to large quantities of NSAIDs can probably induce chronic kidney disease although the percentage of patients affected is small relative to the number of prescriptions written, and even smaller relative to the number of NSAIDs that are bought over-the-counter. The effect of long-term use of selective COX-2 inhibitors on kidney function is unknown. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nonsteroidal antiinflammatory drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The renal damage induced by analgesics is most prominent in the medulla with thickening of the vasa recta capillaries (capillary sclerosis) and patchy areas of tubular necrosis; similar vascular lesions can be found in the renal pelvis and ureter. Later changes include areas of papillary necrosis, focal segmental glomerulosclerosis, and interstitial infiltration and fibrosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms underlying analgesic nephropathy are incompletely understood but likely involve toxic intermediates of phenacetin metabolism that accumulate in the medulla along the medullary osmotic gradient.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      may potentiate the toxicity of phenacetin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      by both depleting cortical and papillary glutathione levels, and altering prostaglandin-dependent renal blood flow within the medulla, rendering it more prone to ischemic damage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/1\">",
"      Buckalew VM Jr, Schey HM. Renal disease from habitual antipyretic analgesic consumption: an assessment of the epidemiologic evidence. Medicine (Baltimore) 1986; 65:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/2\">",
"      De Broe ME, Elseviers MM. Over-the-counter analgesic use. J Am Soc Nephrol 2009; 20:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/3\">",
"      Pint&eacute;r I, M&aacute;tyus J, Cz&eacute;g&aacute;ny Z, et al. Analgesic nephropathy in Hungary: the HANS study. Nephrol Dial Transplant 2004; 19:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/4\">",
"      Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy--an autopsy study. Nephrol Dial Transplant 2006; 21:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/5\">",
"      Nanra RS, Stuart-Taylor J, de Leon AH, White KH. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 1978; 13:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/6\">",
"      Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 1983; 308:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/7\">",
"      Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989; 320:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/8\">",
"      Dubach UC, Rosner B, St&uuml;rmer T. Epidemiologic study of analgesic abuse: mortality study in 7275 working women (1968-1987). Kidney Int 1991; 40:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/9\">",
"      Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee. Nephrol Dial Transplant 1994; 9:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/10\">",
"      Noels LM, Elseviers MM, de Broe ME. Impact of legislative measures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 1995; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/11\">",
"      Nanra RS. Analgesic nephropathy in the 1990s--an Australian perspective. Kidney Int Suppl 1993; 42:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/12\">",
"      Segasothy M, Suleiman AB, Puvaneswary M, Rohana A. Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 1988; 50:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/13\">",
"      Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/14\">",
"      Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/15\">",
"      Agodoa LY, Francis ME, Eggers PW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis 2008; 51:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/16\">",
"      Buckalew VM Jr. Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin. Am J Kidney Dis 1996; 28:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/17\">",
"      Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989; 9:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/18\">",
"      Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/19\">",
"      Barrett BJ. Acetaminophen and adverse chronic renal outcomes: an appraisal of the epidemiologic evidence. Am J Kidney Dis 1996; 28:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/20\">",
"      Emkey RD, Mills JA. Aspirin and analgesic nephropathy. JAMA 1982; 247:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/21\">",
"      D'Agati V. Does aspirin cause acute or chronic renal failure in experimental animals and in humans? Am J Kidney Dis 1996; 28:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/22\">",
"      Rexrode KM, Buring JE, Glynn RJ, et al. Analgesic use and renal function in men. JAMA 2001; 286:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/23\">",
"      Ib&aacute;&ntilde;ez L, Morlans M, Vidal X, et al. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. Kidney Int 2005; 67:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/24\">",
"      Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995; 48:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/25\">",
"      Duggin GG. Combination analgesic-induced kidney disease: the Australian experience. Am J Kidney Dis 1996; 28:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/26\">",
"      Feinstein AR, Heinemann LA, Curhan GC, et al. Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int 2000; 58:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/27\">",
"      Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996; 28:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/28\">",
"      Allen RC, Petty RE, Lirenman DS, et al. Renal papillary necrosis in children with chronic arthritis. Am J Dis Child 1986; 140:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/29\">",
"      Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis 1994; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/30\">",
"      Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006; 70:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/31\">",
"      Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/32\">",
"      Wagner EH. Nonsteroidal anti-inflammatory drugs and renal disease--still unsettled. Ann Intern Med 1991; 115:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/33\">",
"      McLaughlin JK, Lipworth L, Chow WH, Blot WJ. Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int 1998; 54:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/34\">",
"      Delzell E, Shapiro S. A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine (Baltimore) 1998; 77:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/35\">",
"      Gault MH, Barrett BJ. Analgesic nephropathy. Am J Kidney Dis 1998; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/36\">",
"      Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight. J Nephrol 1998; 11:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/37\">",
"      van der Woude FJ, Heinemann LA, Graf H, et al. Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol 2007; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/38\">",
"      Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/39\">",
"      Mihatsch MJ, Hofer HO, Gudat F, et al. Capillary sclerosis of the urinary tract and analgesic nephropathy. Clin Nephrol 1983; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35335/abstract/40\">",
"      Bach PH, Hardy TL. Relevance of animal models to analgesic-associated renal papillary necrosis in humans. Kidney Int 1985; 28:605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7176 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35335=[""].join("\n");
var outline_f34_32_35335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPORTANCE OF PHENACETIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Analgesic mixtures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epidemiologic concerns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7176|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/12/12495\" title=\"figure 1\">",
"      Synergistic tox of analgesics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/43/27318?source=related_link\">",
"      Clinical manifestations and diagnosis of analgesic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1012?source=related_link\">",
"      Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_32_35336="Clinical manifestations, evaluation, and staging of renal cell carcinoma";
var content_f34_32_35336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, evaluation, and staging of renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35336/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35336/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35336/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35336/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/32/35336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant neoplasms involving the kidney may be primary or secondary tumors. Secondary renal neoplasms are usually clinically insignificant and discovered at postmortem examination.",
"   </p>",
"   <p>",
"    Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma or Wilms' tumor is common in children (5 to 6 percent of all primary renal tumors). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=see_link\">",
"     \"Malignancies of the renal pelvis and ureter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical and radiographic presentation of RCC and the methods used for tumor staging, as well as their potential application for screening, will be reviewed here. The prognosis and treatment of RCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RCC can present with a range of symptoms; unfortunately, many patients are asymptomatic until the disease is advanced. At presentation, approximately 25 percent of individuals either have distant metastases or advanced locoregional disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with localized disease can present with a wide array of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laboratory abnormalities, or they may be diagnosed incidentally. In a 1971 review of 309 consecutive patients with RCC, the most common presenting symptoms were hematuria, abdominal mass, pain, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/2\">",
"     2",
"    </a>",
"    ]. In contemporary series, fewer patients have the typical symptoms and there is an increased frequency of incidental diagnosis due to radiologic procedures performed for other indications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link&amp;anchor=H175757290#H175757290\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This shift in pattern of presentation may contribute to better outcomes in RCC. In a series of 701 patients, those who were diagnosed incidentally had a significantly better disease-specific survival at five years (76 versus 44 percent in those with symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/3\">",
"     3",
"    </a>",
"    ]. Multivariate analysis showed that the difference was due to the lower stage and histologic grade at the time of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic triad of RCC (flank pain, hematuria, and a palpable abdominal renal mass) occurs in at most 9 percent of patients; when present, it strongly suggests locally advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Other symptoms and signs are related to invasion of adjacent structures or distant metastases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematuria is observed only with tumor invasion of the collecting system. In an early series, hematuria was observed in almost 40 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/5\">",
"       5",
"      </a>",
"      ]. When severe, the bleeding can cause clots and \"colicky\" discomfort. Clot formation does not occur with glomerular bleeding; thus the presence of clots is a significant finding in patients with otherwise unexplained hematuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link&amp;anchor=H1824471590#H1824471590\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Blood clots'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An abdominal or flank mass, which is associated with lower pole tumors, is more commonly palpated in the thin adult. The mass is generally firm, homogeneous, nontender, and moves with respiration.",
"     </li>",
"     <li>",
"      Scrotal varicoceles, the majority of which are left-sided, are observed in as many as 11 percent of men with RCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/6\">",
"       6",
"      </a>",
"      ]. Varicoceles typically fail to empty when the patient is recumbent. This finding should always arouse suspicion for a kidney tumor that has obstructed the gonadal vein where it enters the renal vein. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/51/5942?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of nonacute scrotal pathology in adult men\", section on 'Varicocele'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inferior vena cava involvement can produce a variety of clinical manifestations, including lower extremity edema, ascites, hepatic dysfunction (possibly related to a Budd-Chiari syndrome), and pulmonary emboli.",
"     </li>",
"     <li>",
"      Among patients with disseminated disease, signs or symptoms may be due to metastatic tumor; the most common sites of involvement include the lung, lymph nodes, bone, liver, and brain. In this setting, the diagnosis is often made either by biopsy of an accessible metastasis or by finding a renal mass on abdominal computed tomography (CT). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32360?source=see_link&amp;anchor=H4#H4\">",
"       \"Surveillance for metastatic disease after nephrectomy for renal cell carcinoma\", section on 'Sites of metastasis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Paraneoplastic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with RCC present with or subsequently develop systemic symptoms or paraneoplastic syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In some instances, these may be due to ectopic production of various hormones (eg, erythropoietin, parathyroid hormone-related protein, gonadotropins, human chorionic somatomammotropin, an ACTH-like substance, renin, glucagon, insulin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia, which can precede the diagnosis of RCC by several months, has been reported in 29 to 88 percent of patients with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ]. The anemia is often disproportionately severe, can be either normocytic or microcytic, and is frequently associated with iron studies typical of those observed with the anemia of chronic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic dysfunction is an uncommon occurrence in patients with RCC that is called Stauffer's syndrome when it occurs in the absence of liver metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In a series of 365 patients, 21 percent had a paraneoplastic elevation in serum alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When hepatic dysfunction is present, it frequently is associated with fever, weight loss, fatigue, and a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/15\">",
"     15",
"    </a>",
"    ]. The dysfunction may result from tumor production of cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and possibly interleukin (IL)-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrectomy may result in the amelioration of hepatic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Recurrent elevations of liver enzymes in such patients may herald local recurrence or distant metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever, which occurs in up to 20 percent of patients, is usually intermittent and is frequently accompanied by night sweats, anorexia, weight loss, and fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]. Its origin is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia occurs in up to 15 percent of patients with RCC, and can result from a number of different mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lytic bone metastases.",
"     </li>",
"     <li>",
"      Overproduction of parathyroid hormone-related protein (PTHrP) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. Concurrent production of IL-6 may enhance the action of PTHrP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased production of prostaglandins that promote bone resorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. In such patients, the hypercalcemia can respond to administration of a nonsteroidal antiinflammatory drug, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis and management of hypercalcemia in patients with malignancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cachexia",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other tumors, patients with RCC may suffer from significant cachexia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link\">",
"     \"Clinical features and pathogenesis of cancer cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Erythrocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrocytosis occurs in 1 to 5 percent of patients with RCC and appears to be due to constitutive production of erythropoietin&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, since the mutated von Hippel-Lindau protein is associated with impaired regulation of hypoxia-induced proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], erythrocytosis may be directly related to impaired degradation of hypoxia-inducible transcription factors under normoxic conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     AA amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary (AA) amyloidosis is found in 3 to 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This finding reflects a chronic inflammatory response as the amyloid fibrils are composed of fragments of the acute phase reactant serum amyloid A protein. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytosis is rare in patients with RCC, but its presence is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The underlying mechanism is not firmly established but could be related to IL-6 production by the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Polymyalgia rheumatica",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome resembling polymyalgia rheumatica has been reported with RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast to idiopathic disease, the symptoms do not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    but are often corrected by nephrectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiographic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unexplained hematuria, or other symptoms, signs, or findings suggestive of a possible RCC, must undergo radiographic evaluation for the presence of a renal mass. The usual first test is abdominal ultrasound or CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60352 \" href=\"mobipreview.htm?1/58/1956\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, incidental diagnosis of RCC is becoming more common due to the frequent use of abdominal CT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ultrasonography for the evaluation of an unrelated problem. Rarely, renal neoplasia is diagnosed in a renal biopsy specimen performed for other reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although ultrasonography is less sensitive than CT in detecting a renal mass, it is useful to distinguish a simple benign cyst from a more complex cyst or a solid tumor. The issues surrounding the evaluation of an asymptomatic renal mass or a cyst are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link\">",
"     \"Simple and complex renal cysts in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, there are three major criteria that allow a simple cyst to be differentiated from a tumor or abscess on ultrasonography (",
"    <a class=\"graphic graphic_table graphicRef67087 \" href=\"mobipreview.htm?14/61/15324\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The cyst is round and sharply demarcated with smooth walls",
"     </li>",
"     <li>",
"      There are no echoes within the cyst (\"anechoic\")",
"     </li>",
"     <li>",
"      There is a strong posterior wall echo indicating good transmission through a cyst",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If all of these criteria are fulfilled, no further evaluation is necessary since the likelihood of a malignancy is extremely small. If the criteria for a simple cyst by ultrasonography are not satisfied, the patient should undergo CT scanning before and after injection of iodinated contrast. On CT, a simple cyst has a smooth appearance without a clearly delineated wall, has no enhancement with intravascular contrast, and is the density of water. CT urography allows imaging of both the renal parenchyma and the collecting system.",
"   </p>",
"   <p>",
"    By comparison, thickened irregular walls or septa (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77721 \" href=\"mobipreview.htm?36/42/37551\">",
"     image 2",
"    </a>",
"    ) and enhancement after contrast injection are suggestive of malignancy (",
"    <a class=\"graphic graphic_table graphicRef67087 \" href=\"mobipreview.htm?14/61/15324\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link&amp;anchor=H2#H2\">",
"     \"Simple and complex renal cysts in adults\", section on 'Bosniak classification of renal cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) may be useful when ultrasonography and CT are nondiagnostic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic contrast cannot be administered because of allergy or poor renal function (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73120 graphicRef51129 \" href=\"mobipreview.htm?0/56/904\">",
"     image 3A-B",
"    </a>",
"    ). MRI may be particularly valuable if a tumor is present to identify the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of involvement of the collecting system",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inferior vena cava. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link&amp;anchor=H5#H5\">",
"     \"Simple and complex renal cysts in adults\", section on 'Category IIF and III'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5546?source=see_link\">",
"     \"Surgical management of localized renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dynamic, contrast-enhance MRI may also be useful in determining histology, with clear cell carcinoma showing greater signal intensity change in the corticomedullary and nephrographic phase than either papillary or chromophobe carcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal arteriography is rarely necessary. If preoperative mapping of the vasculature is required prior to possible nephron-sparing surgery, either CT or MR angiography are preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TISSUE DIAGNOSIS AND STAGING WORKUP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of RCC is occasionally established by a biopsy of a metastasis, nephrectomy or partial nephrectomy is used in most cases to obtain tissue for histology and for treatment. After the presumptive diagnosis has been made based upon imaging studies, the patient must be evaluated for the extent of local involvement and the presence of metastatic disease prior to surgery.",
"   </p>",
"   <p>",
"    RCCs can enlarge locally, invade surrounding fascia and adjacent organs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastasize. The most common sites of metastases are the regional lymphatics, lungs, bone, liver, brain, the ipsilateral adrenal gland, and the contralateral kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. RCC can also metastasize to other anatomic locations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of local and regional involvement is determined primarily by abdominal CT, which is extremely accurate in staging RCC. In a retrospective study of 100 renal cell carcinomas, for example, preoperative CTs were compared with the findings obtained at surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/40\">",
"     40",
"    </a>",
"    ]. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For the detection of renal vein invasion, CT was 78 percent sensitive and 96 percent specific.",
"     </li>",
"     <li>",
"      For the detection of metastatic adenopathy, CT was 83 sensitive and 88 percent specific.",
"     </li>",
"     <li>",
"      For the detection of perinephric invasion, CT was only 46 percent sensitive but was 98 percent specific.",
"     </li>",
"     <li>",
"      For adjacent organ invasion, CT was 100 percent specific.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of CT for detecting nodal metastasis depends upon the size criterion used to define suspicious nodes. At least some data suggest that about 50 percent of patients with radiographically enlarged nodes in the 1 to 2 cm size range do not harbor metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other procedures that may be useful for assessing for distant metastases include a bone scan, CT of the chest, MRI, and positron emission tomography (PET):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A bone scan is indicated only in patients with bone pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevated serum alkaline phosphatase. In one series, for example, fewer than 5 percent of such patients had occult bone metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT of the chest is useful to evaluate for evidence of pulmonary or mediastinal lymph node metastases.",
"     </li>",
"     <li>",
"      MRI scanning with gadolinium is superior to CT for the evaluation of the inferior vena cava and right atrium when tumor involvement is suspected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PET scanning has high sensitivity and specificity for the primary lesion. Although PET may be more sensitive than radionuclide scanning for the detection of bone metastases, it is expensive and has limited use for routine staging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/44-46\">",
"       44-46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although solid renal masses &lt;3 cm were once thought to represent benign adenomas, distinctions based upon size are no longer used, since even small tumors frequently represent carcinomas that will grow over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/47\">",
"     47",
"    </a>",
"    ]. Any solid renal mass requires a histologic diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=see_link\">",
"     \"Simple and complex renal cysts in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to establishing the diagnosis of malignancy, tissue diagnosis provides information about the histopathologic type of RCC, which may have important implications for prognosis and treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with isolated, solid renal masses, resection with either a partial or complete nephrectomy is preferred to biopsy because it provides both the diagnosis and definitive treatment. Preoperative needle biopsies are usually not used for resectable renal lesions because of their low specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/48\">",
"     48",
"    </a>",
"    ] and concerns about tumor seeding of the peritoneum.",
"   </p>",
"   <p>",
"    When metastatic disease is suspected at the initial presentation, pathologic confirmation is required prior to starting therapy. Biopsy of a metastatic site is often easier and more informative than biopsy of the primary tumor. Pre-operative tumor biopsy should be considered in patients being considered for cytoreductive nephrectomy, since this procedure has established utility in conjunction with immunotherapy and immunotherapy has confirmed value only for clear cell carcinoma.",
"   </p>",
"   <p>",
"    However, the advent of effective targeted and antiangiogenic therapies has prompted an ongoing reassessment of the role of cytoreductive nephrectomy even in patients with clear cell RCC. This reassessment will likely influence the decisions regarding preoperative biopsy, especially in patients whose disease burden in concentrated within the primary tumor.",
"   </p>",
"   <p>",
"    In the setting of a patient with a previously diagnosed nonrenal malignancy, metastatic disease is more likely than a new primary RCC. If the renal mass is nonenhancing and there is clinical evidence of progression of the nonrenal malignancy, biopsy confirmation may be unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TNM STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Tumor Node Metastasis (TNM) staging system is used for staging all histologic variants of renal carcinoma. This system was revised in 2010, and is supported by both the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/50\">",
"     50",
"    </a>",
"    ]. These TNM criteria define the anatomic extent of disease and stage and have been shown to correlate with prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2010 version of the TNM system is shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"     table 2",
"    </a>",
"    ). In this system, tumors limited to the kidney are classified as T1 or T2 based upon size. T3 tumors extend into the renal vein or perinephric tissues but not beyond Gerota's fascia, while T4 tumors extend beyond Gerota's fascia, including direct extension into the ipsilateral adrenal gland. Nodal and distant metastases are simply classified as absent or present.",
"   </p>",
"   <p>",
"    Differences from the 2002 version of the TNM system include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T2 lesions have been subdivided into T2a and T2b, based upon a size criterion (&gt;7 but &le;10 cm versus &gt;10 cm)",
"     </li>",
"     <li>",
"      Ipsilateral adrenal involvement is reclassified as T4 if contiguous invasion and M1 if not contiguous",
"     </li>",
"     <li>",
"      Renal vein involvement is reclassified as T3a rather than T3b",
"     </li>",
"     <li>",
"      Nodal involvement is simplified to present or absent (N0 versus N1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SOLID RENAL MASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of solid renal parenchymal masses is incompletely understood and relies upon both the ability of imaging studies to identify simple renal cysts and the likelihood of the lesion exhibiting clinically malignant behavior. The evaluation and initial management of a patient with a solid renal mass is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening of asymptomatic individuals is not recommended because of the low prevalence of RCC in the general population. However, individuals at high risk for the development of RCC should undergo periodic monitoring with abdominal ultrasonography, CT, or magnetic resonance imaging (MRI) to detect early disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35336/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Candidates for screening include patients with any of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited conditions associated with an increased incidence of RCC or other renal tumors, including Von Hippel-Lindau syndrome and tuberous sclerosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=see_link\">",
"       \"Renal manifestations of tuberous sclerosis and renal angiomyolipoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      End-stage renal disease, especially younger subjects without serious comorbid diseases who have been on dialysis for three to five years or more. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=see_link\">",
"       \"Acquired cystic disease of the kidney in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A strong family history of RCC.",
"     </li>",
"     <li>",
"      Prior kidney irradiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/53/30546?source=see_link\">",
"       \"Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with renal cell carcinoma (RCC) can present with a range of symptoms due to the tumor itself (eg, mass, pain), invasion of the urinary tract (eg, hematuria), paraneoplastic syndromes, or the presence of metastases. In addition, RCC is more frequently being diagnosed incidentally as a consequence of increased use of imaging procedures for other reasons. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptoms, signs, or other findings suggestive of RCC should undergo evaluation for the presence of a renal mass. Ultrasound and CT can confirm the presence of a mass, distinguish RCC from a benign cyst, and assess the extent of disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even in the absence of abnormalities suggesting malignancy, imaging studies",
"      <strong>",
"       cannot",
"      </strong>",
"      reliably distinguish a benign renal tumor from an RCC. Thus it is generally recommended that lesions other than simple cysts be resected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=see_link\">",
"       \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The TNM staging system, which is based upon the extent of the primary tumor and the presence or absence of regional lymph node involvement or distant metastases, is preferred (",
"      <a class=\"graphic graphic_table graphicRef54563 \" href=\"mobipreview.htm?14/54/15213\">",
"       table 2",
"      </a>",
"      ). This staging system correlates with prognosis, and provides important information for patient management. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Tissue diagnosis and staging workup'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'TNM staging system'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=see_link\">",
"       \"Prognostic factors in patients with renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals thought to be at increased risk for the development of RCC should be considered for routine screening with abdominal ultrasound, CT, or MRI. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Garnick MB. Primary neoplasms of the kidney. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney, Brady HR, Wilcox CS (Eds), WB Saunders, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/2\">",
"      Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/3\">",
"      Gudbjartsson T, Thoroddsen A, Petursdottir V, et al. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 2005; 66:1186.",
"     </a>",
"    </li>",
"    <li>",
"     DeKernion JB. Real numbers. In: Campbell's Urology, Walsh PC, Gittes RF, Perlmutter AD (Eds), WB Saunders, Philadelphia 1986. p.1294.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/5\">",
"      Gibbons RP, Monte JE, Correa RJ Jr, Mason JT. Manifestations of renal cell carcinoma. Urology 1976; 8:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/6\">",
"      PINALS RS, KRANE SM. Medical aspects of renal carcinoma. Postgrad Med J 1962; 38:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/7\">",
"      Chisholm GD, Roy RR. The systemic effects of malignant renal tumours. Br J Urol 1971; 43:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/8\">",
"      Laski ME, Vugrin D. Paraneoplastic syndromes in hypernephroma. Semin Nephrol 1987; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/9\">",
"      Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 1996; 14:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/10\">",
"      Cherukuri SV, Johenning PW, Ram MD. Systemic effects of hypernephroma. Urology 1977; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/11\">",
"      Sufrin G, Mirand EA, Moore RH, et al. Hormones in renal cancer. J Urol 1977; 117:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/12\">",
"      Walsh PN, Kissane JM. Nonmetastatic hypernephroma with reversible hepatic dysfunction. Arch Intern Med 1968; 122:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/13\">",
"      Utz DC, Warren MM, Gregg JA, et al. Reversible hepatic dysfunction associated with hypernephroma. Mayo Clin Proc 1970; 45:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/14\">",
"      Chuang YC, Lin AT, Chen KK, et al. Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis. J Urol 1997; 158:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/15\">",
"      Boxer RJ, Waisman J, Lieber MM, et al. Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 1978; 119:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/16\">",
"      Chang SY, Yu DS, Sherwood ER, et al. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol 1992; 147:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/17\">",
"      Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/18\">",
"      Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992; 84:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/19\">",
"      Cranston WI, Luff RH, Owen D, Rawlins MD. Studies on the pathogenesis of fever in renal carcinoma. Clin Sci Mol Med 1973; 45:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/20\">",
"      O'Grady AS, Morse LJ, Lee JB. Parathyroid hormone-secreting renal carcinoma associated with hypercalcemia and metabolic alkalosis. Ann Intern Med 1965; 63:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/21\">",
"      LYTTON B, ROSOF B, EVANS JS. PARATHYROID HORMONE-LIKE ACTIVITY IN A RENAL CARCINOMA PRODUCING HYPERCALCEMIA. J Urol 1965; 93:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/22\">",
"      GOLDBERG MF, TASHJIAN AH Jr, ORDER SE, DAMMIN GJ. RENAL ADENOCARCINOMA CONTAINING A PARATHYROID HORMONE-LIKE SUBSTANCE AND ASSOCIATED WITH MARKED HYPERCALCEMIA. Am J Med 1964; 36:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/23\">",
"      Sandhu DP, Munson KW, Harrop JS, et al. Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein. Br J Urol 1993; 72:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/24\">",
"      de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95:2846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/25\">",
"      Weissglas M, Schamhart D, L&ouml;wik C, et al. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 1995; 153:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/26\">",
"      Brereton HD, Halushka PV, Alexander RW, et al. Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma. N Engl J Med 1974; 291:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/27\">",
"      Robertson RP, Baylink DJ, Marini BJ, Adkison HW. Elevated prostaglandins and suppressed parathyroid hormone associated with hypercalcemia and renal cell carcinoma. J Clin Endocrinol Metab 1975; 41:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/28\">",
"      Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/29\">",
"      Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/30\">",
"      Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/31\">",
"      Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med 1982; 73:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/32\">",
"      Chisholm GD. Nephrogenic ridge tumors and their syndromes. Ann N Y Acad Sci 1974; 230:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/33\">",
"      Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/34\">",
"      O'Keefe SC, Marshall FF, Issa MM, et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002; 168:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/35\">",
"      Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy. Arch Intern Med 1993; 153:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/36\">",
"      Pankhurst T, Howie AJ, Adu D, et al. Incidental neoplasms in renal biopsies. Nephrol Dial Transplant 2006; 21:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/37\">",
"      Sun MR, Ngo L, Genega EM, et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology 2009; 250:793.",
"     </a>",
"    </li>",
"    <li>",
"     McDougal WS, Garnick MB. Clinical signs and symptoms of kidney cancer. In: Comprehensive Textbook of Genitourinary Oncology, Vogelzang NJ, Scardino PT, Shipley WU, et al (Eds), Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/39\">",
"      Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983; 10:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/40\">",
"      Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 1987; 148:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/41\">",
"      Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/42\">",
"      Koga S, Tsuda S, Nishikido M, et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 2001; 166:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/43\">",
"      Semelka RC, Shoenut JP, Magro CM, et al. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993; 3:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/44\">",
"      Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/45\">",
"      Wu HC, Yen RF, Shen YY, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 2002; 128:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/46\">",
"      Goldberg MA, Mayo-Smith WW, Papanicolaou N, et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/47\">",
"      Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/48\">",
"      Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003; 169:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/49\">",
"      S&aacute;nchez-Ortiz RF, Madsen LT, Bermejo CE, et al. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer 2004; 101:2195.",
"     </a>",
"    </li>",
"    <li>",
"     Kidney. In: American Joint Committee on Cancer Staging Manual, Springer, New York 2009. p.447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35336/abstract/51\">",
"      Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2983 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-124.240.187.81-3C54767836-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35336=[""].join("\n");
var outline_f34_32_35336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Paraneoplastic symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cachexia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Erythrocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - AA amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiographic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other imaging tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TISSUE DIAGNOSIS AND STAGING WORKUP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TNM STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SOLID RENAL MASSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2983|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/58/1956\" title=\"diagnostic image 1\">",
"      Clear cell carcinoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?36/42/37551\" title=\"diagnostic image 2\">",
"      Cystic renal cell carcinoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/12/40130\" title=\"diagnostic image 3A\">",
"      Clear cell carc MRI A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/42/38562\" title=\"diagnostic image 3B\">",
"      Clear cell carc MRI B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2983|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/61/15324\" title=\"table 1\">",
"      Bosniak criteria renal cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/54/15213\" title=\"table 2\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/51/5942?source=related_link\">",
"      Evaluation of nonacute scrotal pathology in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1754?source=related_link\">",
"      Malignancies of the renal pelvis and ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43303?source=related_link\">",
"      Renal manifestations of tuberous sclerosis and renal angiomyolipoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27704?source=related_link\">",
"      Simple and complex renal cysts in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32360?source=related_link\">",
"      Surveillance for metastatic disease after nephrectomy for renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_32_35337="Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing";
var content_f34_32_35337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Sarah Feldman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Christopher P Crum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/32/35337/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/32/35337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cancer screening detects preinvasive neoplasia, thereby making treatment possible before the disease becomes invasive. Screening is performed using cervical cytology (Pap test), or a human papillomavirus (HPV) test, or a combination of the two tests.",
"   </p>",
"   <p>",
"    Techniques for obtaining specimens for cervical cytology and HPV testing are reviewed here. Screening strategies and interpretation of the cervical cytology report are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HOW TO OBTAIN A SAMPLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell samples for cervical cytology and HPV testing are obtained during the speculum examination. The same specimen can be used for both tests or separate specimens can be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Specimens for cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two methods for preparing a specimen for cervical cytology: the conventional Pap smear and the liquid-based, thin layer preparation (eg, ThinPrep&reg;, SurePath&trade;).",
"   </p>",
"   <p>",
"    For both methods, cells are obtained from the external surface of the cervix (ectocervix) and the cervical canal (endocervix) to evaluate the transformation zone (squamocolumnar junction), the area at greatest risk for neoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Collection device",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several collection devices are available for cervical cytology sampling. We suggest using a spatula and a separate endocervical brush as this combination provides a specimen with more endocervical cells than when only a spatula is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also slightly better for detecting any grade of cervical intraepithelial neoplasia (CIN) than the single broom device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/1\">",
"     1",
"    </a>",
"    ]. Cotton tipped swabs should be avoided because they collect fewer endocervical cells and do not detect CIN as well as other devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 36 randomized trials and six observational studies in women undergoing conventional Pap smears found that the most commonly used spatula (Ayre spatula) (",
"    <a class=\"graphic graphic_figure graphicRef72092 \" href=\"mobipreview.htm?19/45/20183\">",
"     figure 1",
"    </a>",
"    ) collected fewer endocervical cells than spatulas with extended tips (eg, Aylesbury), but both spatula types yielded similar diagnostic results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sample collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain cells from the cervix:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use the spatula to circumferentially scrape the ectocervix (for liquid-based samples, use a plastic rather than a wooden spatula; wood or plastic is fine for conventional smears) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/5\">",
"       5",
"      </a>",
"      ]. Sampling the ectocervix before the endocervix will minimize bleeding during sample collection. Obscuring blood in the sample interferes with interpretation of conventional Pap smears more than with liquid-based specimens.",
"     </li>",
"     <li>",
"      Insert the endocervical brush into the endocervix so that the bristles nearest the examiner are inserted to the level of the external cervical os. Rotate the brush 180&ordm; to obtain a sample.",
"     </li>",
"     <li>",
"      Alternatively, if a broom is used, insert the central bristles into the endocervix with the outer bristles in contact with the ectocervix. Rotate the broom in the same direction for five turns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In women at high risk for vaginal cancer because of in utero diethyl stilbestrol exposure, additional samples from the anterior and posterior fornices should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=see_link&amp;anchor=H4#H4\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\", section on 'Clear cell adenocarcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with cervical stenosis it may be difficult to obtain an endocervical sample, thus resulting in an insufficient result. When it is difficult to insert the sampling device into the endocervix, we use one of the following techniques to facilitate collection of an endocervical sample:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perform Pap testing during menses. Menstrual blood often slightly dilates the cervix.",
"     </li>",
"     <li>",
"      Grasp the anterior lip of the cervix with a single tooth tenaculum. Applying gentle traction will stabilize the cervix and may provide enough conter-tension to insert a sampling device into the external cervical os.",
"     </li>",
"     <li>",
"      Administer a para- or intracervical block and use small mechanical dilators to dilate the cervix.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If endocervical cells are not obtained despite these measures, a negative HPV test is partially reassuring. However, some glandular abnormalities may be present in the absence of a positive HPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Sample preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For conventional Pap smears, the ectocervical spatula is smeared and the endocervical brush is rolled uniformly onto a single slide promptly after obtaining the specimens (",
"    <a class=\"graphic graphic_figure graphicRef72393 \" href=\"mobipreview.htm?38/30/39393\">",
"     figure 2",
"    </a>",
"    ). The slide is then rapidly fixed to avoid air-drying; the usual fixatives are either ethyl ether plus 95 percent ethyl alcohol or 95 percent ethyl alcohol alone. If spray fixatives are used, the spray should be held at least 10 inches away from the slide to prevent disruption of cells by the propellant.",
"   </p>",
"   <p>",
"    For liquid-based thin layer cytology, the collecting device is placed into a liquid fixative solution and vigorously swirled or rotated ten times in the solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/8\">",
"     8",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef58546 \" href=\"mobipreview.htm?38/26/39329\">",
"     figure 3",
"    </a>",
"    ). When the liquid is processed by the cytology laboratory, loose cells are trapped onto a filter and then plated in a monolayer onto a glass slide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HPV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens for HPV testing can be collected from the endocervix using a Dacron swab or cervical brush, which is then placed in HPV test transport medium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/9\">",
"     9",
"    </a>",
"    ]. If liquid-based cytology sampling is performed, the same specimen can be used for HPV testing and cytology.",
"   </p>",
"   <p>",
"    Commercial HPV assays, used with liquid based cytology sampling, only test for HPV types that have been associated with cancer. These HPV types are called oncogenic or high risk HPV (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"mobipreview.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=see_link&amp;anchor=H2#H2\">",
"     \"Virology of human papillomavirus infections and the link to cancer\", section on 'Virology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=see_link&amp;anchor=H4#H4\">",
"     \"Virology of human papillomavirus infections and the link to cancer\", section on 'Molecular pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gonorrhea and chlamydia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cytology sample is generally taken before testing for infection, if indicated, there is no evidence that the order the samples are obtained affects cytology results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/10\">",
"     10",
"    </a>",
"    ]. Liquid-based thin layer cytology systems allow testing for cytology, HPV, gonorrhea, and chlamydia from a single specimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Biopsy of visible lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;During Pap testing, any lesion that is raised, friable, or has the appearance of condyloma should be biopsied, regardless of previous cytology results or other risk factors for cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/11\">",
"     11",
"    </a>",
"    ]. The only visible lesions that do not require biopsy are Nabothian cysts, and only when this diagnosis is confirmed by an experienced examiner. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=see_link&amp;anchor=H13#H13\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Nabothian cysts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SAMPLE INTERPRETATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cytologic analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytopathologists review cervical cytology slides. The interpretation of cytologic smears is subject to considerable inter-observer variability, particularly in the case of non-diagnostic squamous and glandular atypias (atypical squamous cells of undetermined significance [ASCUS] and atypical glandular cells of undetermined significance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some settings, cytotechnologists",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    automated slide interpretation devices perform initial review of the cytology slides to identify a subgroup of slides for subsequent evaluation by a cytopathologist. This subgroup consists of slides with specific abnormal characteristics.",
"   </p>",
"   <p>",
"    One example of an automated slide interpretation system is the ThinPrep&reg; Imaging System, which is approved by the US Food and Drug Association (FDA) for primary screening of slides. This system uses programmed algorithms to review each slide for areas of most concern. If abnormalities are found, the whole slide is reviewed by a cytopathologist. In one study, use of this device increased detection of high grade squamous lesions (HSIL) by 38 percent and low grade squamous lesions (LSIL) by 46 percent compared to manual screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/13\">",
"     13",
"    </a>",
"    ]. In another study, use of the imager resulted in fewer unsatisfactory slides than with conventional cytology (1.8 versus 3.1 percent) and better detection of HSIL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/14\">",
"     14",
"    </a>",
"    ]. Although promising, the clinical effectiveness of automated systems and their role in cervical cancer screening has not been definitively established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, quality assurance regulations require that laboratories rescreen 10 percent of randomly selected cervical cytology smears that were originally interpreted as negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/16\">",
"     16",
"    </a>",
"    ]. Manual rescreening of all negative cytology smears is time consuming, although rapid manual rescreening (30 to 120 seconds per slide) is feasible and practiced in the United Kingdom and elsewhere.",
"   </p>",
"   <p>",
"    Standardized terminology for reporting cervical cytology results were introduced with the Bethesda System in 1988, which was last revised in 2001 (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"mobipreview.htm?18/51/19261\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HPV testing result reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, human papilloma virus (HPV) testing is used as primary screening for cervical cancer (as a co-test with cytology) in women over age 30 and for reflex testing after a cervical cytology result of atypical squamous cells of undetermined significance in women 21 years and older. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two types of available HPV tests (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8248?source=see_link&amp;anchor=H3956630#H3956630\">",
"     \"Cervical cancer screening tests: Evidence of effectiveness\", section on 'HPV testing'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tests that detect the presence or absence of any of 12 to 14 high-risk HPV subtypes that are associated with a high risk of cervical cancer (",
"      <a class=\"graphic graphic_table graphicRef76394 \" href=\"mobipreview.htm?0/27/443\">",
"       table 1",
"      </a>",
"      ). These tests do not report which of the individual subtypes are present. A negative test means that no oncogenic HPV types or only HPV types of low oncogenic risk were detected (however, the laboratory will report a negative test even if no cells are present).",
"     </li>",
"     <li>",
"      Tests that perform HPV genotyping and report the presence or absence of HPV 16 or 18, which are the subtypes most commonly associated with high-grade cervical intraepithelial neoplasia and cervical cancer types [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. In addition, HPV 18 infection appears to be associated with an increased risk of cervical adenocarcinoma compared with other oncogenic types [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing for high-risk subtypes is reported as the ratio of light emission from a sample, relative light units (RLU), to the average of three concurrently tested positive control specimens (PC) containing 1",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    of HPV-16 DNA and the recommended positivity threshold is typically &ge;1",
"    <span class=\"nowrap\">",
"     RLU/PC",
"    </span>",
"    (equivalent to 5000 viral copies per test well) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HPV test detects viral DNA replication. Data suggest that the false negative rate of the Hybrid Capture II HPV test for a finding of cervical intraepithelial lesion (CIN) grade 2 or 3 on biopsy is between one and five percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. False negative HPV tests have been associated with small lesions, unsatisfactory colposcopy, and women older than 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type-specific testing for HPV 16 and 18 is not useful for identifying women who should not receive HPV vaccination, since HPV infection can be transient and it is not known if previous HPV infection is protective against reinfection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link&amp;anchor=H8#H8\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Advisory Committee on Immunization Practices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with apparently normal immune systems may &ldquo;reactivate&rdquo; latent HPV infections and may develop new episodes of cervical, vulvar, or vaginal dysplasia, without a new exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/28\">",
"     28",
"    </a>",
"    ]. For women with latent infections, the virus may remain dormant in the cytoplasm. In such cases, the HPV virus is still technically present, but the HPV test will be negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHOOSING CONVENTIONAL SMEARS VERSUS LIQUID-BASED CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing between conventional smears and liquid-based tests depends upon a variety of factors, including specimen adequacy, screening performance, ability to perform concurrent testing, and cost.",
"   </p>",
"   <p>",
"    These factors, particularly cost and test and laboratory availability for liquid-based methods vary by health care setting, thus, no general recommendation can be made. The American College of Obstetricians and Gynecologists advises that either method is acceptable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/29\">",
"     29",
"    </a>",
"    ]. Liquid-based systems provide greater specimen adequacy, particularly for women with cervical bleeding or inflammation, which may obscure interpretation of a conventional Pap smear. Liquid-based and conventional smears appear to perform equally well for detection of HSIL, but liquid-based methods perform better for detection of glandular abnormalities, ASCUS, and LSIL. The ability to obtain reflex HPV testing, when needed, from a single liquid-based specimen is another advantage of this technique. Costs vary by screening strategy and health care setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Specimen adequacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews and subsequent randomized trials have found that specimen adequacy is better with liquid-based than conventional cytology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/14,30-33\">",
"     14,30-33",
"    </a>",
"    ]. However, in the largest systematic review, this benefit was not clinically significant; there were minimal differences between liquid-based and conventional methods in the percent of unsatisfactory slides (-0.17 percent, interquartile range -0.98 to 0.37 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies did not address specimen adequacy in specific populations. Liquid based cytology may increase the yield of adequate specimens in subgroups of patients, such as those with obscuring blood and inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of comparative studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/31,33,35-38\">",
"     31,33,35-38",
"    </a>",
"    ] and independent reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] have not found that liquid-based cytology performs better than conventional cytology for detection of high grade squamous lesions, which are the lesions most likely to progress to invasive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     HSIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most rigorous systematic review of test performance analyzed 56 comparative studies including over one million slides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/33\">",
"     33",
"    </a>",
"    ]. Study quality was poor overall; only five studies were classified as high quality. In these five studies, there was no evidence that liquid-based cytology significantly improved detection of HSIL compared with conventional smears. Three subsequent large randomized trials, each with over 40,000 women, confirmed this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/32,42,43\">",
"     32,42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     LSIL or ASCUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systematic review and two of the randomized trials described above found that liquid-based methods detected ASCUS or LSIL better than conventional smears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/32,33,42\">",
"     32,33,42",
"    </a>",
"    ]; one randomized trial found no difference in the detection of ASCUS or LSIL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Glandular cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational data suggests that liquid-based cytology performs better than conventional smears for detection of atypical glandular cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/32,44-52\">",
"     32,44-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical and malignant glandular cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Concurrent HPV testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An advantage of liquid-based methods is the ability to use a single specimen for cytology and testing for HPV. With conventional smears, a separate HPV test specimen has to be obtained and held for reflex testing or the patient has to be called to return to clinic for HPV testing in cases of ASCUS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=see_link&amp;anchor=H16#H16\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing as triage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies comparing liquid-based and conventional Pap tests have not evaluated cost-effectiveness. An analysis of cost per invasive cervical cancer avoided performed by the United Kingdom National Health Service found that liquid-based cytology is more cost-effective if screening is performed every two to three years, but not if it is performed every five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/41\">",
"     41",
"    </a>",
"    ]. The relative costs of the two types of Pap tests are controversial and depend both on the performance of each approach and health care delivery costs that vary by health care setting.",
"   </p>",
"   <p>",
"    Cost-effectiveness calculation must include associated costs of each method. As an example, liquid-based slides can be read by the cytopathologist more quickly than conventional smears and may offer an advantage when used with automated screening devices, which may enhance cost-effectiveness. However, liquid-based Paps detect more ASCUS and LSIL, which often do not represent true precancers and lead to higher costs because of more referrals for colposcopy.",
"   </p>",
"   <p>",
"    For clinicians who use liquid-based cytology, there are few data comparing costs for the various liquid-based cytology systems (eg, ThinPrep&reg;, SurePath&trade;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/53\">",
"     53",
"    </a>",
"    ]; high quality data are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MISPERCEPTIONS ABOUT FACTORS THAT INTERFERE WITH SAMPLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a consistent perception that any action that may remove cells from the cervix (eg, prior Pap sampling, cervical cultures, swabbing) will impair Pap test cellularity, and thus compromise efficacy for cervical cancer screening. However, data do not support these concerns.",
"   </p>",
"   <p>",
"    The factors discussed in this section relate to the effects on cytology or HPV testing or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Menses or other genital tract bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, women planning to have screening cytology for cervical cancer have been advised to avoid testing during menses or other genital tract bleeding. We suggest performing rather than deferring the test, unless the blood cannot be cleaned from the cervix. Cleaning the cervix with a large cotton swab will remove obscuring blood and appears to have a minimal or no effect on sample cellularity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is obscuring blood, conventional Pap smears are more likely to be unsatisfactory for interpretation than liquid based methods because liquid-based techniques filter out red blood cells. This was demonstrated in a population-based retrospective study in the Netherlands in which over 100,000 women who reported having regular menstrual cycles were screened for cervical cancer using the conventional Pap smear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/5\">",
"     5",
"    </a>",
"    ]. The rate of unsatisfactory smears was 23 percent during cycle days 0 to 3 versus 2 percent for the remainder of the cycle.",
"   </p>",
"   <p>",
"    For liquid-based Pap tests, timing during the menstrual cycle does not appear to have a clinically significant effect on cytologic results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/30,56\">",
"     30,56",
"    </a>",
"    ]. This was illustrated by a large study in which 5060 women with initial cytology showing ASCUS or LSIL had over 20,000 liquid-based Pap tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/56\">",
"     56",
"    </a>",
"    ]. The phase of the menstrual cycle did not have a significant effect on the rate of unsatisfactory specimens. Although the detection of LSIL or more severe abnormalities was slightly higher in the mid- versus early or late cycle (mid-cycle: 20 percent, early and late cycle: 18 percent), this difference is unlikely to be clinically significant.",
"   </p>",
"   <p>",
"    HPV testing results are not affected by bleeding, although some data suggest that detection of high risk varies with the phase of the menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Interval between Pap tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Pap test may need to be repeated after a brief interval if the sample is unsatisfactory or at the time of colposcopy. A short interval between Pap tests (15 to 30 days) does not appear to affect sensitivity for detection of cervical neoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concern about a short interval between Pap tests is based on the hypothesis that previous scraping for cytology will remove the most superficial layer of cervical cells, where a potential abnormality is most likely to occur. It will then take a period of time (generally estimated as up to two months) for the superficial cells to regenerate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, if sampling is performed too soon, the underlying cells may be sampled and appear normal, yielding a false negative test.",
"   </p>",
"   <p>",
"    The best designed study of the optimum interval between Pap smears evaluated liquid-based Pap tests and HPV testing results in 5055 women with initial Pap tests that showed either ASCUS or LSIL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/59\">",
"     59",
"    </a>",
"    ]. Sensitivity of repeat specimens was assessed by comparing cytology with histology in women with CIN 3 or carcinoma. The interval from initial to repeat Pap test in these women was 8 to 184 days. Adequacy of the sample did not appear to be affected, since cellularity of the sample and HPV viral load did not vary with Pap intervals. In addition, Pap test interval (15 to 120 days) did not significantly affect the finding of abnormal cytology. In fact, the likelihood of a Pap result of LSIL was higher after a shorter versus a longer interval (&le;30 days [30 percent] versus &gt;120 days [20 percent]); this likely represents regression of LSIL with time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gel lubricants and other contaminants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contaminants, such as gel lubricant, vaginal discharge, semen, spermicide, or intravaginal medications have been thought to affect cervical sampling. On a conventional smear, the concern is that these may make the smear thick and difficult to read.",
"   </p>",
"   <p>",
"    If large amounts of vaginal contaminants are present, the discharge can be removed gently with a large cotton swab without interfering with cytology results. Routine removal of a small amount of discharge or other contaminants is unnecessary.",
"   </p>",
"   <p>",
"    Gel lubricant on the speculum or on an examiner's hand before a Pap test is performed is commonly thought to interfere with the results of cervical cytology; however, this does not appear to be a valid concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. This was best illustrated by two large studies (n=3460 and n=8534) in which the speculum used to access the cervix was lubricated with either a water soluble gel or water prior to performing a conventional Pap smear; type of lubricant was randomized by clinic or by month the test was performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Rates of unsatisfactory smears were similar for both groups (gel: 1.1 and 1.4 percent; water: 1.5 and 1.3 percent). One of these studies also evaluated whether the cytologic diagnosis varied with use of gel; there were no differences in the detection rates of each type of cervical abnormality with use of gel.",
"   </p>",
"   <p>",
"    These studies used conventional Pap smears and it is not certain whether their results can be generalized to liquid-based cytology. However, it is plausible that thin layer cytology is less likely than conventional smears to be affected by gel contaminants since contaminants are filtered out of the sample during processing. While more study is needed to confirm that gel lubricants do not interfere with liquid-based Pap tests, the existing data suggest no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, testing for Neisseria gonorrhea and Chlamydia trachomatis cervical infection is often performed concurrently with cervical cytology. Many clinicians avoid use of gel lubricants prior to testing for these bacteria since some lubricants are bacteriostatic (eg, those containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine gluconate",
"    </a>",
"    ). However, one of the studies described above also evaluated DNA probe testing in 5535 women in whom gel or water was used to lubricate the speculum prior to testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/61\">",
"     61",
"    </a>",
"    ]. No significant differences were found between groups in the detection rate of chlamydia (1.5 percent in both groups); the gonorrhea infection rate was too low to analyze. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data regarding the effect of discharge, semen, or intravaginal medications on cervical cytology interpretation. Studies of use of nonoxynol-9 spermicide have had conflicting resulting regarding cervical cytology changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The spermicide nonoxynol-9 is not active against HPV, but detergents, such as sodium dodecyl sulfate (SDS), do inactivate HPV and a",
"    <span class=\"nowrap\">",
"     spermicide/SDS",
"    </span>",
"    combination could be useful in preventing HPV transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vaginal intercourse, douching, and tampon use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are typically advised to refrain from vaginal activities (eg, douching, tampon use, sexual intercourse) during the 48 hours prior to a Pap test. Advising patients to avoid vaginal activities may be cumbersome to clinicians and make timely scheduling of Pap tests difficult for patients. There are few data that directly assess the effect of vaginal activities on the ability of cervical cytology to detect cervical neoplasia.",
"   </p>",
"   <p>",
"    Vaginal intercourse and its effect on cervical cytology have not been studied. However, a study of HPV testing in which women performed self-sampling with synthetic polyester swabs or a tampon found no effect on HPV detection when vaginal intercourse occurred within 48 hours of sampling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/70\">",
"     70",
"    </a>",
"    ]. This was a small study, and the data cannot be generalized to clinician-performed testing in women who have had recent vaginal intercourse prior to Pap testing. Although it is possible that HPV detected in cytology samples following recent sexual activity could be derived from the male partner, this should not alter the standard management algorithm. Further study is needed to evaluate the effect of vaginal intercourse on cervical cytology or HPV testing.",
"   </p>",
"   <p>",
"    Douching did not affect sensitivity of HPV testing in a study of 132 women (sensitivity was 98 percent before douching; 96 percent after douching); results of the effect of douching on cytology results were not reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/32/35337/abstract/71\">",
"     71",
"    </a>",
"    ]. More data are needed to address the effect of douching on cervical cytology and HPV testing.",
"   </p>",
"   <p>",
"    There are no data regarding tampon use or barrier contraception and cervical cytology or HPV testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=see_link\">",
"       \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical cancer screening tests detect cellular changes or infection with types of human papillomavirus (HPV) that predispose women to invasive cervical cancer. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conventional cervical smears are performed by smearing the specimen on a slide. With liquid-based methods, the specimen is placed into a liquid fixative solution. Both methods are referred to as cervical cytology or a Pap test. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sample preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several types of collection devices can be used for cervical cytology sampling. We suggest sampling with both a spatula and endocervical brush. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Collection device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Choosing between conventional smears and liquid-based tests depends upon a variety of factors, including specimen adequacy, screening performance, ability to perform concurrent testing, and cost. These factors, particularly cost and test and laboratory availability for liquid-based methods vary by health care setting, thus, no general recommendation can be made. &nbsp;(See",
"      <a class=\"local\" href=\"#H14\">",
"       'Choosing conventional smears versus liquid-based cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HPV testing detects strains of the virus that are associated with a high risk of cervical neoplasia. There is no commercially available test for detection of low risk HPV strains. A specimen for HPV testing can be obtained using a Dacron swab or an endocervical brush or the liquid-based cytology sample can also be used for HPV testing. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HPV testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with vaginal bleeding, cleaning the cervix with a large cotton swab prior to performing a Pap test will remove obscuring blood and appears to have a minimal or no effect on sample cellularity. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Menses or other genital tract bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If cervical cytology needs to be repeated (eg, a previous test was unsatisfactory), a short interval of 15 to 30 days between tests does not appear to affect diagnostic results. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Interval between Pap tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sexual intercourse, douching, and tampon use may remove the most superficial layer of cervical cells. However, it appears that removal of cells by these activities or by swabbing (to remove blood or discharge) does not diminish the ability to diagnose cervical abnormalities or HPV infection. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Vaginal intercourse, douching, and tampon use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of gel lubricants before performing a Pap test does not appear to interfere with results of cytology or testing for cervical infection. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Gel lubricants and other contaminants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/1\">",
"      Marchand L, Mundt M, Klein G, Agarwal SC. Optimal collection technique and devices for a quality pap smear. WMJ 2005; 104:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/2\">",
"      Martin-Hirsch P, Jarvis G, Kitchener H, Lilford R. Collection devices for obtaining cervical cytology samples. Cochrane Database Syst Rev 2000; :CD001036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/3\">",
"      Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007; 18:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/4\">",
"      Harrison DD, Hernandez E, Dunton CJ. Endocervical brush versus cotton swab for obtaining cervical smears at a clinic. A cost comparison. J Reprod Med 1993; 38:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/5\">",
"      Vooijs GP, van der Graaf Y, Elias AG. Cellular composition of cervical smears in relation to the day of the menstrual cycle and the method of contraception. Acta Cytol 1987; 31:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/6\">",
"      Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/7\">",
"      Zhao C, Austin RM. High-risk human papillomavirus DNA test results are useful for disease risk stratification in women with unsatisfactory liquid-based cytology pap test results. J Low Genit Tract Dis 2009; 13:79.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.thinprep.com/hcp/specimen_collection/brush_spatula.html (Accessed on April 25, 2012).",
"    </li>",
"    <li>",
"     file://www.thehpvtest.com/~/media/5C4BD0982BED4E3788F65B36AF829AAD.ashx (Accessed on April 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/10\">",
"      Hildesheim A, Bratti MC, Edwards RP, et al. Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward. Clin Diagn Lab Immunol 1998; 5:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/11\">",
"      Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/12\">",
"      Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/13\">",
"      Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol 2007; 104:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/14\">",
"      Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 2007; 335:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/15\">",
"      Willis BH, Barton P, Pearmain P, et al. Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. Health Technol Assess 2005; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/16\">",
"      Tabbara SO, Sidawy MK. Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure. Diagn Cytopathol 1996; 14:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/17\">",
"      The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989; 262:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/18\">",
"      Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/19\">",
"      Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/20\">",
"      Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/21\">",
"      Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006; 94:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/22\">",
"      Castellsagu&eacute; X, D&iacute;az M, de Sanjos&eacute; S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/23\">",
"      Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol 2005; 124:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/24\">",
"      Crum CP, Beach KJ, Hedley ML, et al. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. J Infect Dis 2004; 189:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/25\">",
"      del Pino M, Rodriguez-Carunchio L, Alonso I, et al. Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2. Gynecol Oncol 2011; 122:515.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm (Accessed on April 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/27\">",
"      Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009; 5:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/28\">",
"      Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/29\">",
"      Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/30\">",
"      Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001; 185:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/31\">",
"      Sulik SM, Kroeger K, Schultz JK, et al. Are fluid-based cytologies superior to the conventional Papanicolaou test? A systematic review. J Fam Pract 2001; 50:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/32\">",
"      Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007; 335:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/33\">",
"      Davey E, Barratt A, Irwig L, et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet 2006; 367:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/34\">",
"      Lee KR, Ashfaq R, Birdsong GG, et al. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol 1997; 90:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/35\">",
"      Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/36\">",
"      Abulafia O, Pezzullo JC, Sherer DM. Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol 2003; 90:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/37\">",
"      Moseley RP, Paget S. Liquid-based cytology: is this the way forward for cervical screening? Cytopathology 2002; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/38\">",
"      Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:687.",
"     </a>",
"    </li>",
"    <li>",
"     Noorani HZ, Brown A, Skidmore B, Stuart GC. Liquid-based cytology and human papillomavirus testing in cervical cancer screening. Technology report no 40. Ottawa: Canadian Coordinating Office of Health Technology Assessment, 2003.",
"    </li>",
"    <li>",
"     Medical Services Advisory Committee of Australia. Liquid based cytology for cervical screening. MSAC reference 12a. Assessment report. August, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/41\">",
"      Karnon J, Peters J, Platt J, et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004; 8:iii, 1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/42\">",
"      Beerman H, van Dorst EB, Kuenen-Boumeester V, Hogendoorn PC. Superior performance of liquid-based versus conventional cytology in a population-based cervical cancer screening program. Gynecol Oncol 2009; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/43\">",
"      Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009; 302:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/44\">",
"      Lee KR, Darragh TM, Joste NE, et al. Atypical glandular cells of undetermined significance (AGUS): Interobserver reproducibility in cervical smears and corresponding thin-layer preparations. Am J Clin Pathol 2002; 117:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/45\">",
"      Wang N, Emancipator SN, Rose P, et al. Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional Pap smear. Acta Cytol 2002; 46:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/46\">",
"      Bai H, Sung CJ, Steinhoff MM. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix. Diagn Cytopathol 2000; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/47\">",
"      Ducatman BS, Wang HH, Jonasson JG, et al. Tubal metaplasia: a cytologic study with comparison to other neoplastic and non-neoplastic conditions of the endocervix. Diagn Cytopathol 1993; 9:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/48\">",
"      Ashfaq R, Gibbons D, Vela C, et al. ThinPrep Pap Test. Accuracy for glandular disease. Acta Cytol 1999; 43:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/49\">",
"      Hecht JL, Sheets EE, Lee KR. Atypical glandular cells of undetermined significance in conventional cervical/vaginal smears and thin-layer preparations. Cancer 2002; 96:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/50\">",
"      Marshall Austin R. The detection of precancerous cervical lesions can be significantly increased. Arch Pathol Lab Med 2003; 127:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/51\">",
"      Johnson JE, Rahemtulla A. Endocervical glandular neoplasia and its mimics in ThinPrep Pap tests. A descriptive study. Acta Cytol 1999; 43:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/52\">",
"      Wood MD, Horst JA, Bibbo M. Weeding atypical glandular cell look-alikes from the true atypical lesions in liquid-based Pap tests: a review. Diagn Cytopathol 2007; 35:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/53\">",
"      Sweeney BJ, Haq Z, Happel JF, et al. Comparison of the effectiveness of two liquid-based Papanicolaou systems in the handling of adverse limiting factors, such as excessive blood. Cancer 2006; 108:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/54\">",
"      Kotaska AJ, Matisic JP. Cervical cleaning improves Pap smear quality. CMAJ 2003; 169:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/55\">",
"      Hans N, Cave AJ, Szafran O, et al. Papanicolaou smears: to swab or not to swab. Can Fam Physician 2007; 53:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/56\">",
"      Sherman ME, Carreon JD, Schiffman M. Performance of cytology and human papillomavirus testing in relation to the menstrual cycle. Br J Cancer 2006; 94:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/57\">",
"      Schmeink CE, Massuger LF, Lenselink CH, et al. Effect of the menstrual cycle and hormonal contraceptives on human papillomavirus detection in young, unscreened women. Obstet Gynecol 2010; 116:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/58\">",
"      Bishop JW, Hartinger JS, Pawlick GF. Time interval effect on repeat cervical smear results. Acta Cytol 1997; 41:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/59\">",
"      Jeronimo J, Khan MJ, Schiffman M, et al. Does the interval between papanicolaou tests influence the quality of cytology? Cancer 2005; 105:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/60\">",
"      KOSS LG, STEWART F, FOOTE FW, et al. SOME HISTOLOGICAL ASPECTS OF BEHAVIOR OF EPIDERMOID CARCINOMA IN SITU AND RELATED LESIONS OF THE UTERINE CERVIX. A LONG-TERM PROSPECTIVE STUDY. Cancer 1963; 16:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/61\">",
"      Griffith WF, Stuart GS, Gluck KL, Heartwell SF. Vaginal speculum lubrication and its effects on cervical cytology and microbiology. Contraception 2005; 72:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/62\">",
"      Amies AM, Miller L, Lee SK, Koutsky L. The effect of vaginal speculum lubrication on the rate of unsatisfactory cervical cytology diagnosis. Obstet Gynecol 2002; 100:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/63\">",
"      Hathaway JK, Pathak PK, Maney R. Is liquid-based pap testing affected by water-based lubricant? Obstet Gynecol 2006; 107:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/64\">",
"      Harer WB, Valenzuela G Jr, Lebo D. Lubrication of the vaginal introitus and speculum does not affect Papanicolaou smears. Obstet Gynecol 2002; 100:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/65\">",
"      Tavernier LA, Connor PD, Gates D. Water vs gel lubricant for cervical cytology specimens. J Fam Pract 2003; 52:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/66\">",
"      Poindexter AN 3rd, Levine H, Sangi-Haghpeykar H, et al. Comparison of spermicides on vulvar, vaginal, and cervical mucosa. Contraception 1996; 53:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/67\">",
"      Halpern V, Rountree W, Raymond EG, Law M. The effects of spermicides containing nonoxynol-9 on cervical cytology. Contraception 2008; 77:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/68\">",
"      Auborn KJ, Carter TH. Treatment of human papillomavirus gynecologic infections. Clin Lab Med 2000; 20:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/69\">",
"      Marais D, Carrara H, Kay P, et al. The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res 2006; 121:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/70\">",
"      Harper DM, Longacre MR, Noll WW, et al. Factors affecting the detection rate of human papillomavirus. Ann Fam Med 2003; 1:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/32/35337/abstract/71\">",
"      Chen FC, Shaw SW, Cheng PJ, et al. Diagnosis of human papillomavirus infection by abnormal cervical cytology is highly reproducible after vaginal douching. Taiwan J Obstet Gynecol 2008; 47:412.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3219 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35337=[""].join("\n");
var outline_f34_32_35337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HOW TO OBTAIN A SAMPLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Specimens for cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Collection device",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sample collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Sample preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HPV testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gonorrhea and chlamydia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Biopsy of visible lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SAMPLE INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cytologic analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HPV testing result reporting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHOOSING CONVENTIONAL SMEARS VERSUS LIQUID-BASED CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Specimen adequacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - HSIL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - LSIL or ASCUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Glandular cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Concurrent HPV testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MISPERCEPTIONS ABOUT FACTORS THAT INTERFERE WITH SAMPLING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Menses or other genital tract bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Interval between Pap tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gel lubricants and other contaminants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vaginal intercourse, douching, and tampon use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3219|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/45/20183\" title=\"figure 1\">",
"      Pap test Ayre spatula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/30/39393\" title=\"figure 2\">",
"      Pap test smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/26/39329\" title=\"figure 3\">",
"      Pap test liquid-based",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/51/19261\" title=\"table 2\">",
"      Bethesda class cervix cytol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/3/8248?source=related_link\">",
"      Cervical cancer screening tests: Evidence of effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9624?source=related_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_32_35338="Atypical Spitz histo 3";
var content_f34_32_35338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Histology of atypical Spitz tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical Spitz tumor. There is a lentiginous melanocytic proliferation with increased cytological atypia and pleomorphism. The lesion lacks eosinophilic globules (Kamino bodies).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35338=[""].join("\n");
var outline_f34_32_35338=null;
var title_f34_32_35339="ANCA accuracy in GN in children";
var content_f34_32_35339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ANCA results for pauci-immune crescentic glomerulonephritis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of PI-CGN",
"       </td>",
"       <td class=\"subtitle1\">",
"        PPV for PI-CGN",
"       </td>",
"       <td class=\"subtitle1\">",
"        NPV for PI-CGN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapidly progressive glomerulonephritis*",
"       </td>",
"       <td>",
"        48 percent (10/21)",
"       </td>",
"       <td>",
"        98 percent",
"       </td>",
"       <td>",
"        80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine &gt;3 mg/dL",
"       </td>",
"       <td>",
"        16 percent (6/38)",
"       </td>",
"       <td>",
"        90 percent",
"       </td>",
"       <td>",
"        95 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine 1.5-3 mg/dL",
"       </td>",
"       <td>",
"        15 percent (6/39)",
"       </td>",
"       <td>",
"        89 percent",
"       </td>",
"       <td>",
"        95 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine &lt;1.5 mg/dL",
"       </td>",
"       <td>",
"        1 percent (1/162)",
"       </td>",
"       <td>",
"        30 percent",
"       </td>",
"       <td>",
"        100 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated positive predictive values (PPV) and negative predictive values (NPV) of ANCA results for pauci-immune crescentic glomerulonephritis (PI-CGN) in children (&lt;18 years old) with different clinical presentation using an assay approach (that has a 72.5 percent sensitivity and a 98.4 percent specificity).",
"    <div class=\"footnotes\">",
"     * This clinical presentation presumed from renal biopsy showing &gt;50 percent of glomeruli with crescents.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jennette, JC, Wilkman, AS, Falk, RJ, Kidney Int 1998; 53:796.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35339=[""].join("\n");
var outline_f34_32_35339=null;
var title_f34_32_35340="Chemotherapy radiation sensitiz";
var content_f34_32_35340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77210&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy agents associated with radiation enhancement and radiation recall",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Radiation enhancement",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bleomycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dactinomycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Doxorubicin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluorouracil with and without cisplatin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hydroxyurea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          6-Mercaptopurine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methotrexate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Paclitaxel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gemcitabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chlorambucil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Capecitabine",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Radiation recall",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Arsenic trioxide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bleomycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Capecitabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cyclophosphamide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytarabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Dactinomycin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Daunorubicin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Docetaxel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Doxorubicin (free and liposomal)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Etoposide",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fluorouracil",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gemcitabine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hydroxyurea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Idarubicin",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lomustine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Melphalan",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Methotrexate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Paclitaxel",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pemetrexed",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tamoxifen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Vinblastine",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Localized reactions typically involving areas of occluded skin (ifosfamide, topical carmustine, docetaxel, thiotepa) or the infusion site.",
"    </div>",
"    <div class=\"reference\">",
"     Data from from Susser, WS, et al. Mucucutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367; Alley, E, et al. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212; and Keung, YK, et al. Leukemia 2003; 17:1417.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35340=[""].join("\n");
var outline_f34_32_35340=null;
var title_f34_32_35341="PK and UK";
var content_f34_32_35341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between plasma potassium and urinary potassium excretion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 249px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean values for plasma potassium concentration and steady-state urinary potassium excretion in adrenalectomized dogs given different levels of aldosterone replacement (20, 40, or 250 &micro;g per day) and studied at increasing levels of K+ intake. The dashed line represents the effects seen when K+ excretion is 50 meq/day. Higher levels of aldosterone result in increasing potassium excretion at the same plasma potassium concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Young, DB, Paulsen, AW, Am J Physiol 1983; 244:F28.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35341=[""].join("\n");
var outline_f34_32_35341=null;
var title_f34_32_35342="Lip swelling CD";
var content_f34_32_35342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lip swelling with fissures in a child with Crohn disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lip swelling of one or both lips may occur in patients with Crohn disease. Persistent enlargment may lead to the development of fissures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hardy S, Fleming P, Rowland M, et al. A prospective study of the oral manefestations of Crohn's disease. Clin Gastroenterol Hepatol 2005; 3:886. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35342=[""].join("\n");
var outline_f34_32_35342=null;
var title_f34_32_35343="Esophageal web Endosc";
var content_f34_32_35343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obstructive cervical esophageal web seen on endoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of an obstructing cervical esophageal web in a patient with recessive dystrophic epidermolysis bullosa. The esophageal lumen at the level of the web is barely visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gulchin A Ergun, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_32_35343=[""].join("\n");
var outline_f34_32_35343=null;
